Antitumor Antagonists

By developing bispecific anti-tumor antagonists that combine TGFβ1 and PD-1/PD-L1 or VEGF, the problem of cancer cells' resistance to checkpoint inhibitors is solved, the immune system's ability to attack cancer cells is improved, and the immune system's ability to attack cancer cells is improved. Treatment effect.

CN112638401BActive Publication Date: 2024-11-19SUZHOU ZELGEN BIOPHARML
View PDF 69 Cites 0 Cited by

Patent Information

Application Number
CN201980056646.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-03-26
Filing Date
2019-06-28
Publication Date
2024-11-19
Estimated Expiration
2039-06-28

AI Technical Summary

Technical Problem

Existing cancer treatments are difficult to overcome the resistance of cancer cells to TGF and VEGF checkpoint inhibitors, making it difficult for the immune system to effectively recognize and eliminate cancer cells.

Method used

A bispecific antitumor antagonist has been developed, including domains that specifically bind TGFβ1 and PD-1 or PD-L1, as well as domains that specifically bind VEGF, or improved on the basis of bevacizumab, Used to enhance the attack ability of cancer cells.

Benefits of technology

These antagonists can effectively inhibit the TGFβ and VEGF pathways, improve the immune system's ability to recognize and attack cancer cells, overcome resistance, and improve treatment effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112638401B_ABST
    Figure CN112638401B_ABST
Patent Text Reader

Abstract

The present application discloses an anti-tumor antagonist that specifically binds to an immune checkpoint regulator, an angiogenesis pathway regulator, and / or a TGF pathway regulator. The present application also discloses a method for treating proliferative diseases, infections, and immune diseases using the anti-tumor antagonist described herein.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to U.S. Provisional Patent Application Serial No. 62 / 691,658, filed on June 29, 2018, and U.S. Provisional Patent Application Serial No. 62 / 823,989, filed on March 26, 2019, the contents of which are expressly incorporated herein by reference. Technical Field

[0002] The present invention relates generally to cancer treatment, and more particularly to bispecific inhibitors capable of regulating pathways related to tumorigenesis, tumor immunity, and angiogenesis. Background Art

[0003] The inability of the host to eliminate cancer cells remains a major problem. Although a growing number of therapeutic monoclonal antibodies have been approved for the treatment of various cancers, the emergence of resistance to these antibodies is frequently observed given the many different molecular pathways involved in cancer growth and progression to metastasis. Although the immune system is a primary mechanism for cancer prevention, cancer cells can circumvent immune surveillance. Natural control mechanisms have been identified that limit T cell activation to prevent collateral damage caused by unrestrained T cell activity. Tumor cells have exploited this process to evade the immune response. Restoring the ability of immune effector cells, particularly T cells, to recognize and eliminate cancer is a major goal of immunotherapy. Both TGFβ and angiogenesis pathways have been implicated in resistance to checkpoint inhibitors.

[0004] There is a need for improved therapeutic binding antagonists or antibodies and methods for treating cancer and chronic viral infections that are able to overcome resistance to checkpoint inhibitors that inhibit TGF and VEGF. Summary of the Invention

[0005] One aspect of the present application relates to an anti-tumor antagonist, comprising a first targeting domain that specifically binds to TGFβ1 and a second targeting domain that specifically binds to PD-1 or PD-L1.

[0006] Another aspect of the present application relates to an anti-tumor antagonist, comprising a first targeting domain that specifically binds to TGFβ1 and a second targeting domain that specifically binds to VEGF.

[0007] Another aspect of the present application relates to an anti-tumor antagonist comprising an improved form of bevacizumab having increased expression in mammalian cells.

[0008] Another aspect of the present application relates to a method for treating a cell proliferative disease in a subject, wherein the method comprises the step of administering an effective amount of the anti-tumor antagonist of the present application to a subject in need of such treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] Figure 1 The complementary determining region (CDR) sequences of some anti-PD-1 monoclonal antibodies are shown. The corresponding framework region (FR) sequences are shown in Figure 36 Listed as SEQ ID NOs: 130-159.

[0010] Figures 2A-2B Several embodiments of anti-PD-1 antibody variable region domain sequences are shown.

[0011] Figure 3 The CDR sequences of some anti-PD-L1 monoclonal antibodies are shown. The corresponding FR sequences are Figure 36 Listed as SEQ ID NOs: 160-182.

[0012] Figures 4A-4C Several embodiments of anti-PD-L1 antibody variable region domain sequences are shown.

[0013] Figures 5A-5B Four different bispecific anti-tumor antagonist configurations are shown: Bi-PB-1, Bi-PLB-1, Bi-PB-2, and Bi-PLB-2, each comprising (1) an anti-PD-1 or anti-PD-L1 variable region and (2) a TGF-βRII ECD domain.

[0014] Figure 6 Exemplary functional domain sequences corresponding to the bispecific antibodies in Figure 5 are shown.

[0015] Figure 7 Exemplary heavy chain (HC) and light chain (LC) sequences corresponding to selected bispecific antibodies in FIG. 5 are shown.

[0016] Figures 8A-8C Three different bispecific antagonists, Bi-AB-1, Bi-AlB-1, and Bi-ZB-1, are shown, each containing a carboxy-terminal TGF-β1 RII extracellular domain (ECD) within a mutant IgG1 (K447A) scaffold. Both Bi-AB-1 and Bi-AlB-1 contain amino-terminal anti-VEGF variable regions (VH1, VL1) from Avastin / bevacizumab; Bi-AlB-1 contains two amino acid substitutions in the VH region (E6Q, L11V). Bi-ZB-1 contains an amino-terminal aflibercept domain upstream of the IgG1 Fc (K447A) region.

[0017] Figure 9A and 9B The various functional domain sequences present in the bispecific antagonists shown in Figure 8 are shown.

[0018] Figure 10 The heavy chain (HC) and light chain (LC) amino acid sequences corresponding to the bispecific antagonists shown in Figure 8 are shown.

[0019] Figure 11 The arrangement of the functional domains in the bispecific antagonists shown in FIG8 is summarized.

[0020] Figure 12 is a Coomassie blue-stained polyacrylamide gel showing the expression levels of bispecific antibody antagonists Bi-AB-1 and Bi-AlB-1 containing E6Q and L11V mutations when transiently transfected into HEK293 cells, as determined by non-reducing polyacrylamide gel electrophoresis (PAGE).

[0021] Figure 13A Size exclusion chromatography (SEC) curves of Bi-AB-1 and Bi-AlB-1 are shown. Figure 13B Protein A purified Bi-AB-1 and Bi-AlB-1 showed low levels of high molecular weight (HMW, 1%, 1%, respectively) and low molecular weight (LMW, 0.4%, 0.4%, respectively) species compared to the dimer (98.6%, 98.7%, respectively).

[0022] Figure 14A and 14B Shown in the non-reducing ( Figure 14A ) and reductive ( Figure 14B ) conditions.

[0023] Figure 15 Size exclusion chromatography (SEC) curves are shown, indicating that Protein A purified Bi-ZB-1 has low levels of high molecular weight (HMW, 3.4%) and low molecular weight (LMW, 0.5%) species compared to the dimer (96.1%).

[0024] Figure 16 Shown are the results of a cell-based assay in which recombinant HEK-293 cells expressing human VEGFR2 and firefly luciferase under the control of a NFAT response element were stimulated with huVEGF165 in the presence of serial dilutions of two anti-VEGF antagonists, Bi-AlB-1 and Antibody A. Biological activity was determined by measuring the decrease in luciferase-mediated luminescence.

[0025] Figure 17ELISA analysis showing that TGF-β1 and VEGF165 are simultaneously bound by Bi-A1B-1, wherein 96-well plates coated with huTGF-β1 were incubated with serially diluted samples of Bi-A1B-1 and then with biotinylated huVEGF165, whereby bound molecules were detected by streptavidin-HRP using TMB substrate.

[0026] Figure 18 Shown are the results of a cell-based assay in which recombinant HEK-293 cells expressing the human TGF-β1 RII receptor and firefly luciferase were stimulated with huTGF-β1 under the control of a SMAD response element and in the presence of serial dilutions of Bi-AlB-1, Bi-ZB-1, and controls, each containing a TGF-β1 RII extracellular domain (ECD) fusion protein. Biological activity was determined by the reduction in luciferase-mediated luminescence.

[0027] Figure 19 Pharmacokinetic curve showing the in vivo half-life (T) of the bispecific antagonist Bi-AlB-1 after tail vein injection in 6-10 week old female CD1 mice. 1 / 2 The Bi-AlB-1 antagonist was recovered from the serum at different times after injection and analyzed by ELISA.

[0028] Figures 20A-20B Two bispecific anti-tumor antagonists Bi-PB-1.2 ( Figure 20A ) and Bi-PLB-1.2( Figure 20B ), each comprising an antibody backbone (IgG4K447A or IgG1K447A) and variable region domains from anti-PD-1 and anti-PD-L1, respectively, and also including a TGF-RII ECD fused to the carboxyl terminus of each heavy chain CH3 region.

[0029] Figure 21 Shows Figure 20A and 20B Functional domain sequences present in bispecific antibodies.

[0030] Figure 22 Shows the corresponding Figure 20A and 20B The heavy chain (HC) and light chain (LC) amino acid sequences of the bispecific antagonist are shown in .

[0031] Figure 23 The arrangement of the functional domains in the bispecific antagonists shown in Figures 13 and 24 is summarized.

[0032] Figure 24ANative polyacrylamide gel (PAGE) analysis shows increased expression of Bi-PB-1.2 and Bi-PLB-1.2 in a transient expression system after Protein A affinity purification compared to the parental control antibody (2P17). Figure 24B Shown are size exclusion chromatography (SEC) curves showing Protein A purified Bi-PB-1.2, Bi-PLB-1.2 and a benchmark antibody (2P17). Figure 24C Bi-PB-1.2, Bi-PLB-1.2, and a benchmark antibody (2P17) were shown to have low levels of high molecular weight (HMW) and low molecular weight (LMW) species compared to the dimer.

[0033] Figures 25A-25B Display Bi-PB-1.2( Figure 25A ) and Bi-PLB-1.2( Figure 25B ) showed good stability at 4 °C for at least 4 weeks in the dimer, HMW and LMW forms.

[0034] Figures 26A-26E showed that PD-1 and TGF-β1 bind to Bi-PB-1.2 (respectively Figure 26A , 26B) and the corresponding anti-PD-1 and anti-PDL1-TGF-β1 RII ECD benchmark molecules (respectively Figure 26C , 26D) and their resulting binding affinity constants ( Figure 26E ).

[0035] Figures 27A-27E showed that PD-L1 and TGF-β1 bind to Bi-PLB-1.2 (respectively Figure 27A , 27B) and the anti-PDL1-TGF-β1 RII ECD benchmark molecule ( Figure 27C , 27D) and their resulting binding affinity constants ( Figure 27E ).

[0036] Figure 28A An ELISA assay is shown demonstrating that TGF-β1 and PD-1 are simultaneously bound by Bi-PB-1.2, wherein 96-well plates coated with huTGF-β1 were incubated with serially diluted samples of Bi-PB-1.2 and then incubated with biotinylated huPD-1, and the bound molecules were detected by streptavidin-HRP using TMB substrate. Figure 28BAn ELISA assay is shown demonstrating that TGF-β1 and PD-L1 are simultaneously bound by Bi-PLB-1.2, wherein a 96-well plate coated with hu TGF-β1 was incubated with serially diluted samples of Bi-PLB-1.2 and then with biotinylated hu PD-L1, and the bound molecules were detected by streptavidin-HRP using TMB substrate.

[0037] Figure 29A The ability of Bi-PB-1.2 and an anti-PD-1 benchmark antibody to block the binding of PD-1 to PD-L1 is shown. Figure 29B Results from a cell-based assay are shown, demonstrating the ability of Bi-PB-1.2 and anti-PDL1-TGF-β1 RII ECD benchmark molecules to block TGF-β1 activation of luciferase expression under the control of SMAD response elements. Biological activity was determined by a decrease in luciferase-mediated luminescence.

[0038] Figures 30A-30B Bi-PB-1.2 and anti-human PD-1 and anti-cynomolgus PD-1 benchmark antibodies were shown to be highly sensitive to human PD-1 ( Figure 30A ) and macaque PD-1( Figure 30B ) and their corresponding EC 50 The values ​​reflect the half-maximal effective concentration (EC) that produces a response halfway between baseline and maximal response for binding to human PD-1 and cynomolgus monkey PD-1, respectively. 50 ).

[0039] Figure 31A The ability of Bi-PLB-1.2 and an anti-PD-L1 benchmark antibody to block the binding of PD-L1 to PD-1 is shown. Figure 31B Results from a cell-based assay are shown, demonstrating the ability of serial dilutions of Bi-PLB-1.2 and anti-PDL1-TGF-β1 RII ECD benchmark molecules to block the activation of luciferase expression by TGF-β1 under the control of SMAD response elements. Biological activity was determined by a decrease in luciferase-mediated luminescence.

[0040] Figures 32A-32B Bi-PLB-1.2 and anti-human PD-L1 and anti-cynomolgus PD-L1 benchmark antibodies showed strong affinity to human PD-L1 ( Figure 32A ) and macaque PD-L1( Figure 32B ) and their corresponding EC 50 The values ​​reflect the half-maximal effective concentration (EC) that produces a response halfway between baseline and maximal response for binding to human PD-1 and cynomolgus monkey PD-1, respectively. 50 )

[0041] Figures 33A-33B Shown are the effects of Bi-PB-1.2-treated human PBMCs (Donor 1, Figure 33A ; Donor 2, Figure 33B ) increased IFN-γ secretion. Figures 33C-33D Shown are the effects of Bi-PB-1.2-treated human PBMCs (Donor 1, Figure 33C ; Donor 2, Figure 33D ) increased IL-2 secretion.

[0042] Figures 34A-34B Shown are the effects of human PBMCs with Bi-PLB-1.2 (donor 9, Figure 34A ; Donor 9, Figure 34B ) increased IFN-γ secretion. Figures 34C-34D Shown are the effects of human PBMCs (donor 9, Figure 34C ; Donor 9, Figure 34D ) increased IL-2 secretion.

[0043] Figures 35A-35F The results showed that Bi-PB-1.2 and Bi-PLB-1.2 exhibited improved pharmacokinetic characteristics relative to the benchmark antibody after tail vein injection into 6-10 week old female CD1 mice. The antibody antagonists Bi-PB-1.2, Bi-PLB-1.2 and the benchmark were recovered from the serum at different times after injection and analyzed by ELISA (see Figure 35A , 35C, 35E) and Western blotting (respectively Figure 35B , 35D, 35F) for analysis.

[0044] Figure 36 Shows the corresponding Figure 1 and 3 Framework regions (FRs) of anti-PD-1 and anti-PD-L1 CDRs. DETAILED DESCRIPTION

[0045] definition

[0046] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosed methods and compositions belong. It must be noted that, as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural forms unless the context clearly indicates otherwise. Thus, for example, reference to "a peptide" includes reference to "one or more" peptides or "several" peptides. Any issued patent or patent application publication described in this application is expressly incorporated herein by reference with respect to the teachings of this application.

[0047] As used herein, the term "PD-1" refers to any form of PD-1 and variants thereof that retain at least a portion of the activity of PD-1. Unless otherwise indicated, for example, by specific reference to human PD-1, PD-1 includes native sequence PD-1 from all mammalian species, such as humans, dogs, cats, horses, and cattle.

[0048] As used herein, the term "PD-L1" refers to any form of PD-L1 and variants thereof that retain at least a portion of the activity of PD-L1. Unless otherwise indicated, for example, by specific reference to human PD-L1, PD-L1 includes native sequence PD-L1 of all mammalian species, such as humans, dogs, cats, horses, and cattle.

[0049] The term "agonist" refers to a substance that promotes (i.e., induces, causes, enhances, or increases) the biological activity or effect of another molecule. The term agonist includes substances that bind to receptors, such as antibodies, and substances that promote receptor function without binding to it (e.g., by activating related proteins).

[0050] The term "antagonist" or "inhibitor" refers to a substance that prevents, blocks, inhibits, neutralizes or reduces the biological activity or effect of another molecule, such as a receptor or ligand.

[0051] As used herein, the term "antibody" refers to a polypeptide or polypeptide complex that specifically recognizes and binds to an antigen through one or more immunoglobulin variable regions. An antibody can be a complete antibody, an antigen-binding fragment, or a single chain thereof. The term "antibody" encompasses a variety of polypeptides that can be distinguished biochemically. Those skilled in the art will appreciate that heavy chains are classified as alpha, delta, epsilon, gamma, and mu, or alpha, delta, epsilon, gamma, and mu, with several subclasses (e.g., gamma 1-gamma 4). The properties of this chain determine the "class" of the antibody, i.e., IgG, IgM, IgA, IgG, or IgE, respectively. Immunoglobulin subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, etc., are well characterized and are known to have functional specificities. In view of the present disclosure, modified forms of each of these classes and isotypes are readily discernible to those skilled in the art and are therefore within the scope of the present disclosure. All immunoglobulin classes are within the scope of the present disclosure, and the following discussion will generally be directed to the IgG class of immunoglobulin molecules.

[0052] The antibodies or antibody antagonists of the present application may include, but are not limited to, polyclonal, monoclonal, multispecific, bispecific, human, humanized, primatized, chimeric and single-chain antibodies. Antibodies disclosed herein may be from any animal origin, including birds and mammals. Preferably, the antibody is an antibody of a human, murine, rat, donkey, rabbit, goat, guinea pig, camel, llama, horse or chicken. In some embodiments, the origin of the variable region may be a marine organism (condricthoid) (e.g., from a shark).

[0053] The term "antibody fragment" or "antigen-binding fragment" is used to refer to a portion of an antibody, such as F(ab')2, F(ab)2, Fab', Fab, Fv, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv), fragments comprising a VL or VH domain, fragments produced by a Fab expression library, and anti-idiotypic (anti-Id) antibodies. Regardless of the structure, antibody fragments bind to the same antigen recognized by the intact antibody. The term "antibody fragment" includes DARTs and diabodies. The term "antibody fragment" also includes any synthetic or genetically engineered protein comprising an immunoglobulin variable region that acts like an antibody by binding to a specific antigen to form a complex. "Single-chain fragment variable region" or "scFv" refers to a fusion protein of the variable regions of the heavy chain (VH) and light chain (VL) of an immunoglobulin. In some aspects, the region is connected to a short linker peptide of 10 to about 25 amino acids. The linker can be rich in glycine for flexibility and serine or threonine for solubility, and can connect the N-terminus of VH or the C-terminus of VL, or vice versa. Despite the removal of the constant region and the introduction of the linker, this protein still retains the specificity of the original immunoglobulin. Regarding IgG, the standard immunoglobulin molecule contains two identical light chain polypeptides with a molecular weight of about 23,000 daltons and two identical heavy chain polypeptides with a molecular weight of 53,000-70,000. The four chains are usually connected by disulfide bonds in a "Y" configuration, wherein the light chain is connected to the heavy chain from the mouth of the "Y" and extends through the variable region.

[0054] Both light and heavy chains are divided into regions that are structurally and functionally homologous. The terms "constant" and "variable" are used functionally. In this regard, it will be understood that the variable region domains of the light (VL) and heavy (VH) chain portions determine antigen recognition and specificity. In contrast, the constant domains of the heavy chain (CH1, CH2 or CH3) and the constant domain (CL) of the light chain confer important biological properties, such as secretion, placental mobility, Fc receptor binding, complement fixation, etc. By convention, the numbering of the constant region domains in conventional antibodies increases as they are away from the antigen binding site or amino terminus of the antibody. In conventional antibodies, the N-terminal portion is the variable region, while the C-terminal portion is the constant region. The CH3 and CL domains actually comprise the carboxyl termini of the heavy and light chains, respectively.

[0055] As mentioned above, the variable region allows the antibody to selectively recognize and specifically bind to the epitope on the antigen. That is, the VL domain and VH domain of the antibody or the complementary determining region (CDR) subset of the antibody combine to form a variable region that limits the three-dimensional antigen binding site. This four-membered antibody structure forms the antigen binding site present at the end of each arm of each Y configuration. More specifically, the antigen binding site is defined by three CDRs (i.e., HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3) on each of the VH and VL chains. In some cases, for example, some immunoglobulin molecules are derived from camelid species or are engineered based on camelid immunoglobulins. Alternatively, the immunoglobulin molecule can be composed of a heavy chain without a light chain or a light chain without a heavy chain.

[0056] In naturally occurring antibodies, the six CDRs present in each antigen-binding domain are short, non-continuous amino acid sequences. Since the antibody presents its three-dimensional configuration in an aqueous environment, these CDRs are specifically positioned to form an antigen-binding domain. The remaining amino acids in the antigen-binding domain, referred to as "framework" region domains, show less intermolecular variability. The framework region mainly adopts a β-sheet conformation, and the CDRs form loops that connect and, in some cases, form a part of the β-sheet structure. Therefore, the framework region plays the role of forming a scaffold that positions the CDRs in the correct direction through interchain non-covalent interactions. The antigen-binding domain formed by the positioned CDRs defines a surface complementary to the epitope on the immunoreactive antigen. This complementary surface promotes the non-covalent binding of the antibody to its associated epitope (cognate epitope). Due to having been precisely defined, those of ordinary skill in the art can easily identify the amino acids comprising CDRs and framework regions, respectively, for any given heavy or light chain variable region.

[0057] As used herein, the terms "VH1" and "VH2" refer to immunoglobulin heavy chain variable region domains that correspond to two different binding specificities. Similarly, the terms "VL1" and "VL2" refer to light chain variable region domains that correspond to two different binding specificities. When used together, it will be understood that the VH1 and VL1 regions define a common binding specificity, and the VH2 and VL2 domains define another binding specificity.

[0058] As used herein, the term "framework region (FR)" refers to the variable region domain residues other than the CDR residues. Each variable region domain typically has four FRs that flank the corresponding CDRs. For example, a VH domain typically has four HFRs: HFR1, HFR2, HFR3, and HFR4, which flank three HCDRs in the configuration of HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4. Similarly, an LH domain typically has four LFRs that flank three LCDRs in the configuration of LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4. Exemplary FRs that can be used in the antagonists described herein are summarized in Figure 36 middle.

[0059] Light chains are classified as either kappa or lambda (κ, λ). Each heavy chain class can be associated with either a κ or λ light chain. Typically, when immunoglobulins are produced by hybridomas, B cells, or genetically engineered host cells, the light and heavy chains are covalently bonded to each other, and the "tail" portions of the two heavy chains are bonded to each other via covalent disulfide bonds or non-covalent bonds. In the heavy chain, the amino acid sequence extends from the N-terminus at the forked end of the Y configuration to the C-terminus at the base of each chain.

[0060] As used herein, the term "light chain constant region" or "CL" is used interchangeably herein when referring to an amino acid sequence derived from an antibody light chain. Preferably, the light chain constant region comprises at least one of a constant kappa domain or a constant lambda domain.

[0061] As used herein, the term "heavy chain constant region" includes amino acid sequences derived from immunoglobulin heavy chains. A polypeptide comprising a heavy chain constant region comprises at least one of the following: a CH1 domain, a hinge (e.g., upper, middle, and / or lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment thereof. For example, an antigen-binding polypeptide for use in the present disclosure may comprise a polypeptide chain having a CH1 domain; a polypeptide chain having a CH1 domain, at least a portion of a hinge domain, and a CH2 domain; a polypeptide chain having a CH1 domain and a CH3 domain; a polypeptide chain having a CH1 domain, at least a portion of a hinge domain, and a CH3 domain; or a polypeptide chain having a CH1 domain, at least a portion of a hinge domain, a CH2 domain, and a CH3 domain. In some embodiments, a polypeptide of the present disclosure comprises a polypeptide chain having a CH3 domain. In addition, an antibody for use in the present disclosure may lack at least a portion of a CH2 domain (e.g., all or part of a CH2 domain). It will be appreciated that the heavy chain constant regions may be modified such that their amino acid sequence differs from that of naturally occurring immunoglobulin molecules.

[0062] For example, as reflected in the disclosure herein below, Applicants have discovered that CH3 domains can tolerate or adapt to large insertions (e.g., greater than 100 amino acids) in the Fc loop of the CH3 domain (e.g., see Figure 5B Thus, in this application, any disclosed inhibitor domain (including but not limited to SEQ ID NOs: 123-125) can be similarly inserted into the Fc loop of the heavy chain in a manner similar to the insertion of the TGFβRII ECD domain in the Fc loop.

[0063] The heavy chain constant regions of the antibodies disclosed herein can be derived from different immunoglobulin molecules. For example, the heavy chain constant region of the polypeptide can include a CH1 domain derived from an IgG1 molecule and a hinge region derived from an IgG3 molecule. In another example, the heavy chain constant region can include a hinge region that is partially derived from an IgG1 molecule and partially derived from an IgG3 molecule. In another example, the heavy chain portion can include a chimeric hinge region that is partially derived from an IgG1 molecule and partially derived from an IgG4 molecule.

[0064] A "light chain-heavy chain pair" refers to a collection of light and heavy chains that can form dimers through a disulfide bond between the CL domain of the light chain and the CH1 domain of the heavy chain.

[0065] The subunit structures and three-dimensional configurations of the constant regions of the various immunoglobulin classes are well known. As used herein, the term "VH domain" includes the amino-terminal variable region domain of an immunoglobulin heavy chain, while the term "CH1 domain" includes the first (most amino-terminal) constant region domain of an immunoglobulin heavy chain. The CH1 domain is adjacent to the VH domain and is amino-terminal to the hinge region of the immunoglobulin heavy chain molecule.

[0066] As used herein, the term "CH2 domain" includes the portion of a heavy chain molecule extending from about residue 244 to residue 360 ​​of an antibody, for example, using the conventional numbering scheme (residues 244 to 360, Kabat numbering system; and residues 231-340, EU numbering system). The CH2 domain is unique in that it is not closely paired with another domain. Instead, two N-linked branched carbohydrate chains are inserted between the two CH2 domains of an intact native IgG molecule. The CH3 domain extends from the CH2 domain of the IgG molecule to the C-terminus and comprises approximately 108 residues.

[0067] As used herein, the term "hinge region" includes the portion of the heavy chain molecule that connects the CH1 domain to the CH2 domain. The hinge region comprises approximately 25 residues and is flexible, thus allowing the two N-terminal antigen-binding regions to move independently. The hinge region can be subdivided into three distinct domains: the upper, middle, and lower hinge domains.

[0068] As used herein, the term "disulfide bond" includes a covalent bond formed between two sulfur atoms. The amino acid cysteine ​​contains a thiol group that can form a disulfide bond or bridge with another thiol group. In most naturally occurring IgG molecules, the CH1 and CL regions are linked by disulfide bonds, and the two heavy chains are linked by two disulfide bonds at positions corresponding to 239 and 242 (using the Kabat numbering system (positions 226 or 229, EU numbering system)).

[0069] As used herein, a "variant" of an antibody, antibody fragment, or antibody domain refers to an antibody, antibody fragment, or antibody domain that: (1) has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the original antibody, antibody fragment, or antibody domain, and (2) specifically binds to the same target that the original antibody, antibody fragment, or antibody domain specifically binds to. It should be understood that where sequence identity is expressed in the form of "at least x% identical" or "at least x% identical," such embodiments include any and all numerical percentages equal to or above the lower limit. Furthermore, it should be understood that where an amino acid sequence is presented in this application, it should be interpreted as additionally disclosing or encompassing an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to that amino acid sequence.

[0070] As used herein, the phrase "humanized antibody" refers to an antibody derived from a non-human antibody, typically a mouse monoclonal antibody. Alternatively, a humanized antibody can be derived from a chimeric antibody that retains or substantially retains the antigen-binding properties of the parent non-human antibody but exhibits reduced immunogenicity when administered to humans compared to the parent antibody.

[0071] As used herein, the phrase "chimeric antibody" refers to an antibody in which the immunoreactive region or site is obtained or derived from a first species and the constant region (which may be complete, partial or modified according to the present disclosure) is obtained from a second species. In certain embodiments, the target binding region or site will be from a non-human source (e.g., mouse or primate) and the constant region is human.

[0072] Included within the scope of the multispecific antibodies of the present application are various compositions and methods, including asymmetric IgG-like antibodies (e.g., triomab / quadroma, TrionPharma / Fresenius Biotech); knobs-into-holes antibodies (Genentech); Cross MAb (Roche); electrostatically matched antibodies (AMGEN); LUZ-Y (Genentech); chain exchange engineered domain (SEED) bodies (EMD Serono; Biolononic, Merus); Fab exchange antibodies (Genmab), symmetric IgG-like antibodies (e.g., dual targeting (DT)-Ig (GSK / Domantis); two-in-one antibodies (Genentech); cross-linked monoclonal antibodies (Karmanos Cancer Center), mAb2 (F-star); Cov X-body (Cov X / Pfizer); dual variable domain (DVD)-Ig fusion protein (Abbott); IgG-like bispecific antibody (Eli Lilly); Ts2Ab (Medimmune / AZ); BsAb (ZymoGenetics); HERCULES (Biogen Idec, TvAb, Roche); scFv / Fc fusion; SCORPION (Emergent BioSolutions / Trubion, ZymoGenetics / BMS); dual affinity repositioning technology (Fc-DART), MacroGenics; bis(scFv)2-Fabs (National Research Center for Antibody Medicine) Medicine); F(ab)2 fusion proteins (Medarex / AMGEN); bi-acting or Bis-Fab (Genentech); Dock-and-Lock (DNL, ImmunoMedics); Fab-Fv (UCB-Celltech); scFv-based antibodies and diabody-based antibodies (e.g., bispecific T cell engagers (BiTEs, Micromet); tandem diabodies (Tandab, Affimed); DARTs (MacroGenics); single-chain diabodies; TCR-like antibodies (AIT, Receptor Logics);Human serum albumin scFv fusion protein (Merrimack), COMBODIES (Epigen Biotech) and IgG / no n-IgG fusion proteins (e.g., immunocytokines (EMDSerono, Philogen, ImmunGene, ImmunoMedics)).

[0073] "Specific binding" or "having specificity" generally refers to the binding of an antibody to an epitope through its antigen binding domain, and binding requires a certain complementarity between the antigen binding domain and the epitope. According to this definition, an antibody is said to "specifically bind" to an epitope when it binds to the epitope more easily through its antigen binding domain than to a random, unrelated epitope. The term "specificity" is used herein to qualify the relative affinity with which an antibody binds to an epitope. For example, antibody "A" can be considered to have a higher specificity for a given epitope than antibody "B", or it can be said that antibody "A" binds to epitope "C" with a higher specificity than to a related epitope "D". In some embodiments, an antibody or antibody fragment is considered to bind to an antigen with an (IQ) equal to or less than 10 -6 M, equal to or less than 10 -7 M, equal to or less than 10 -8 M, equal to or less than 10 -9 M or equal to or less than 10 -10 The dissociation constant (K d ) form a complex, then the antibody or antibody fragment is "specific" for the antigen.

[0074] The term "immune checkpoint modulator" refers to a functional class of agents that inhibit or stimulate signaling through immune checkpoints. "Immune checkpoint modulators" include receptors and their associated ligands, which together provide signal transduction pathways associated with the inhibition or stimulation of T cell activation. Immune checkpoint modulators, which are cell surface receptors, are typically members of the TNF receptor or B7 superfamily that can induce checkpoint signaling pathways to inhibit immune responses, including agents that bind to negative co-stimulatory molecules, including but not limited to PD-1, TIGIT, LAG-3, TIM-3, BTLA, VISTA, CTLA-4, and their respective ligands.

[0075] The terms "immune checkpoint modulator antagonist," "immune checkpoint binding antagonist," and "immune checkpoint antagonist" are used interchangeably herein and refer to a class of agents that interfere with (or inhibit) the activity of immune checkpoint modulators, whereby, as a result of binding to the checkpoint modulator or its ligand, signaling through the checkpoint modulator receptor is blocked or inhibited. By inhibiting this signaling, immunosuppression can be reversed, thereby reestablishing or enhancing T cell immunity against cancer cells. Exemplary immune checkpoint antagonists include, but are not limited to, PD-1 and its ligands PD-L1 and PD-L2; TIGIT and its CD 155 ligand PVR; LAG-3 and its ligands, including liver sinusoidal endothelial cell lectin (LSECtin) and galectin-3; CTLA-4 and its ligands B7-1 and B7-2; TIM-3 and its ligand galectin-9; CD122 and its CD122R ligand; CD70, B7H3, B and T lymphocyte attenuating agent (BTLA) and VISTA. Immune checkpoint regulator antagonists may include antibody fragments, peptide inhibitors, dominant negative peptides, and small molecule drugs, which may be in isolated form or as part of a fusion protein or conjugate.

[0076] The terms "immune checkpoint binding agonist" and "immune checkpoint agonist" are used interchangeably herein and refer to a class of agents that stimulate the activity of immune checkpoint regulators, whereby signaling through checkpoint regulator receptors is stimulated due to binding to the checkpoint regulator or its ligand. By stimulating this signaling, T cell immunity against cancer cells can be reestablished or enhanced. Exemplary immune checkpoint regulator agonists include, but are not limited to, members of the tumor necrosis factor (TNF) receptor superfamily, such as CD27, CD40, OX40 (CD134), glucocorticoid-induced TNFR family-related protein (GITR) and 4-1BB (CD137) and their ligands. Other checkpoint regulator agonists belong to the B7-CD28 superfamily, including CD28 and ICOS. Immune checkpoint regulators can include antibody fragments, peptide inhibitors, dominant negative peptides and small molecule drugs, which can be in isolated form or as part of a fusion protein or conjugate.

[0077] The term "antagonist antibody" refers to an antibody that binds to a target and prevents or reduces the biological effect of the target. In some embodiments, the term can refer to an antibody that prevents the target to which it binds, such as PD-1, from performing a biological function.

[0078] As used herein, "anti-PD-1 antagonist antibody" refers to an antibody that is capable of inhibiting PD-1 biological activity and / or one or more downstream events mediated by PD-1. Anti-PD-1 antagonist antibodies include antibodies that block, antagonize, inhibit or reduce (including significantly reduce to any extent) PD-1 biological activity (including PD-1-mediated downstream events, such as PD-1 binding and downstream signaling, inhibition), inhibition of T cell proliferation, inhibition of T cell activation, inhibition of IFN secretion, inhibition of IL-2 secretion, inhibition of TNF secretion, induction of IL-10, and inhibition of anti-tumor immune response. For the purposes of the present invention, it will be expressly understood that the term "anti-PD-1 antagonist antibody" (interchangeably referred to as "antagonist PD-1 antibody", "antagonist anti-PD-1 antibody" or "PD-1 antagonist antibody") includes all previously defined terms, titles, functional states and characteristics, thereby substantially inactivating, reducing or neutralizing PD-1 itself, the biological activity of PD-1, or the consequences of biological activity to any meaningful extent. In some embodiments, the anti-PD-1 antagonist antibody binds to PD-1 and upregulates an anti-tumor immune response.

[0079] As used herein, "anti-PD-L1 antagonist antibodies" refer to antibodies that can inhibit the biological activity of PD-L1 and / or one or more downstream events mediated by PD-L1. Anti-PD-L1 antagonist antibodies include antibodies that block, antagonize, inhibit or reduce (to any extent, including a significant extent) the biological activity of PD-L1, including downstream events mediated by PD-L1, such as PD-L1 binding and downstream signaling, inhibition of T cell proliferation, inhibition of T cell activation, inhibition of IFN secretion, inhibition of IL-2 secretion, inhibition of TNF secretion, induction of IL-10, and inhibition of anti-tumor immune responses. For purposes of the present invention, it will be expressly understood that the term "anti-PD-L1 antagonist" (interchangeably referred to as "antagonist PD-L1 antibody," "antagonist anti-PD-L1 antibody," or "PD-L1 antagonist antibody") encompasses all previously identified terms, titles, functional states, and characteristics that substantially inactivate, reduce, or neutralize, to any meaningful extent, PD-L1 itself, the biological activity of PD-L1, or the consequences of biological activity. The anti-PD-L1 antagonist antibody is designed to bind to PD-L1 and upregulate an anti-tumor immune response.

[0080] The phrase "dominant negative protein" or "dominant negative peptide" refers to a protein or peptide derived from a wild-type protein that has been genetically modified by mutation and / or deletion such that the modified protein or peptide interferes with the function of the endogenous wild-type protein from which it is derived.

[0081] The phrase "VEGF binding antagonist" refers to a functional class of agents that bind to VEGF-A or its receptor VEGFR-2, thereby blocking or inhibiting the activation of VEGFR-2 by VEGF-A due to the binding. As used herein, the term "VEGF binding antagonist" includes antibody fragments, peptide inhibitors, dominant negative peptides, and small molecule drugs, which can be in isolated form or as part of a fusion protein or conjugate.

[0082] The term "Tie2 tyrosine kinase receptor binding antagonist" refers to a functional agent that binds to the Tie2 tyrosine kinase receptor or one of its ligands. Due to the binding, the activation of the Tie2 tyrosine kinase receptor by one or more of its ligands (i.e., Ang1, Ang2, Ang3, and Ang4) is blocked or inhibited. As used herein, the term "Tie2 tyrosine kinase receptor binding antagonist" includes antibody fragments, peptide inhibitors, dominant negative peptides, and small molecule drugs, which can be in isolated form or as part of a fusion protein or conjugate.

[0083] The phrase "small molecule drug" refers to a molecular entity that is typically organic or organometallic, but not a polymer, that is pharmaceutically active, and that has a molecular weight of less than about 2 kDa, less than about 1 kDa, less than about 900 Da, less than about 800 Da, or less than about 700 Da. The term encompasses most pharmaceutical compounds referred to as "drugs" other than proteins or nucleic acids, although small peptides or nucleic acid analogs may also be considered small molecule drugs. Examples include chemotherapeutic anticancer drugs and enzyme inhibitors. Small molecule drugs can be synthetic, semisynthetic (i.e., synthesized from naturally occurring precursors), or biological in origin.

[0084] When polypeptide domain arrangements are described with hyphens between the various domains (eg, CH2-CH3), it is understood that the order in which the domains are listed is from amino-terminus to carboxyl-terminus.

[0085] The term "immunoconjugate" refers to an antibody fused to an inhibitory peptide or small molecule drug via a covalent bond. The peptide or small molecule drug can be linked to the C-terminus of the constant heavy chain or the N-terminus of the variable light chain and / or heavy chain.

[0086] "Linkers" can be used to connect peptides or small molecule drugs such as maytansinoid to anti-tumor antagonists in a stable covalent manner. Under conditions where the compound or antibody remains active, the linker can be sensitive to or substantially tolerate acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage. Suitable linkers are well known in the art and include, for example, disulfide groups, thioether groups, acid-labile groups, light-labile groups, peptidase-labile groups, and esterase-labile groups. Linkers also include GGGGS, charged linkers, and hydrophilic forms thereof, as described herein and known in the art. The immunoconjugate may further include a flexible 3-15 amino acid peptide (or spacer) between the anti-tumor antagonist and the peptide and / or small molecule drug. In some embodiments, the linker comprises 3, 4, 5, 6, 7, or 8 repeats of GGGGS. In some embodiments, the linker is composed of 3 or 4 repeats of GGGGS.

[0087] As used herein, the term "immunoglobulin scaffold" refers to any amino acid polymer that exhibits desired properties that support antagonist function, including increasing antibody specificity, enhancing antibody function, or supporting antibody structure and stability. The immunoglobulin scaffold can have one or more immunoglobulin constant regions, including CH1, CH2, and / or CH3 regions from an immunoglobulin heavy chain and / or CL regions from an immunoglobulin light chain. The immunoglobulin scaffold can be grafted with the binding domain of a donor polypeptide to impart binding specificity to the donor polypeptide on the scaffold.

[0088] As used herein, the phrase "multispecific inhibitor" refers to a molecule comprising at least two targeting domains with different binding specificities. In some embodiments, a multispecific inhibitor is a polypeptide comprising a scaffold and two or more immunoglobulin antigen binding domains that target different antigens or epitopes. In certain embodiments, a multispecific inhibitor is a bispecific antibody or antagonist. In other embodiments, a multispecific inhibitor is a trispecific antibody or antagonist.

[0089] As used herein, the phrase "bispecific" refers to a molecule comprising at least two targeting domains with different binding specificities. Each targeting domain is capable of specifically binding to a target molecule and inhibiting the biological function of the target molecule when bound to the target molecule. In some embodiments, a bispecific checkpoint regulator antagonist is a polymer molecule having two or more peptides. In some embodiments, the targeting domain comprises an antigen-binding domain or CDR of an antibody. In some embodiments, a bispecific inhibitor is a bispecific antibody.

[0090] The terms "bispecific antibody" and "bispecific antagonist" are used interchangeably herein and refer to antibodies that can specifically bind to two different antigens (or epitopes). In some embodiments, a bispecific antibody is a full-length antibody that binds to one antigen (or epitope) on one of its two binding arms (a pair of HC / LC) and binds to a different antigen (or epitope) on its second arm (another pair of HC / LC). In these embodiments, the bispecific antibody has two different antigen-binding arms (both in specificity and CDR sequences) and is monovalent for each antigen to which it binds.

[0091] In other embodiments, bispecific antibodies are full-length antibodies that can bind to two different antigens (or epitopes) in each of their two binding arms (two pairs of HC / LC). In these embodiments, the bispecific antibodies have two identical antigen-binding arms with the same specificity and the same CDR sequences, and are bivalent for each antigen to which they bind.

[0092] Exemplary bispecific antibodies can include asymmetric IgG-like antibodies (e.g., triomab / quadroma, Trion Pharma / Fresenius Biotech); buttonhole antibodies (Genentech); crossover monoclonal antibodies (Roche); electrostatic matching antibodies (AMGEN); LUZ-Y (Genentech); chain exchange engineered domain (SEED) bodies (EMD Serono; biolonic, Merus); Fab exchange antibodies (Genmab), symmetrical IgG-like antibodies (e.g., dual targeting (DT)-Ig (GSK / Domantis); two-in-one antibodies (Genentech); cross-linked monoclonal antibodies (Karmanos Cancer Center), mAb2 (F-star); Cov X-body (Cov X / Pfizer); dual variable region domain (DVD)-Ig fusion protein (Abbott); IgG-like bispecific antibodies (Eli Lilly); Ts2Ab (Medimmune / AZ); BsAb (ZymoGenetics); HERCULES (Biogen Idec, TvAb, Roche); scFv / Fc fusion protein; SCORPION (Emergent BioSolutions / Trubion, ZymoGenetics / BMS); dual affinity redirection technology (Fc-DART), MacroGenics; bis(scFv)2-Fabs (National Center for Antibody Medicine); F(ab)2 fusion proteins (Medarex / AMGEN); dual-action or Bis-Fab (Genentech); dock-and-lock (DNL, ImmunoMedics); Fab-Fv (UCB-Celltech); scFv-based antibodies and diabody-based antibodies (e.g., bispecific T cell engagers (BiTEs, Micromet); tandem diabodies (Tandab, Affimed); DARTs (MacroGenics); single-chain diabodies; TCR-like antibodies (AIT, ReceptorLogics); human serum albumin scFv fusion proteins (Merrimack); combodies (Epigen Biotech); and IgG / non-IgG fusion proteins (e.g., immunocytokines) (EMDSerono, Philogen, ImmunGene, ImmunoMedics).

[0093] The terms "treat" and "treatment" refer to alleviating one or more symptoms associated with a cell proliferative disorder; preventing or delaying the onset of one or more symptoms of a cell proliferative disorder; and / or reducing the severity or frequency of one or more symptoms of a cell proliferative disorder.

[0094] The phrases "a patient in need thereof," "a patient in need of treatment," or "a subject in need of treatment" include subjects, such as mammalian subjects, who would benefit from administration of an anti-tumor antagonist of the present disclosure for treating a cell proliferative disorder.

[0095] The terms "therapeutically effective amount," "pharmacologically effective amount," and "physiologically effective amount" are used interchangeably and refer to the amount of an anti-tumor antagonist required to provide a threshold level of active antagonist in the bloodstream or in the target tissue. The precise amount will depend on many factors, such as the specific active agent, the components and physical properties of the composition, the intended patient population, patient considerations, etc., and can be readily determined by one skilled in the art based on the information provided herein or other information provided in the relevant literature.

[0096] As used herein, the terms "improve," "increase," or "decrease" refer to a value or parameter measured relative to a baseline, e.g., measurement in the same individual before starting a treatment described herein or measurement in a control individual (or multiple control individuals) in the absence of a treatment described herein.

[0097] A "control individual" is an individual who has the same cell proliferative disorder as the individual being treated and is of the same age as the individual being treated to ensure that the disease stages of the treated individual and the control individual are comparable. The individual being treated (also referred to as a "patient" or "subject") can be a fetus, infant, child, adolescent, or adult with a cell proliferative disorder.

[0098] The term "cell proliferative disorder" refers to a disease characterized by abnormal cell proliferation. A proliferative disorder does not imply any restriction on the rate of cell growth, but rather a loss of normal controls that influence growth and cell division. Thus, in some embodiments, cells of a proliferative disorder may have the same cell division rate as normal cells, but do not respond to signals that restrict such growth. Included within the scope of a "cell proliferative disorder" are neoplasms, cancers, or tumors.

[0099] The term "cancer" or "tumor" refers to any of a variety of malignancies characterized by proliferating cells that have the ability to invade surrounding tissues and / or metastasize to new colonization sites, and includes leukemias, lymphomas, carcinomas, melanomas, sarcomas, germ cell tumors, and blastomas. Exemplary cancers treated with the methods of the present disclosure include brain cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, head and neck cancer, kidney cancer, lung cancer, non-small cell lung cancer, mesothelioma, ovarian cancer, prostate cancer, gastric cancer, and uterine cancer, leukemia, and medulloblastoma.

[0100] The term "leukemia" refers to a progressive malignant disease of the blood-forming organs and is generally characterized by abnormal proliferation and development of white blood cells and their precursors in the blood and bone marrow. Exemplary leukemias include, for example, acute non-lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, leukocytic leukemia, basophilic leukemia, blast cell leukemia, bovine leukemia, chronic myeloid leukemia, corneal leukemia, embryonic leukemia, eosinophilic leukemia, Gross's leukemia, hairy cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, and leukemia of the genotype. leukemia), histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphoid leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenic leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myeloid granulocytic leukemia leukemia, myelomonocytic leukemia, Negley's leukemia, plasma cell leukemia, plasma cell leukemia, promyelocytic leukemia, Liddle's cell leukemia, Schilling's leukemia, stem cell leukemia, subleukemia and undifferentiated cell leukemia.

[0101] The term "carcinoma" refers to a malignant growth of epithelial cells that readily infiltrates surrounding tissues and causes metastasis. Exemplary carcinomas include, for example, acinar carcinoma, acinar carcinoma, adenoid cystic carcinoma, adenoma carcinoma, adrenocortical carcinoma, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basement membrane carcinoma, basosquamous carcinoma, bronchoalveolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocarcinoma, choriocarcinoma, colloid carcinoma, comedo carcinoma, body carcinoma, cribriform carcinoma, armor carcinoma, cutaneous carcinoma, cylindrical carcinoma, cylindrical cell carcinoma, ductal carcinoma, dural carcinoma, embryonal carcinoma, cerebriform carcinoma, epithelial carcinoma, epithelial gland carcinoma, exophytic carcinoma, ulcerative carcinoma, fibroma, gelatinous carcinoma, colloid carcinoma, giant cell carcinoma, glandular carcinoma, carcinoma, adenocarcinoma, granular cell carcinoma, pilomatric carcinoma, hemorrhoidal carcinoma, hepatocellular carcinoma, Hürthle cell carcinoma, hyaline membrane carcinoma, herpetiform carcinoma, infantile embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Crompton's carcinoma, Kurtzky cell carcinoma, large cell carcinoma, enticular carcinoma, lenticular carcinoma, lipomatous carcinoma, lymphoepithelial carcinoma, medullary carcinoma, melanoma carcinoma, nevus carcinoma, mucinous carcinoma, mucinous carcinoma, mucous cell carcinoma, mucoepidermoid carcinoma, mucinous carcinoma, mucinous carcinoma muciparum), mucinous carcinoma (carcinomamucocellulare), nasopharyngeal carcinoma, oat cell carcinoma, ossifying carcinoma, osteoid carcinoma, papillary carcinoma, portal vein carcinoma, preinvasive carcinoma, prick cell carcinoma, pustular carcinoma, renal cell carcinoma of the kidney, reserve cell carcinoma, sarcomatous carcinoma, Schneider's carcinoma, sclerosing carcinoma, scrotal carcinoma, signet ring cell carcinoma, simple carcinoma, small cell carcinoma, eggplant-shaped carcinoma, spheroid cell carcinoma, spindle cell carcinoma, cavernous carcinoma, squamous cell carcinoma, squamous cell carcinoma, linear carcinoma, telangiectatic carcinoma, telangiectatic carcinoma, transitional cell carcinoma, nodular carcinoma, tuberous carcinoma, verrucous carcinoma, and villous carcinoma.

[0102] The term "sarcoma" refers to tumors composed of material similar to embryonic connective tissue and usually consists of tightly packed cells embedded in a fibrous or homogeneous substance. Exemplary sarcomas include, for example, chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, green algal sarcoma, choriocarcinoma, embryonal sarcoma, Wilns tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic polychromatic hemorrhagic sarcoma, B-cell immunoblastic sarcoma, lymphoma (e.g., lymphoma), Janssen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukocytic sarcoma, malignant mesothelioma sarcoma, peritoneal sarcoma, reticulum cell sarcoma, Rous sarcoma, serous sarcoma, and synovial sarcoma.

[0103] The term "melanoma" refers to tumors of the melanocyte system of the skin and other organs. Melanomas include, for example, horn melanoma, enamel melanoma, benign juvenile melanoma, Cloudman melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, tonsillar melanoma, malignant melanoma, nodular melanoma, sublingual melanoma, and superficial melanoma.

[0104] Other cancers include, for example, Hodgkin's disease, multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, lung cancer, rhabdomyosarcoma, essential thrombocythemia, essential macroglobulinemia, small cell lung cancer, primary brain tumors, gastric cancer, colon cancer, malignant pancreatic insulinoma, malignant carcinoid, premalignant skin lesions, testicular cancer, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, hypercalcemia of malignancy, cervical cancer, endometrial cancer, and adrenocortical carcinoma.

[0105] I. Bispecific antagonists targeting TGF-β

[0106] TGF-β is considered to be the main cytokine that mediates immunosuppression by inducing and maintaining T regulatory cells and directly inhibiting innate and acquired immune cells (such as NK, DC and T cells). TGF-β also plays a role in the following aspects: neoangiogenesis and stabilization of tumor blood vessels and directly affecting tumors through epithelial-mesenchymal transition, leading to cell migration and invasion. As a potent inducer of angiogenesis, TGF-β provides a critical support system for solid tumors and plays an important role in tumor cell dissemination. Therefore, TGF-β status is a powerful predictor of anti-PD1 / PD-L1 resistance and overall survival of various tumors.

[0107] Many cells synthesize TGF-β, and almost all cells have specific receptors for these peptides. TGF-β1, TGF-β2, and TGF-β3 all act through the same receptor signal transduction system. The active form of TGF-β is a dimer that signals by forming a membrane-bound heterotetramer (composed of type 1 and type 2 serine-threonine receptors TGF-βRI and TGFβRII, respectively). Recently, TGF-β pathway inhibitors have been developed, such as antibodies or binding fragments directed against TGF-β1 or TGF-β1 RII, such as dominant-negative fusion protein fragments containing the extracellular domain (ECD) of TGF-β1 RII.

[0108] In one aspect, the present application provides bispecific antagonists that simultaneously inhibit the TGFβ pathway and the PD-1 / PD-L1 checkpoint regulator pathway.

[0109] In another aspect, the present application provides bispecific antagonists that simultaneously inhibit the TGFβ pathway and the vascular endothelial growth factor (VEGF) pathway, vascular endothelial growth factor receptor (VEGFR), or both.

[0110] A. Bispecific antagonists targeting TGF-β and PD-1 / PD-L1 pathways

[0111] In some embodiments, the bispecific antagonist comprises a first targeting domain that specifically inhibits the TGF-β pathway and a second targeting domain that specifically binds to PD-1 or PD-L1. In some embodiments, the first targeting domain comprises a TGF-β pathway inhibitor.

[0112] TGF-β pathway inhibitors

[0113] The TGF-β pathway involves a multifunctional peptide group that controls cell proliferation and differentiation, migration and adhesion, extracellular matrix modification (including tumor stroma and immunosuppression), angiogenesis and fibrosis (desmoplasia), apoptosis, and other functions in many cell types. TGF-β is considered to be the main cytokine that mediates immunosuppression by inducing and maintaining T regulatory cells and directly inhibiting innate and acquired immune cells such as NK, DC and T cells. TGFB also plays a role in neoangiogenesis and stabilization of tumor blood vessels, as well as directly leading to tumorigenesis through epithelial-mesenchymal transition, leading to cell migration and invasion. As a potent inducer of angiogenesis, TGF-β1 provides a key support system for solid tumors and a mechanism for the spread of tumor cells.

[0114] For many cancers, TGF-β status is a strong predictor of resistance to anti-PD1 / PD-L1 and overall survival. For example, high TGF-β1 levels are associated with poor response to PD1 / PD-L1 inhibition in patients with metastatic urothelial carcinoma (Nature (2018) 554(7693): 544-548), and high TGF-β signaling is associated with poor prognosis in 33 different types of cancer (Immunity (2018) 48: 812-830). Inhibiting TGFβ with anti-PD1 / PD-L1 further releases CD8 effectors to kill tumor cells and stimulates other cell types to increase tumor killing capacity.

[0115] Many cells synthesize TGF-β, and nearly all possess specific receptors for these peptides. TGF-β1, TGF-β2, and TGF-β3 all act through the same receptor signaling system. The active form of TGF-β is a dimer that signals by forming a membrane-bound heterotetramer composed of the serine-threonine type 1 and type 2 receptors, TGF-βRI and TGF-RII, respectively.

[0116] As used herein, a TGF-β pathway inhibitor can be in the form of, for example, an antibody or variable region domain fragment directed against TGF-β1, or TGF-β1 RII, a TGF-binding peptide, or a dominant negative fusion protein fragment such as the extracellular domain (ECD) of TGF-β1 RII.

[0117] TGF-β1 RII ECD

[0118] In some embodiments, the TGF-β pathway inhibitor comprises TGF-βRII ECD. An exemplary human TGF-β1RII ECD (wild type) has the amino acid sequence set forth in SEQ ID NO:89.

[0119] In some embodiments, a TGF-β pathway inhibitor is fused to the carboxyl terminus of an IgG in a bispecific anti-tumor antagonist, such as Figures 5A-5B and Figures 8A-8C Alternatively, the TGF-β1 RII ECD can be fused to the amino terminus of the IgG in a bispecific anti-tumor antagonist. In other embodiments, the TGF-β1 RII ECD is inserted into the IgG Fc receptor (i.e., the CH2 or CH3 region) of the IgG, as shown. Figure 5B shown.

[0120] In some embodiments, an anti-TGF-β1, anti-TGF-β1 RII antibody, or a variable region fragment thereof, can be used in place of the TGF-β1 RII ECD. Exemplary anti-TGF-β1 antibodies are described in U.S. Patent Nos. 7,067,637, 7,494,651, 7,527,791, and 7,619,069. Exemplary anti-TGF-β1 RII antibodies are described in U.S. Patent No. 7,579,186. Alternatively, the TGF-β1 RII ECD can be replaced by one or more anti-TGF-β1 and / or anti-TGF-β1 RII peptide inhibitors. An exemplary TGF-β1 peptide inhibitor is KRIWFIPRSSWYERA (SEQ ID NO: 111).

[0121] Anti-PD-1 antibodies and anti-PD-1 antibody fragments

[0122] In some embodiments, the bispecific TGFβ pathway antagonist comprises an anti-PD-1 antibody or antibody fragment. In one embodiment, the PD-1 inhibitor used in the present application is an antibody or an antigen-binding portion thereof comprising: an immunoglobulin heavy chain complementary determining region 1 (CDR1) sequence selected from SEQ ID NOs: 1, 4, 7, 9, and 12; an immunoglobulin heavy chain CDR2 sequence selected from SEQ ID NOs: 2, 5, 10, and 13; an immunoglobulin heavy chain CDR3 sequence selected from SEQ ID NOs: 3, 6, 8, 11, and 14; an immunoglobulin light chain CDR1 sequence selected from SEQ ID NOs: 15, 18, 21-23, and 26; an immunoglobulin light chain CDR2 sequence selected from SEQ ID NOs: 16, 19, 24, and 27; or an immunoglobulin light chain CDR3 sequence selected from SEQ ID NOs: 17, 20, 25, and 28.

[0123] In another embodiment, the PD-1 inhibitor used in the present application (as, for example, the second targeting domain) is an antibody, or an antigen-binding portion thereof, comprising: an immunoglobulin heavy chain CDR1 sequence selected from the group consisting of SEQ ID NOs: 1, 4, 7, 9 and 12; an immunoglobulin heavy chain CDR2 sequence selected from the group consisting of SEQ ID NOs: 2, 5, 10 and 13; an immunoglobulin heavy chain CDR3 sequence selected from the group consisting of SEQ ID NOs: 3, 6, 8, 11 and 14; an immunoglobulin light chain CDR1 sequence selected from the group consisting of SEQ ID NOs: 15, 18, 21-23 and 26; an immunoglobulin light chain CDR2 sequence selected from the group consisting of SEQ ID NOs: 16, 19, 24 and 27; and an immunoglobulin light chain CDR3 sequence selected from the group consisting of SEQ ID NOs: 17, 20, 25 and 28.

[0124] In another embodiment, the PD-1 inhibitor used in the present application comprises: an immunoglobulin heavy chain variable region (HCVR) that is at least 80%, 85%, 90%, 95% or 99% identical to a HCVR amino acid sequence selected from SEQ ID NOs: 29, 31, 33, 35, 37 and 39; an immunoglobulin light chain variable region (LCVR) that is at least 80%, 85%, 90%, 95% or 99% identical to a LCVR amino acid sequence selected from SEQ ID NOs: 30, 32, 34, 36, 38 and 40; or both.

[0125] In another embodiment, the PD-1 inhibitor used in the present application comprises: a HCVR amino acid sequence selected from SEQ ID NOs: 29, 31, 33, 35, 37, and 39; a LCVR amino acid sequence selected from SEQ ID NOs: 30, 32, 34, 36, 38, and 40; or both.

[0126] In one embodiment, the PD-1 inhibitor comprises: a HCVR having at least 80%, 85%, 90%, 95%, or 99% identity to the HCVR amino acid sequence of SEQ ID NO: 39; a LCVR having at least 80%, 85%, 90%, 95%, or 99% identity to the LCVR amino acid sequence of SEQ ID NO: 40; or both. In a more specific embodiment, the PD-1 inhibitor has the HCVR sequence of SEQ ID NO: 39; and the LCVR amino acid sequence of SEQ ID NO: 40; or both.

[0127] In another embodiment, the PD-1 inhibitor has an immunoglobulin HCVR comprising: (1) a heavy chain CDR1 of SEQ ID NO: 12, a heavy chain CDR2 of SEQ ID NO: 13, and a heavy chain CDR3 of SEQ ID NO: 14; and (2) a heavy chain framework region (FR) 1 that is at least 80%, 85%, 90%, 95%, or 99% identical to the amino acid sequence of SEQ ID NO: 150, a heavy chain FR2 that is at least 80%, 85%, 90%, 95%, or 99% identical to the amino acid sequence of SEQ ID NO: 144, a HFR3 that is at least 80%, 85%, 90%, 95%, or 99% identical to the amino acid sequence of SEQ ID NO: 155, and a HFR4 that is at least 80%, 85%, or 90% identical to the amino acid sequence of SEQ ID NO: 141, and an immunoglobulin heavy chain variable region comprising: (1) a light chain CDR1 of SEQ ID NO: 26, a heavy chain CDR2 of SEQ ID NO: 13, and a heavy chain CDR3 of SEQ ID NO: 14; NO: 27 LCDR2 and SEQ ID NO: 28 LCDR3, and (2) LFR1 having at least 80%, 85%, 90%, 95% or 99% identity with the amino acid sequence set forth in SEQ ID NO: 156, LFR2 having at least 80%, 85%, 90%, 95% or 99% identity with the amino acid sequence set forth in SEQ ID NO: 157, LFR3 having at least 80%, 85%, 90%, 95% or 99% identity with the amino acid sequence set forth in SEQ ID NO: 158, and LFR4 having at least 80%, 85%, 90%, 95% or 99% identity with the amino acid sequence set forth in SEQ ID NO: 159.

[0128] In another embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-1 inhibitor comprising: an immunoglobulin heavy chain having at least 80%, 85%, 90%, 95% or 99% identity to the amino acid sequence set forth in SEQ ID NO: 92 or SEQ ID NO: 106; a light chain having at least 80%, 85%, 90%, 95% or 99% identity to the amino acid sequence set forth in SEQ ID NO: 93; or both. In a more specific embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-1 inhibitor comprising: an immunoglobulin heavy chain having the amino acid sequence set forth in SEQ ID NO: 92 or SEQ ID NO: 106; and an immunoglobulin light chain having the amino acid sequence set forth in SEQ ID NO: 93; or both.

[0129] In another embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-1 inhibitor comprising: an immunoglobulin heavy chain having at least 80%, 85%, 90%, 95% or 99% identity to the amino acid sequence set forth in SEQ ID NO: 94 or SEQ ID NO: 126; an immunoglobulin light chain having at least 80%, 85%, 90%, 95% or 99% identity to the LCVR amino acid sequence of SEQ ID NO: 95; or both. In a more specific embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-1 inhibitor comprising: an immunoglobulin heavy chain having the amino acid sequence set forth in SEQ ID NO: 94 or SEQ ID NO: 126; and an immunoglobulin light chain having the amino acid sequence set forth in SEQ ID NO: 95; or both. In another embodiment, the PD-1 / TGF-β1 anti-tumor antagonist comprises a TGF-β1 RII ECD inserted into the CH3 loop, such as Figure 5B shown.

[0130] In one embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-1 inhibitor comprising: a heavy chain having at least 80%, 85%, 90%, 95%, or 99% identity to the amino acid sequence set forth in SEQ ID NO: 107; a light chain having at least 80%, 85%, 90%, 95%, or 99% identity to the amino acid sequence set forth in SEQ ID NO: 108; or both. In a more specific embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-1 inhibitor comprising: an immunoglobulin heavy chain having the amino acid sequence set forth in SEQ ID NO: 107; an immunoglobulin light chain having the amino acid sequence set forth in SEQ ID NO: 108; or both.

[0131] Other PD-1 targeted antagonists include anti-PD-1 antibodies, such as nivolumab (BMS-936558, MDX-1106, OPDIVO TM ), humanized immunoglobulin G4 (IgG4) mAb (Bristol-Myers Squibb); pembrolizumab (MK-3475, lambrolizumab, KEYTRUDA TM ) (Merck); pidilizumab (CT-011) (Medivation); and AMP-224 (Merck). Anti-PD-1 antibodies are available, for example, from ABCAM (AB137132), BIOLEGEND TM(EH12.2H7, RMP1-14) and AFFYMETRIX EBIOSCIENCE (J105, J116, MIH4) were purchased. Anti-PD-1 targeted anti-tumor antagonists may include HCVR, LCVR and CDRs derived from any anti-PD-1 antibody described herein, including Figure 1 -Those described in 2.

[0132] Anti-PD-L1 antibodies and anti-PD-L1 antibody fragments

[0133] In some embodiments, the bispecific TGF-β1 pathway antagonist further comprises an anti-PD-L1 antibody or antibody fragment. In one embodiment, the PD-L1 inhibitor for use in the present application is an antibody or antigen-binding portion thereof comprising: an immunoglobulin heavy chain CDR1 sequence selected from the group consisting of SEQ ID NOs: 41, 44, 50, and 53; an immunoglobulin heavy chain CDR2 sequence selected from the group consisting of SEQ ID NOs: 42, 45, 47, 49, 51, and 54; an immunoglobulin heavy chain CDR3 sequence selected from the group consisting of SEQ ID NOs: 43, 46, 48, 52, and 55; an immunoglobulin light chain CDR1 sequence selected from the group consisting of SEQ ID NOs: 56, 59, 63, 66, and 69; an immunoglobulin light chain CDR2 sequence selected from the group consisting of SEQ ID NOs: 57, 60, 64, 67, and 70; or an immunoglobulin light chain CDR3 sequence selected from the group consisting of SEQ ID NOs: 58, 61, 62, 65, 68, and 71.

[0134] In another embodiment, the PD-L1 inhibitor for use in the present application (as, for example, the second targeting domain) is an antibody, or an antigen-binding portion thereof, comprising: an immunoglobulin heavy chain CDR1 sequence selected from the group consisting of SEQ ID NOs: 41, 44, 50, and 53; an immunoglobulin heavy chain CDR2 sequence selected from the group consisting of SEQ ID NOs: 42, 45, 47, 49, 51, and 54; an immunoglobulin heavy chain CDR3 sequence selected from the group consisting of SEQ ID NOs: 43, 46, 48, 52, and 55; an immunoglobulin light chain CDR1 sequence selected from the group consisting of SEQ ID NOs: 56, 59, 63, 66, and 69; an immunoglobulin light chain CDR2 sequence selected from the group consisting of SEQ ID NOs: 57, 60, 64, 67, and 70; and an immunoglobulin light chain CDR3 sequence selected from the group consisting of SEQ ID NOs: 58, 61, 62, 65, 68, and 71.

[0135] In another embodiment, the PD-L1 inhibitor for use herein comprises: an immunoglobulin HCVR having at least 80%, 85%, 90%, 95% or 99% identity to a HCVR amino acid sequence selected from the group consisting of SEQ ID NOs: 72, 74, 76, 78, 80, 82, 84 and 86; an immunoglobulin LCVR having at least 80%, 85%, 90%, 95% or 99% identity to a LCVR amino acid sequence selected from the group consisting of SEQ ID NOs: 73, 75, 77, 79, 81, 83, 85 and 87; or both. In another embodiment, the PD-L1 inhibitor for use herein comprises: a HCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 72, 74, 76, 78, 80, 82, 84 and 86; a LCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 73, 75, 77, 79, 81, 83, 85 and 87; or both.

[0136] In one embodiment, the PD-L1 inhibitor comprises: a HCVR having at least 80%, 85%, 90%, 95%, or 99% identity to the HCVR amino acid sequence of SEQ ID NO: 86; a LCVR having at least 80%, 85%, 90%, 95%, or 99% identity to the LCVR amino acid sequence of SEQ ID NO: 87; or both. In a more specific embodiment, the PD-L1 inhibitor comprises: a HCVR having the amino acid sequence set forth in SEQ ID NO: 86; and a LCVR having the amino acid sequence set forth in SEQ ID NO: 87; or both.

[0137] In another embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-L1 inhibitor comprising: an immunoglobulin heavy chain having at least 80%, 85%, 90%, 95%, or 99% identity to the amino acid sequence set forth in SEQ ID NO: 94 or SQ ID NO: 126; an immunoglobulin light chain having at least 80%, 85%, 90%, 95%, or 99% identity to the amino acid sequence set forth in SEQ ID NO: 95; or both. In a more specific embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-L1 inhibitor comprising: an immunoglobulin heavy chain having the amino acid sequence set forth in SEQ ID NO: 94 or SQ ID NO: 126; an immunoglobulin light chain having the amino acid sequence set forth in SEQ ID NO: 95; or both.

[0138] In another embodiment, the PD-L1 / TGF-β1 anti-tumor antagonist comprises a TGF-β1RII ECD inserted into the CH3 loop, such as Figure 5B shown.

[0139] In a specific embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-L1 inhibitor comprising: an immunoglobulin heavy chain having at least 80%, 85%, 90%, 95%, or 99% identity to the amino acid sequence set forth in SEQ ID NO: 109; an immunoglobulin light chain having at least 80%, 85%, 90%, 95%, or 99% identity to the amino acid sequence set forth in SEQ ID NO: 110; or both. In a more specific embodiment, the TGF-β1 anti-tumor antagonist comprises a PD-L1 inhibitor comprising: an immunoglobulin heavy chain having the amino acid sequence set forth in SEQ ID NO: 109; an immunoglobulin light chain having the amino acid sequence set forth in SEQ ID NO: 110; or both.

[0140] Other anti-PD-L1 targeted antagonists include anti-PD-L1 antibodies, such as atezolizumab (MPDL3280A, RG7446), a fully human IgG4 mAb Genentech / Roche); BMS-936559 (MDX-1105), a fully human IgG4 mAb (Bristol-Myers Squibb); MEDI4736, a humanized IgG antibody (Medimmune / AstraZeneca); and MSB0010718C, a fully human IgG4 monoclonal antibody (Merck, EMD Serono). Anti-PD-L1 targeted anti-tumor antagonists may include HCVRs, LCVRs, and CDRs derived from any of the anti-PD-L1 antibodies described herein, including Figure 3 -Those described in 4.

[0141] B. Bispecific Antagonists Targeting TGF-β1 and One or More Angiogenic Pathways

[0142] In another aspect, the bispecific anti-tumor antagonist of the present application comprises a first targeting domain that specifically binds to TGFβ1 or TGFβ1 RII and a second targeting domain that specifically binds to VEGF-A, VEGFR, Ang1, Ang2, Tie2R, or a combination thereof. In these embodiments, any of the above-mentioned TGF-β1 binding fragments or TGFβ1 RII binding fragments can be used in combination with the second targeting domain.

[0143] Angiogenesis pathway

[0144] Angiogenesis is the formation of new blood vessels from pre-existing blood vessels and is crucial for tumor growth and metastasis. Angiogenesis inhibition provides a potentially valuable strategy for treating diseases (e.g., cancer) where disease progression (e.g., metastasis) depends on new blood vessel formation. Inhibition of angiogenesis leads to tumor cell death, which may allow tumor antigens to be delivered to host antigen presentation pathways. Angiogenesis pathway inhibitors can be in the form of, for example, antibodies, variable region domain fragments, or dominant-negative fusion protein fragments.

[0145] 1. VEGF / VEGFR pathway

[0146] The primary VEGF pathway is mediated by the transmembrane tyrosine kinase VEGF-R2. Various VEGF isoforms, particularly VEGF-A, bind to VEGFR-2, leading to dimerization and activation through phosphorylation by various downstream tyrosine kinases.

[0147] In some embodiments, the antagonists of the present application include VEGF pathway antagonists that bind to VEGF-A or its receptor VEGFR-2, such that, as a result of binding, activation of VEGFR-2 by VEGF-A is blocked or inhibited.

[0148] In one embodiment, the TGFβ pathway antagonist further includes a VEGF pathway antagonist in the form of a dominant negative VEGFR antagonist corresponding to the extracellular domain (ECD) of human VEGF receptor 1 or 2. In a specific embodiment, the TGFβ pathway antagonist includes aflibercept (also known as Zaltrap), a recombinant fusion protein comprising the VEGF-A binding portion from the extracellular domain of human VEGF receptors 1 and 2 fused to the Fc portion of human IgG1. The VEGFR ECD, such as aflibercept, acts as a soluble receptor decoy for VEGF-A.

[0149] In one embodiment, the bispecific anti-tumor antagonist comprises a first targeting domain comprising a TGFβ pathway inhibitor and a second targeting domain that specifically binds to VEGF-A, wherein the second targeting domain comprises aflipid. A suitable source of aflipid comprises the amino acid sequence set forth in SEQ ID NO: 88. In some embodiments, the bispecific anti-tumor antagonist comprises a modified immunoglobulin heavy chain comprising an amino-terminal aflipid domain linked at the carboxyl terminus to a TGF-β1 RII ECD via an IgG1 or IgG4 Fc receptor (Bi-ZB-1), such as Figure 8CIn one embodiment, the modified immunoglobulin heavy chain has the amino acid sequence shown in SEQ ID NO: 105. Alternatively, the TGF-β1 RII ECD can be located at the amino terminus and the afoptin domain can be located at the carboxyl terminus.

[0150] In another embodiment, TGFβ pathway antagonists also include VEGF pathway antagonists comprising anti-VEGF A or anti-VEGFR-2 variable region sequences, such as those derived from bevacizumab. TM ) is a humanized antibody comprising mutated human IgG1 framework regions (FRs) and antigen-binding complementarity-determining regions from murine anti-hVEGF monoclonal antibody A.4.6.1, which blocks binding of human VEGF-A to VEGFR-2. Approximately 93% of the amino acid sequence of bevacizumab (including most of the framework regions) is derived from human IgG1, and approximately 7% of the sequence is derived from murine antibody A4.6.1. Bevacizumab has a molecular weight of approximately 149,000 daltons and is glycosylated. In one embodiment, the HCVR of bevacizumab used in this application has the amino acid sequence set forth in SEQ ID NO: 90, and the LCVR of bevacizumab has the amino acid sequence set forth in SEQ ID NO: 91.

[0151] In some embodiments, bevacizumab / AVASTIN antibodies or fragments thereof may comprise amino acid substitutions as described in U.S. Patent No. 7,575,893. Exemplary amino acid substitutions include, but are not limited to, E1Q, E6Q, L11V, Q13K, L18V, R19K, A23K, or combinations thereof. In one embodiment, the mutant HCVR of bevacizumab used in the present application has the amino acid sequence set forth in SEQ ID NO: 96, which can be used in combination with the LCVR of SEQ ID NO: 91.

[0152] In one embodiment, the bispecific anti-tumor antagonist comprises a first targeting domain that specifically binds to TGFβ1 (e.g., TGFβ1 RII ECD (or contains an anti-TGFβ1- or anti-TGFβ1 RII variable region domain)) and a second targeting domain that specifically binds to VEGFA or VEGFR2 (e.g., bevacizumab or any other anti-VEGF or anti-VEGFR2 antibody, a variable region fragment thereof, or a functionally active mutant fragment thereof).

[0153] In certain embodiments, the bispecific anti-tumor TGFβ / VEGF-VEGFR2 antagonist comprises an immunoglobulin heavy chain having the amino acid sequence of SEQ ID NO: 102, an immunoglobulin light chain having the amino acid sequence of SEQ ID NO: 103, or both, such as Bi-AB-1 ( Figure 8A ).

[0154] In another embodiment, the bispecific anti-tumor TGF-β antagonist further comprises an immunoglobulin heavy chain having the amino acid sequence shown in SEQ ID NO: 104, an immunoglobulin light chain having the amino acid sequence shown in SEQ ID NO: 103, or both, such as Bi-A1B-1 ( Figure 8B ), which comprises a mutated bevacizumab variable region sequence.

[0155] Additional anti-VEGF or anti-VEGFR antibodies or fragments thereof can be based on ranibizumab (trade name Lucentis TM ), a monoclonal antibody fragment derived from the same parent murine antibody as bevacizumab; the G6 or B20 series antibodies (e.g., G6-23, G6-31, B20-4.1) described in U.S. Publication Nos. 2006 / 0280747, 2007 / 0141065, and / or 2007 / 0020267, and U.S. Patent Nos. 7,297,334, 7,060,269, 6 ,884,879, 6,582,959, 6,703,020; 6,054,297; antibodies described in U.S. Patent Application Publication Nos. US2007 / 059312, US2006 / 009360, US2005 / 0186208, US2003 / 0206899, US2003 / 0190317 and US2003 / 0203409.

[0156] An exemplary anti-VEGFR-2 antibody antagonist is the humanized IgG1 monoclonal antibody Ramucirumab, which binds to the extracellular domain of VEGFR-2, thereby blocking its interaction with VEGF-A. Other anti-VEGFR-2 antibodies are described in U.S. Patent Nos. 7,498,414, 6,448,077, and 6,365,157.

[0157] In some embodiments, the anti-tumor antagonist may further include one or more small molecule antagonists of the VEGF pathway, such as multikinase inhibitors of VEGFR-2, including sunitinib, sorafenib, cediranib, pazopanib, and sinedanib.

[0158] Ang-Tie2R pathway

[0159] In some embodiments, the bispecific antagonist comprises a targeting domain comprising at least one Tie2 receptor binding antagonist. The Tie2 tyrosine kinase receptor binding antagonist binds to the Tie2 tyrosine kinase receptor or one of its ligands (i.e., Ang1, Ang2, Ang3, and Ang4), and thus, due to the binding, activation of the Tie2 tyrosine kinase receptor by one or more of its ligands is blocked or inhibited. Like VEGF, angiopoietin 2 (Ang2) plays a key role in tumor angiogenesis. ANG2 and VEGF can also work together to prevent antigen presentation in dendritic cells and macrophages, enhance Treg accumulation, and inhibit Teff accumulation. It has been previously shown that inhibition of both VEGF and Ang2 can improve survival in the mouse breast cancer model Tg MMTV-PyMT. In addition, the addition of anti-PD1 further improved the response.

[0160] The Tie2 tyrosine kinase receptor binding antagonists used in this application can include antibody fragments, peptide inhibitors, dominant negative peptides, and small molecule drugs in isolated form or as part of a fusion protein or conjugate. In one embodiment, the Tie2 receptor binding antagonist is the inhibitory peptide TBN-P from trebananib. In a specific embodiment, the inhibitory peptide comprises the following amino acid sequence:

[0161] AQQEECEWDPWTCEHMGSGSATGGSGSTASSGSGSATHQEE CEWDPWTCEHMLE (SEQ ID NO: 113). In another embodiment, the Tie2 receptor binding antagonist comprises SEQ ID NO:114.

[0162] Other peptide inhibitors of Tie2 activation (including Ang-2 inhibitors) useful herein include A-11 (Compugen), which comprises the amino acid sequence ETFLSTNKLENQ (SEQ ID NO: 123); CVX-060 peptide

[0163] QK(Ac)YQPLDEK(Ac)DK(OP)TLYDQFMLQQG (SEQ ID NO: 124, Pfizer); CVX-037 peptide (DFB)TNFMPMDDLEK(OP)RLYEQFILQQG (SEQ ID NO: 125, Pfizer); and CGEN-25017 (Compugen). Other peptide inhibitors of Tie2 activation are described in U.S. Patent No. 7,138,370.

[0164] Antibody inhibitors of Tie2 activation (and / or angiopoietin 2) used in the present application include AMG-780 (Amgen), MEDI-3617 (Medlmmune / AstraZeneca), DX-2240 (Dyax / Sanofi-Aventis), REGN-910 (Sanofi / Regeneron), RG7594 (Roche), LC06 (Roche), TAvi6 (Roche), AT-006 (Roche / Affitech). Other Tie2 receptor binding antibody antagonists and their antibody binding sequences are described in U.S. Patent Nos. 7,521,053, 7,658,924, and 8,030,025 and U.S. Patent Application Publication Nos. 2013 / 0078248, 2013 / 0259859, and 2015 / 0197578.

[0165] Tie2 binding antagonists used in the present application may further include small molecule inhibitors CGI-1842 (CGI Pharmaceuticals), LP-590 (Locus Pharmaceuticals), ACTB-1003 (Act Biotech / Bayer AG), CEP-11981 (Cephalon / Teva), MGCD265 (Methylgene), Regorafenib (Bayer), Cabozantinib / XL-184 / BMS-90735l (Exelixis), Foretnib (Exelixis), MGCD-265 (MethylGene Inc.)

[0166] In certain specific embodiments, the bispecific checkpoint regulator antagonist is a full-length antibody that binds to human PD-1 or PD-L1 on one of its two binding arms (the HC / LC pair) and binds to a different antigen (or epitope) on its second arm (the other HC / LC pair). In these embodiments, the bispecific antibody has two different antigen-binding arms (in specificity and CDR sequence) and is monovalent for each antigen it binds.

[0167] In some embodiments, the bispecific checkpoint modulator antagonist is a full-length antibody that can bind to human PD-1 and / or PD-L1 in each of its two binding arms (HC / LC pair). In these embodiments, the bispecific checkpoint modulator antagonist has two identical antigen-binding arms with the same specificity and the same CDR sequences and is bivalent for each antigen it binds.

[0168] Immunoglobulin and non-immunoglobulin scaffolds

[0169] The bispecific anti-tumor antagonists of the present application can be constructed with an immunoglobulin skeleton or a non-immunoglobulin scaffold as described herein. In some embodiments, the bispecific antagonist framework of the present invention is constructed with an immunoglobulin scaffold, such as an IgG1, IgG2 or IgG4 scaffold comprising a CH1, CH2 and / or CH3 domain. The use of the IgG1 skeleton is preferred for cancer therapy, where the target is present on antigen-presenting cells that can mediate antibody-dependent cell-mediated cytotoxicity (ADCC). The use of the IgG4 skeleton can allow for targeted antigens, where antigen binding alone is sufficient to produce the desired therapeutic benefit. Antagonists based on IgG4 exclude undesirable effector functions associated with, for example, IgG1 antibodies, including FcγR binding and complement activation.

[0170] Preferably, the first and second targeting domains are present in a humanized IgG1 or IgG4 scaffold. In addition, the second targeting domain can be fused to the carboxyl terminus of the IgG1 or IgG4 scaffold. In addition, the IgG1 or IgG4 scaffold can have an N297A or K447A amino acid substitution. In some embodiments, the first targeting domain can comprise one or more framework regions comprising one or more amino acid substitutions selected from E1Q, E6Q, L11V, Q13K, L18V, R19K, A23K, or any combination thereof. In other embodiments, one or more amino acid residues in the IgG1 or IgG4 scaffold are deglycosylated or mutated to produce a glycosylated variant thereof. Exemplary immunoglobulin scaffolds for the bispecific molecules described herein can be selected from SEQ ID NOs: 103, 104, 105, 115-122, and 127-129.

[0171] Any of the antibodies or antagonists can be constructed in the form of a monoclonal antibody, a chimeric antibody, a humanized antibody, a scFv or a multispecific antibody. In addition, any antibody antagonist described herein may include multiple binding specificities targeting PD-1, PD-L1, VEGF, VEGFR, angiopoietin and / or Tie2R. In addition, any antibody antagonist can be engineered to target multiple epitopes in a given target. In addition, in some embodiments, the included checkpoint antagonists and / or angiogenesis specificities can be in the form of dominant negative fusion proteins, such as the extracellular domain (ECD) from the corresponding receptor.

[0172] The HCVRs and LCVRs described herein can be linked to naturally occurring Fc regions or non-naturally occurring or mutated Fc regions, such as an effector-less or largely effector-less Fc (e.g., human IgG2 or IgG4), or, alternatively, a region with enhanced binding to one or more activating Fc receptors (FcγRI, FcγRIIa, or FcγRIIIa) to enhance T cell survival in the tumor environment. reg Consumed Fc. Therefore, in certain embodiments, the anti-PD-1, anti-PD-L1, and / or anti-VEGF, HCVR and LCVR described herein can generally be connected to an Fc comprising one or more modifications to change one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding and / or antigen-dependent cellular cytotoxicity. In addition, the antibodies described herein can be chemically modified (e.g., one or more chemical moieties can be attached to the antibody) or can be modified to change its glycosylation, thereby changing one or more functional properties of the antibody. More specifically, in certain embodiments, the antibodies in the present application may include modifications in the Fc region to produce antibodies with (a) increased or decreased antibody-dependent cell-mediated cytotoxicity (ADCC), (b) increased or decreased complement-mediated cytotoxicity (CDC), (c) increased or decreased affinity for C1q, and / or (d) increased or decreased affinity for Fc receptors (relative to the parent Fc). Such Fc region variants will generally include at least one amino acid modification in the Fc region. Combining amino acid modifications is considered particularly desirable. For example, a variant Fc region may include two, three, four, five, etc. substitutions therein (e.g., in the particular Fc region positions identified herein).

[0173] For uses in which effector functions are completely avoided, for example when antigen binding alone is sufficient to produce the desired therapeutic benefit and effector functions only result in undesirable side effects (or increase the risk of side effects), IgG4 antibodies can be used, or antibodies or fragments thereof lacking an Fc region or substantial fragment can be designed, or the Fc region can be mutated to completely eliminate glycosylation (e.g., N297A). Alternatively, a hybrid construct of human IgG2 (CH1 domain and hinge region) and human IgG4 (CH2 and CH3 domains) can be generated that lacks effector functions, lacks the ability to bind FcγR (e.g., IgG2) and activate complement (e.g., IgG4). When using an IgG4 constant domain, it is generally preferred to include a substitution of S228P, which mimics the hinge sequence in IgG1 and thereby stabilizes the IgG4 molecule, thereby reducing Fab arm exchange between the therapeutic antibody and endogenous IgG4 in the treated patient.

[0174] In certain embodiments, anti-PD-1, anti-PD-L1, anti-VEGF, angiopoietin, and / or anti-Tie2R antibodies or fragments thereof can be modified to increase their biological half-life. Various methods can be used, including, for example, those methods that increase the binding affinity of the Fc region to FcRn. In one embodiment, as described in U.S. Patent Nos. 5,869,046 and 6,121,022, the antibody is changed in the CH1 or CL region to include a salvage receptor binding epitope (salvage receptor binding epitope) intercepted from two loops of the CH2 domain of the Fc region of IgG. The residue numbering in the Fc region is the numbering of the EU index. The sequence variants disclosed herein are provided with reference to the residue numbering, and the amino acid followed by the residue numbering is the natural amino acid that is substituted, optionally, before the position was a natural residue. Where multiple amino acids may be present at a given position, for example, if the sequence between the natural isotypes (isotypes) is different, or if there may be multiple mutations at the position, they are separated by slashes (e.g., "X / Y / Z").

[0175] Exemplary Fc variants that increase binding to FcRn and / or improve pharmacokinetic properties include substitutions at positions 259, 308, and 434, including, for example, 259I, 308F, 428L, 428M, 434S, 434H, 434F, 434Y, and 434M. Other variants that increase Fc binding to FcRn include: 250E, 250Q, 428L, 428F, 250Q / 428L (Hinton et al., 2004, J. Biol. Chem. 279(8):6213-6216, Hinton et al. 2006 Journal of Immunology 176:346-356), 256A, 272A, 305A, 307A, 311A, 312A, 378Q, 380A, 382A, 434A (Shields et al., 2006, J. Biol. Chem. 279(8):6213-6216, Hinton et al. 2006 Journal of Immunology 176:346-356), al. (2001) J. Biol. Chem., 276(9): 6591-6604), 252F, 252Y, 252W, 254T, 256Q, 256E, 256D, 433R, 434F, 434Y, 252Y / 254T / 256E, 433K / 434F / 436H (Dall'Acqua et al. (2002) J. Immunol., 169: 5171-5180, Dall'Acqua et al. (2006) J. Biol. Chem., 281: 23514-23524 and U.S. Patent No. 8,367,805.

[0176] Modification of certain conserved residues in the IgG Fc (I253, H310, Q311, H433, N434), such as the N434A variant (Yeung et al. (2009) J. Immunol. 182:7663), has been proposed as a method to increase FcRn affinity and thereby extend the half-life of antibodies in circulation (WO 98 / 023289). A combined Fc variant comprising M428L and N434S has been shown to increase FcRn binding and extend serum half-life by fivefold (Zalevsky et al. (2010) Nat. Biotechnol. 28:157). A combined Fc variant comprising T307A, E380A, and N434A modifications also extended the half-life of IgG1 antibodies (Petkova et al. (2006) Int. Immunol. 18:1759). In addition, it has been shown that a combination Fc variant comprising M252Y-M428L, M428L-N434H, M428L-N434F, M428L-N434Y, M428L-N434A, M428L-N434M and M428L-N434S can extend half-life (US2006 / 173170). In addition, it has been reported that a combination Fc variant comprising M252Y, S254T and T256E increased half-life by nearly 4-fold (Dall'Acqua et al. (2006) J. Biol. Chem. 281: 23514).

[0177] Homopolymers and heterodimers

[0178] One of the challenges in efficiently generating bispecific antibody formulations involves mispairing of the heavy and light chains when co-expressing chains with different binding specificities. Table 1 lists several amino acid substitutions that can be used to overcome mispairing between heavy chains with different binding specificities, thereby "enhancing" or preferentially promoting proper binding between the desired heavy chains. Any method that prevents or reduces mispairing between heavy chains can be used to prepare bispecific anti-tumor antagonists according to the present invention.

[0179] The "knob-in-hole" (KiH) approach relies on modifying the interface between the two CH3 domains, where most interactions occur. Typically, bulky residues are introduced into the CH3 domain of an antibody heavy chain, acting like a key. A "hole" is formed in the other heavy chain that accommodates the bulky residues, similar to a lock. The resulting heterodimeric Fc portion can be further stabilized by artificial disulfide bonds.

[0180] An alternative approach is based on charged residues with ionic interactions or steric complementarity. This involves modifying the charge polarity in the CH3 interface so that co-expression of electrostatically matched Fc domains supports favorable attractive interactions and heterodimer formation while retaining the hydrophobic core, while unfavorable repulsive charge interactions inhibit homodimerization. See Table 1. The amino acid numbering in Table 1 follows the Kabat numbering scheme and can be applied to the heavy chain amino acid sequences of the antibodies described herein.

[0181] In another approach, the bispecific molecules of the present application can be constructed with a non-immunoglobulin scaffold comprising a leucine zipper (LZ) domain. Leucine zippers are common three-dimensional structural motifs in proteins and are typically part of the DNA binding domain in various transcription factors. A single LZ typically contains 4-5 leucine residues at intervals of approximately 7 residues, forming an amphipathic alpha helix with a hydrophobic region extending along one side. In a specific embodiment, the heterodimeric protein scaffold comprises an LZ from a c-jun transcription factor and an LZ from a c-fos transcription factor. Although it is known that c-jun can form jun-jun homodimers and c-fos cannot form homodimers, the formation of jun-fos heterodimers is more favorable than jun-jun homodimers.

[0182] The leucine zipper domain can replace the CH2-CH3 sequence in the protein scaffold, or it can be placed at the carboxyl termini of the two heavy chains in the bispecific anti-tumor antagonist. In the latter case, a furin protease cleavage site can be introduced between the carboxyl terminus of CH3 and the amino terminus of the leucine zipper. When the heavy and light chains of the bispecific anti-tumor antagonist are co-expressed in an appropriate mammalian cell expression system, furin-mediated cleavage of the leucine zipper after the heterodimerization step can be promoted (see Wranik et al., J. Biol. Chem., 287(5):43331-43339, 2012).

[0183] Table 1

[0184]

[0185] The amino acid numbering in Table 1 follows the Kabat numbering scheme and can be applied to the heavy chain amino acid sequences of the antibodies described herein. The mutations described in Table 1 can be applied to the sequences (published or otherwise) of any immunoglobulin IgG1 heavy chain, as well as other immunoglobulin classes and subclasses (or isotypes) therein.

[0186] When the heavy and light chains of a bispecific antibody are co-expressed, it is also possible that a light chain with one binding specificity may mispair with a heavy chain with the other binding specificity. Therefore, in certain embodiments, portions of the heavy chain, light chain, or both can be modified relative to the "wild-type" antibody chain from which they are derived to prevent or reduce mispairing of the two heavy chain constant regions with each other and mispairing of the light chain constant region with its heavy chain counterpart.

[0187] The light chain mispairing problem can be solved in several ways. In some embodiments, spatial complementary mutations and / or disulfide bonds can be introduced into two VL / VH interfaces. In other embodiments, mutations can be introduced based on ionic or electrostatic interactions. In some embodiments, light chain mispairing can be prevented or reduced by using a first arm having an S183E mutation in the CH1 domain of the heavy chain and an S176K mutation in the CL domain of the light chain. The second arm can include an S183K mutation in the CH1 domain of the heavy chain and an S176E mutation in the CL domain of the light chain. In other embodiments, a "CrossMab" approach is adopted, in which one arm in a bispecific anti-tumor antagonist (e.g., Fab) remains unchanged, but in another arm comprising other binding specificities, one or more domains in the light chain are exchanged (swap) with one or more domains in the heavy chain at the heavy chain: light chain interface.

[0188] Methods, immunoglobulin domain sequences, including specific mutations as described above for preventing mispairing of heavy and light chains are further described in U.S. Patent Application Publication Nos. 2014 / 0243505 and 2013 / 0022601.

[0189] Conjugate

[0190] In certain embodiments, the anti-tumor antagonists of the present application are chemically coupled to one or more peptides and / or small molecule drugs. The peptides or small molecule drugs may be the same or different. The peptides or small molecule drugs may, for example, be linked to reduced SH groups and / or carbohydrate side chains. Methods for preparing covalent or non-covalent conjugates of peptides or small molecule drugs with antibodies are known in the art, and any such known methods may be used.

[0191] In some embodiments, peptide or small molecule drug is attached to the hinge region of the reduced antibody component via disulfide bond formation. Alternatively, heterobifunctional cross-linking agents such as N-succinyl 3-(2-pyridyldithio) propionate (SPDP) can be used to connect such reagents. The general technology for this coupling is well known in the art. In some embodiments, peptide or small molecule drug is coupled through the carbohydrate portion in the antibody Fc region. The carbohydrate group can be used to increase the load of the same reagent combined with the thiol group, or the carbohydrate group can be used to combine different therapeutic agents or diagnostic agents. The method of coupling peptide inhibitors or small molecule drugs to antibodies through the antibody carbohydrate portion is well known to those skilled in the art. For example, in one embodiment, the method includes reacting an antibody component with an oxidized carbohydrate portion with a carrier polymer having at least one free amine function. The reaction produces an initial Schiff base (imine) bond, which can be stabilized by being reduced to a secondary amine to form a final conjugate. Exemplary methods for conjugating small molecule drugs and peptides to antibodies are described in U.S. Patent Publication No. 2014 / 0356385.

[0192] Preferably, the anti-tumor antagonists of the present disclosure retain certain desirable features and pharmacokinetic properties of antibodies, including desirable in vitro and in vivo stability (e.g., individual half-life and half-life stability), efficient delivery to desired target cells, increased affinity for binding partner molecules, desirable antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and reduced renal clearance or excretion. Therefore, consideration of size and the need for specific constant region effector functions can be considered in the design of anti-tumor antagonists.

[0193] The bispecific anti-tumor antagonists described herein can range in size from 50 kD to 300 kD, 50 kD to 250 kD, 60 kD to 250 kD, 80 kDa to 250 kD, 100 kD to 250 kD, 125 kD to 250 kD, 150 kD to 250 kD, 60 kD to 225 kD, 75 kD to 225 kD, 100 kD to 225 kD, 125 kD to 225 kD, 150 kD to 225 kD, 60 kD to 20 kD, 75kD to 200kD, 100kD to 125kD to 200kD, 150kD to 200kD, 60kD to 150kD, 75kD to 150kD, 100kD to 150kD, 60kD to 125kD, 75kD to 125kD, 75kD to 100kD, or any range specified by any combination of all the numbers listed in the above ranges.

[0194] Reagent test kit

[0195] The present application further provides a kit comprising a checkpoint regulator antagonist or anti-tumor antagonist of the present application. In some embodiments, the kit comprises one or more bispecific immune checkpoint regulators containing at least one TGFβ pathway inhibitory domain. In some embodiments, the kit further comprises other reagents, including a second antibody for detection, and other human antibodies as described herein (e.g., human antibodies with complementary activities that bind to different epitopes in the same antigen, etc.). The kit typically includes a label and instructions indicating the intended use of the contents of the kit. The term label includes any text or recorded material provided according to the kit or provided with the kit.

[0196] II. Methods of using anti-tumor antagonists

[0197] The anti-tumor antagonists of the present application have numerous in vitro and in vivo utilities, including, for example, enhancing immune responses and treating cancer, infectious diseases or autoimmune diseases.

[0198] The anti-tumor antagonists of the present application can be administered in vitro or ex vivo to cells in culture, or in vivo to human subjects to enhance immunity in a variety of diseases. Therefore, the present invention provides a method for changing the immune response in a subject, which comprises administering an antibody or antigen-binding fragment thereof as described herein to the subject, thereby enhancing, stimulating or upregulating the immune response of the subject. Preferred subjects include human patients in need of an enhanced immune response. The method is particularly suitable for treating human patients with diseases that can be treated by enhancing an immune response (e.g., a T cell-mediated immune response). The method is particularly suitable for in vivo treatment of cancer or chronic infection. For example, the anti-tumor antagonist can be administered together with an antigen of interest, or the antigen may already be present in the subject to be treated (e.g., a subject with a tumor or carrying a virus) to enhance antigen-specific immunity. When the anti-tumor antagonist is administered together with another agent, the two components can be administered separately or simultaneously.

[0199] In some embodiments, the checkpoint regulator antagonist in the above methods is an anti-PD-1 antibody, an anti-PD-L1 antibody, a VEGF antibody, a VEGFR antibody or any fragment thereof and TGFβRII ECD (VEGFR ECD), or both.

[0200] In any of the antibody embodiments described herein, the antibody is preferably a human or humanized antibody.

[0201] Also within the scope of the present application are methods for detecting and / or measuring the presence of a target molecule in a sample, the method comprising contacting the sample and a control sample with an antibody, antibody fragment, or bispecific antagonist of the present application (which specifically binds to the target molecule under conditions that allow formation of a complex between the antagonist and the target molecule), and then detecting the formation of a complex, wherein a difference in complex formation between the sample and the control sample indicates the presence of the target molecule in the sample.

[0202] In view of the fact that the anti-tumor antagonists of the present application have the ability to block the inhibition or co-inhibition of T cell responses (such as antigen-specific T cell responses), provided herein are methods for stimulating, enhancing or raising antigen-specific T cell responses, such as anti-tumor T cell responses, using antibodies as described herein. In certain embodiments, CD3 stimulation (for example, by co-incubation with cells expressing cell membrane CD3) is also provided, and the stimulation can be provided while, before or after treatment with an immune checkpoint regulator antagonist. For example, provided herein is a method for enhancing antigen-specific T cell responses, the method comprising contacting the T cells with immune checkpoint regulator antagonists as described herein, and optionally contacting with CD3, so as to enhance antigen-specific T cell responses, for example, by removing the inhibitory effect mediated by the immune checkpoint regulator. Any suitable indicator of antigen-specific T cell responses can be used to measure antigen-specific T cell responses. Non-limiting examples of such suitable indicators include T cell proliferation increased in the presence of antibodies and / or increasing the generation of cytokines in the presence of antibodies. In a preferred embodiment, the generation of interleukin-2 and / or interferon-γ by antigen-specific T cells is enhanced.

[0203] Further included in the present application is a method for enhancing a subject's immune response (e.g., an antigen-specific T cell response), the method comprising administering a bispecific anti-tumor antagonist as described herein to a subject, thereby enhancing the immune response (e.g., antigen-specific T cell response) in the subject. In a preferred embodiment, the subject is a subject with a tumor, and the anti-tumor immune response is enhanced. The tumor can be a solid tumor or a liquid tumor, such as a hematological malignancy. In certain embodiments, the tumor is an immunogenic tumor. In other embodiments, the tumor is non-immunogenic. In certain embodiments, the tumor is PD-L1 positive. In other embodiments, the tumor is PD-L1 negative. The subject can also be a subject carrying a virus, and the result of administering the bispecific anti-tumor antagonist as described herein is to enhance the antiviral immune response.

[0204] In one embodiment, a method for inhibiting tumor cell growth in a subject comprises administering a bispecific anti-tumor antagonist as described herein to the subject, thereby inhibiting tumor growth in the subject. Also provided is a method for treating a chronic viral infection in a subject, comprising administering a bispecific anti-tumor antagonist as described herein to the subject, thereby treating the chronic viral infection in the subject.

[0205] Also contemplated herein is the depletion of T cells from the tumor microenvironment of a subject having a tumor, e.g., a cancerous tumor. reg A method for stimulating T cells in a tumor microenvironment comprising administering to a subject a therapeutically effective amount of a bispecific anti-tumor antagonist as described herein. reg Cell-depleted Fc. The Fc can be, for example, an Fc that has effector function or enhanced effector function, such as binding or enhanced binding to one or more activated Fc receptors.

[0206] In a preferred embodiment, T cells are generated in the tumor microenvironment. reg consumption without significantly depleting or suppressing T eff , and did not significantly deplete or inhibit T cells outside the tumor microenvironment. eff and T reg In certain embodiments, for example, in a tumor microenvironment, the subject is in a T reg Levels of checkpoint regulators on T cells were higher than in T eff In certain embodiments, the bispecific antagonist can deplete TIGIT levels in tumors. regs and / or T cells in tumor-infiltrating lymphocytes (TILs) regs For example, in the CT26 tumor model, anti-mouse TIGIT antibodies formulated as mouse IgG2a (which exhibit effector functions) have been found to partially deplete T cells. reg and CD8 + T cells, but does not deplete CD4 + T cells. The counterpart antibody or antagonist, which is formed as a non-effector mouse IgG1 D265A, does not deplete T cells.

[0207] In certain embodiments, the bispecific anti-tumor antagonists described herein are administered to subjects as adjuvant therapy. Treatment of cancer patients with the bispecific anti-tumor antagonists described herein may result in long-term sustained responses relative to current standards of care; long-term survival of at least 1, 2, 3, 4, 5, 10 years or longer, and recurrence-free survival of at least 1, 2, 3, 4, 5, or 10 years or longer. In certain embodiments, treatment of cancer patients with bispecific anti-tumor antagonists can prevent the recurrence of cancer or delay the recurrence of cancer for example, 1, 2, 3, 4, 5, or 10 years or longer. Therefore, treatment with these antagonists can be used as a primary or secondary treatment regimen.

[0208] In certain preferred embodiments, the subject suffers from a cell proliferative disease or cancer. Provided herein are methods for treating a subject suffering from cancer, comprising administering to the subject a bispecific anti-tumor antagonist as described herein, thereby treating the subject, for example, inhibiting or reducing the growth of a cancerous tumor and / or causing tumor regression. The bispecific anti-tumor antagonists as described herein can be used alone to inhibit the growth of a cancerous tumor. Alternatively, any of these anti-tumor antagonists can be used in combination with another agent, such as another anti-cancer target, an immunogenic agent, a standard cancer treatment method, or other antibodies, as described below.

[0209] Thus, provided herein are methods for treating cancer, for example, by inhibiting tumor cell growth in a subject, comprising administering to the subject a therapeutically effective amount of a bispecific anti-tumor antagonist described herein.Preferably, the antibody comprises a human or humanized immunoglobulin sequence.

[0210] Cancers whose growth can be inhibited using the antibodies of the invention include cancers that are typically responsive to immunotherapy. Non-limiting examples of cancers for treatment include squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, squamous non-small cell lung cancer (NSCLC), non-NSCLC, gliomas, gastrointestinal cancer, renal cancer (e.g., cell carcinoma), ovarian cancer, liver cancer, colorectal cancer, endometrial cancer, kidney cancer (e.g., renal cell carcinoma (RCC)), prostate cancer (e.g., hormone-refractory prostate adenocarcinoma), thyroid cancer, neuroblastoma, pancreatic cancer, glioblastoma (glioblastoma multiforme), cervical cancer, gastric cancer, bladder cancer, liver cancer, breast cancer, colon cancer and head and neck cancer (or cancer), gastric cancer, germ cell tumors, pediatric sarcomas, sinonasal natural killer cells (sinonasal natural killer cells ... killer,), melanoma (e.g., metastatic malignant melanoma, such as cutaneous or intraocular malignant melanoma), bone cancer, skin cancer, uterine cancer, cancer of the anal region, testicular cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, esophageal cancer, small intestine cancer, endocrine system cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, solid tumors of childhood, ureteral cancer, renal pelvis cancer, central nervous system tumors (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumors, brainstem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancers (including those induced by asbestos), virus-associated cancers (e.g., tumors associated with human papillomavirus (HPV)), and cancers derived from one of the two major blood cell lineages, the myeloid cell lineage (which produces granulocytes, erythrocytes, platelets, macrophages, and hematological malignancies of the lymphoid cell line (which gives rise to B, T, NK and plasma cells) or lymphoid cell lineage (which gives rise to B, T, NK and plasma cells), such as all types of leukemias, lymphomas and myelomas, such as acute, chronic, lymphocytic and / or myeloid leukemias, such as acute leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML), undifferentiated AML (MO), myeloblastic leukemia (M1), myeloblastic leukemia (M2; as the cells mature), promyelocytic leukemia (M3 or M3 variant [M3V]), myelomonocytic leukemia (M4 or M4 with eosinophilia [M4E]), monocytic leukemia (M5), erythroleukemia (M6), megakaryocytic leukemia (M7), isolated granulocytic sarcoma and chloroma;Lymphomas, such as Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NEIL), B-cell lymphoma, T-cell lymphoma, lymphoplasmacytoid lymphoma, monocytic B-cell lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma, anaplastic (e.g., Ki 1+) large cell lymphoma, adult T-cell lymphoma / leukemia, mantle cell lymphoma, angioimmunoblastic T-cell lymphoma, angiocentric lymphoma, intestinal T-cell lymphoma, primary mediastinal B-cell lymphoma, precursor T-lymphoblastic lymphoma, T-lymphocyte and lymphoma / leukemia (T-Lbly / T-ALL), peripheral T-cell lymphoma, lymphoblastic lymphoma, post-transplant lymphoproliferative disorder, true histiocytic lymphoma, primary central nervous system Lymphoma, primary effusion lymphoma, lymphoblastic lymphoma (LBL), hematopoietic neoplasms of the lymphoid lineage, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, Burkitt lymphoma, follicular lymphoma, diffuse histiocytic lymphoma (DHL), immunogenic large cell lymphoma, precursor B-lymphoblastic lymphoma, cutaneous T-cell lymphoma (CTLC) (also known as mycosis fungoides or Sézary syndrome), and leukemia with Waldenstrom's giant globulin. Lymphoplasmacytoid lymphoma (LPL) of leukemia; myelomas, such as IgG myeloma, light chain myeloma, nonsecretory myeloma, smoldering myeloma (also called indolent myeloma), solitary plasmacytoma and multiple myeloma; chronic lymphocytic leukemia (CLL); hairy cell lymphoma; hematopoietic neoplasms of the myeloid lineage; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; seminoma, teratoma, central and peripheral nerve tumors, including astrocytoma, schwannoma Tumors of mesenchymal origin, including fibrosarcoma, rhabdomyomas, and osteosarcomas; and other tumors, including melanoma, xeroderma pigmentosum, keratoacanthoma, seminoma, thyroid follicular carcinoma, and teratoma, hematopoietic tumors of the lymphoid lineage, such as T-cell and B-cell tumors, including but not limited to T-cell diseases, such as T-cell prolymphocytic leukemia (T-PLL), including small cell and cerebrospinal cell types; large granular lymphocytic leukemia (LGL), preferably T-cell type; a / d T-NHL hepatosplenic lymphoma; peripheral / post-thymic T-cell lymphoma (polymorphic and immunoblastic subtypes); angiocentric (nasal) T-cell lymphoma; head and neck cancer, renal cancer, rectal cancer, thyroid cancer; acute myeloid lymphoma, and any combination of the above cancers. The methods described herein can also be used to treat metastatic cancers, refractory cancers (e.g., cancers refractory to previous immunotherapy, such as with blocking CTLA-4 or PD-1 antibodies), and relapsed cancers.

[0211] The bispecific anti-tumor antagonist of the present application can be administered alone, in combination with another anti-tumor antagonist, or simultaneously with another anti-tumor antagonist. The bispecific anti-tumor antagonist can also be administered simultaneously with immunogenic agents (e.g., cancer cells, tumor vaccines, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells transfected with genes encoding immunostimulatory cytokines in cancer vaccine strategies (He et al. (2004) J. Immunol. 173: 4919-28) or oncolytic viruses.

[0212] Many experimental strategies for vaccination against tumors have been designed. In one of these strategies, vaccines are prepared using autologous or allogeneic tumor cells. Some of these cell vaccines have been shown to be most effective when tumor cells are transduced to express GM-CSF. GM-CSF has been shown to be an effective antigen presentation activator for tumor vaccination (Dranoff et al. (1993) Proc. Natl. Acad. Sci. USA 90: 3539-43). In preclinical models, cancer vaccines have been shown to enhance the infiltration of effector T cells into tumors. The main types of cancer vaccines include peptide vaccines, vector-based antigen-specific vaccines, whole cell vaccines, and dendritic cell vaccines. All vaccine-based therapies are designed to deliver single or multiple antigen epitopes or antigens from whole cells to patients and induce tumor-specific effector T cells. Therefore, vaccine-based therapies may be the most effective method for inducing T cell infiltration into tumors.

[0213] Studies of gene expression and large-scale gene expression patterns in various tumors have led to the definition of so-called tumor-specific antigens (Rosenberg, SA (1999) Immunity 10: 281-7). In many cases, these tumor-specific antigens are differentiation antigens expressed in tumors and cells of tumor origin, such as the melanocyte antigen gp100, MAGE antigens, and Trp-2. More importantly, many of these antigens can be shown to be targets of tumor-specific T cells found in the host.

[0214] Checkpoint regulator pathways, TGF-β pathways and / or inhibition of angiogenesis pathways can be used in combination with a series of recombinant proteins and / or peptides expressed in tumors to generate an immune response against these proteins. Such proteins can be regarded as self-antigens by the immune system and can therefore be tolerated. Tumor antigens may include protein telomerase, which is a protein necessary for chromosome telomere synthesis and is expressed in more than 85% of human cancers and only in a limited number of somatic tissues (Kim et al. (1994) Science 266: 2011-2013). Tumor antigens can also be “neoantigens” in cancer cells because somatic mutations change the protein sequence or form a fusion protein between two unrelated sequences (i.e., bcr-abl in the Philadelphia chromosome), or a specific genotype (idiotype) from a B cell tumor.

[0215] Non-limiting examples of tumor vaccines include sipuleucel- an FDA-approved tumor vaccine for metastatic prostate cancer; tumor cells transfected to express the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), such as the whole-cell GM-CSF-secreting irradiated allogeneic pancreatic cancer vaccine (GVAX; Johns Hopkins); a peptide vaccine composed of immunogenic peptides derived from breast cancer antigens, neu, legumain, and β-catenin, which, when combined with an anti-PD-1 antibody, prolonged progression-free survival in vaccine-induced tumor-bearing mice (Karyampudi L. et al. (2014) Cancer Res 74:2974-2985); peptides of melanoma antigens, such as gp100, MAGE antigens, Trp-2, MARTI, and / or tyrosinase, or other tumor vaccines, including viral proteins associated with human cancers, such as human papillomavirus (HPV) (e.g., and Hepatitis B virus (e.g., Engerix-B and Recombivax HB); Hepatitis C virus (HCV), Kaposi's sarcoma-associated herpes sarcoma virus (KSHV). Another form of tumor-specific antigen that can be used in combination with TIGIT inhibition is purified heat shock proteins (HSPs) isolated from the tumor tissue itself. These heat shock proteins contain protein fragments from tumor cells, and these HSPs are very effective in delivering to antigen-presenting cells to elicit tumor immunity. Talimogenelaherparepvec (T-VEC or ) is an FDA-approved oncolytic virus used to treat some patients with metastatic melanoma that cannot be surgically removed.

[0216] Dendritic cells (DC) are effective antigen-presenting cells that can be used to trigger antigen-specific responses. DC can be produced in vitro and loaded with various protein and peptide antigens, as well as tumor cell extracts (Nestle et al. (1998) Nature Medicine 4: 328-332). DC can also be transduced by genetic means to express these tumor antigens. For immune purposes, DC has also been directly fused to tumor cells (Kugler et al. (2000) Nature Medicine 6: 332-336). As a vaccination method, DC immunity can be effectively combined with checkpoint regulator blocking to activate (release) a more effective anti-tumor response.

[0217] Checkpoint regulator pathways, TGF-β pathways and / or angiogenesis pathway inhibition can also be used in combination with standard cancer treatment methods (such as surgery, radiotherapy and chemotherapy). In particular, checkpoint regulator inhibition can be effectively combined with chemotherapy regimens. In these cases, it is possible to reduce the dose of the chemotherapeutic agent administered (Mokyr et al. (1998) Cancer Research 58: 5301-5304). An example of such a combination is an anti-tumor antagonist combined with decarbazine for the treatment of melanoma. Another example of such a combination is a combination of a checkpoint regulator antagonist or an anti-tumor antagonist with interleukin-2 (IL-2) for the treatment of melanoma. For example, the scientific basis for the use of checkpoint regulator inhibition, TGF-β1 / TGF-β1 RII inhibition and / or angiogenesis pathway inhibition in combination with chemotherapy to promote cell death is the result of the cytotoxic effect of most chemotherapeutic compounds, which leads to increased levels of tumor antigens in the antigen presentation pathway. Other combination therapies that may synergize through cell death with checkpoint regulator inhibition, TGF-β1 RII inhibition, and / or angiogenesis inhibition are radiation, surgery, and hormone deprivation. Each of these regimens creates a source of tumor antigens in the host.

[0218] The bispecific anti-tumor antagonists described herein can also be constructed into a bispecific antibody combination targeting Fcα or Fcγ receptor-expressing effector cells to tumor cells (see, for example, U.S. Patent Nos. 5,922,845 and 5,837,243). For example, anti-Fc receptor / anti-tumor antigen (e.g., Her-2 / neu) bispecific antibodies have been used to target macrophages to tumor sites. This type of targeting can make these embodiments more effective in activating tumor-specific responses. The T cell arm of these reactions will be enhanced by inhibiting one or more checkpoint regulator antagonists described herein. Alternatively, the antigen can be delivered directly to DC by using bispecific antibodies that bind to tumor antigens and dendritic cell-specific cell surface markers.

[0219] Tumors evade host immune surveillance through a variety of mechanisms. Many of these mechanisms can be overcome by inactivating immunosuppressive proteins expressed by tumors. These include TGF-β, IL-10, and Fas ligand. Antibodies against each of these entities can be used in combination with the anti-tumor antagonists described herein to counteract the effects of immunosuppressants and promote the host's tumor immune response.

[0220] Other antibodies that activate the host immune response can be used in combination with the anti-tumor antagonists described herein. These include molecules on the surface of dendritic cells that activate DC function and antigen presentation. Anti-CD40 antibodies can effectively replace the helper activity of T cells (Ridge et al. (1998) Nature 393:474-478) and can be used in combination with the bispecific antagonists described herein. Activating antibodies against T cell co-stimulatory molecules, such as OX-40 (Weinberg et al. (2000) Immunol 164: 2160-2169), CD137 / 4-1BB (Melero et al. (1997) Nature Medicine 3: 682-685 (1997), and ICOS (Hutloff et al. (1999) Nature 397: 262-266) can also be provided to increase the level of T cell activation. In addition, as further described below, inhibitors of other immune checkpoint regulators can also be used in combination with other anti-tumor antagonists described herein.

[0221] Bone marrow transplantation is currently used to treat a variety of hematopoietic tumors. Although graft-versus-host disease (GVHD) is a consequence of this treatment, checkpoint regulator inhibition could be used to enhance the effectiveness of transplanted tumor-specific T cells from the donor by reducing GVHD.

[0222] In certain embodiments, the anti-tumor antagonists described herein can be administered to subjects with infectious diseases, especially chronic infections. In this case, similar to its application to cancer, antibody-mediated checkpoint regulator inhibition can be used alone or in combination with vaccines as an adjuvant to enhance immune responsiveness to pathogens, toxins, and self-antigens. Exemplary pathogens to which this treatment method can be applied include, but are not limited to, HIV, hepatitis (type A, B, and C), influenza, herpes, Giardia lamblia, malaria, Leishmania, Staphylococcus aureus, and Pseudomonas aeruginosa. Checkpoint inhibition, TGF-β1 / TGF-β1 RII inhibition, and / or angiogenesis inhibition are particularly suitable for resisting infections by pathogens such as HIV that have been clearly identified during infection by presenting new or altered antigens. Administration of bispecific anti-tumor antagonists can allow these antigens to be recognized as foreign, thereby eliciting appropriate T cell responses.

[0223] Other pathogenic viruses that cause infections that can be treated by the methods described herein include HIV, hepatitis (types A, B, and C), herpes virus infections (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr Virus), and infections caused by adenovirus, influenza virus, flavivirus, echovirus, rhinovirus, coxsackievirus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus, arboviral encephalitis virus, or a combination thereof.

[0224] Exemplary pathogenic bacteria or diseases caused by them that can be treated by the methods described herein include Chlamydia, Rickettsia, Mycobacteria, Staphylococci, Streptococci, Pneumonococci, Meningococci and Gonococci, Klebsiella, Proteus, teus, Serratia, Pseudomonas, Legionella, Diphtheria, Salmonella, Bacilli, Cholera, Leptospirosis tetanus, botulism, anthrax, plague, and Lyme disease.

[0225] Exemplary pathogenic fungi that cause infections that can be treated by the methods described herein include Candida (e.g., albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (e.g., fumigatus, niger, etc.), Mucorales (e.g., mucor, absidia, rhizopus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis, and Histoplasma capsulatum.

[0226] Exemplary pathogenic parasites that cause infections that can be treated by the methods described herein include Entamoeba histolytica, Balantidium coli, Naegleria fowleri, Acanthamoeba sp., Giardia Zambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Nippostrongylus brasiliensis.

[0227] In all of the above approaches, checkpoint inhibition, TGF-β1 / TGF-β1 RII inhibition, and / or angiogenesis inhibition can be combined with other forms of immunotherapy, such as cytokine therapy (e.g., interferon, GM-CSF, G-CSF, IL-2) or bispecific antibody therapy that uses two different binding specificities to enhance presentation of tumor antigens.

[0228] The bispecific anti-tumor antagonists described herein can be co-administered with one or more of these antibodies with an antigen of interest (e.g., a vaccine) to enhance antigen-specific immune responses. Accordingly, provided herein are methods for enhancing an immune response to an antigen in a subject, the method comprising administering to the subject: (i) an antigen; (ii) a bispecific anti-tumor antagonist, such that the immune response to the antigen in the subject is enhanced. The antigen can be, for example, a tumor antigen, a viral antigen, a bacterial antigen, or an antigen from a pathogen. Non-limiting examples of such antigens include those discussed in the above sections, such as the tumor antigens (or tumor vaccines) discussed above, or antigens from the above-mentioned viruses, bacteria, or other pathogens.

[0229] In certain embodiments, peptides or fusion proteins comprising the epitope to which a bispecific anti-tumor antagonist binds can be used as a vaccine instead of or in addition to the anti-tumor antagonist.

[0230] Suitable routes for administering the antibody compositions described herein (e.g., human monoclonal antibodies, multispecific antibodies, or antagonists and immunoconjugates) in vivo and in vitro are well known in the art and can be selected by one of ordinary skill. For example, the antibody compositions can be administered by injection (e.g., intravenously or subcutaneously). The appropriate dosage of the molecule used will depend on the age and weight of the subject and the concentration and / or dosage form of the antibody composition.

[0231] Combination therapy

[0232] In another aspect, the present application provides a combination therapy for enhancing antigen-specific T cell responses in a subject. In one embodiment, the method comprises contacting T cells with a bispecific anti-tumor antagonist, in combination with a second antibody, antibody fragment, antagonist or drug, thereby enhancing antigen-specific T cell responses or apoptosis pathways. For example, in some embodiments, the first bispecific anti-tumor antagonist specifically binds to a first checkpoint regulator, such as PD-1 or PD-L1, and the second bispecific anti-tumor antagonist specifically binds to a different checkpoint regulator or a different epitope. In some embodiments, the second antibody or antibody fragment comprises one or more different HCVRs, LCVRs or CDRs from PD-1 and / or PD-L1.

[0233] In a related aspect, a method of reducing or depleting regulatory T cells in a tumor of a subject in need thereof comprises administering an effective amount of an antibody or antibody fragment, in combination with a second antibody, antibody fragment, antagonist or drug, thereby reducing the number of regulatory T cells in the subject.

[0234] In some embodiments, the subject has a cell proliferative disorder or cancer described herein.

[0235] In other embodiments, the subject has a chronic viral infection, inflammatory disease, or autoimmune disease as described herein.

[0236] Providing two different signals to T cells is a widely accepted model of lymphocyte activation of resting T lymphocytes by antigen presenting cells (APCs). This model further provides a distinction between self and non-self and immune tolerance. The primary signal or antigen-specific signal is transduced by the T cell receptor (TCR), which then recognizes foreign antigenic peptides presented in the context of the major histocompatibility complex (MHC). The second or co-stimulatory signal is delivered to the T cell by co-stimulatory molecules expressed on the antigen presenting cell (APC). This induces T cells to promote clonal expansion, cytokine secretion and effector function. In the absence of co-stimulation, T cells may become refractory to antigen stimulation, resulting in a tolerant response to exogenous or endogenous antigens.

[0237] In the dual-signal model, T cells receive both positive co-stimulatory and negative co-inhibitory signals. This regulation of positive and negative signals is crucial for maximizing the host's protective immune response while maintaining immune tolerance and preventing autoimmunity. Negative signals appear to be necessary for inducing T cell tolerance, while positive signals promote T cell activation. Both co-stimulatory and co-inhibitory signals are provided to T cells exposed to antigens, and the interaction between co-stimulatory and co-inhibitory signals is crucial for controlling the magnitude of the immune response. In addition, the signals provided to T cells change as the infection or immune challenge clears, worsens, or persists, and these changes strongly influence the responding T cells and reshape the immune response.

[0238] The mechanism of co-stimulation has therapeutic implications, as manipulation of co-stimulatory signals has been shown to provide a means of enhancing or terminating cell-based immune responses. Recently, it has been found that T cell dysfunction or anergy can occur in conjunction with the induction and sustained expression of immune checkpoint regulators such as programmed death 1 polypeptide (PD-1) and its ligands PD-L1 and PD-L2. PD-L1 is overexpressed in many cancers and is generally associated with poor prognosis (Thompson RH et al., Cancer Res 2006, 66(7):3381). In addition, in contrast to T lymphocytes in normal tissues and peripheral blood, most tumor-infiltrating T lymphocytes predominantly express PD-1, suggesting that upregulation of PD-1 on tumor-reactive T cells can lead to impaired anti-tumor immune responses (Blood 2009 114(8):1537). This may be due to the utilization of PD-L1 signaling resulting from the interaction of PD-L1-expressing tumor cells with PD-1-expressing T cells, leading to attenuated T cell activation and evasion of immune surveillance. Inhibition of PD-L1 / PD-1 interactions provides a means to enhance T cell immunity, including CD8 + T cell-mediated killing of cancer cells and tumors. Similar enhancement of T cell immunity has been observed by inhibiting the binding of PD-L1 to its binding partner molecule B7-1. Therefore, therapeutic targeting of PD-1 and other immune checkpoint regulators is an area of ​​considerable interest.

[0239] Combining inhibition of TGF-β1 signaling, checkpoint regulator signaling, and / or angiogenic signaling with inhibition of other signaling pathways dysregulated in tumor cells may provide a means to enhance therapeutic efficacy. In recent years, a number of immune checkpoint regulators in the form of receptors and their ligands have been identified. An important family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the B7 family, which includes CTLA-4 and its ligands B7-1 and B7-2; PD-1 and its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC); B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6. Other immune checkpoint antagonists include, but are not limited to, TIM-3 and its ligand galectin-9; LAG-3 and its ligands, including liver sinusoidal endothelial cell lectin (LSECtin) and galectin-3; CD122 and its CD122R ligand; CD70, B7H3, B and T lymphocyte attenuating agonist (BTLA) and VISTA (Le Mercier et al. (2015) Front. Immunol., (6), Article 418). In addition, many checkpoint regulator antagonists have been identified and tested in a variety of clinical and preclinical models and / or have received FDA approval (Kyi et al., FEBS Letters, 588:368-376 (2014). The concept of inhibitory receptor blockers (also known as immune checkpoint blockers) has been validated by, for example, the FDA-approved PD-1 inhibitors nivolumab and pembrolizumab and the anti-CTLA-4 antibody ipilimumab for metastatic melanoma.

[0240] Immune checkpoint antagonists regulate or interfere with the activity of immune checkpoint regulators, thereby blocking or inhibiting the signal transduction by checkpoint regulator receptors due to binding with checkpoint regulators or their ligands. By inhibiting this signal transduction, immunosuppression can be reversed, thereby reconstructing or enhancing T cell immunity against cancer cells. On the contrary, immune checkpoint agonists (e.g., co-stimulatory molecules) stimulate the activity of immune checkpoint regulators, thereby stimulating the signal transduction by checkpoint regulator receptors due to binding with checkpoint regulators or their ligands. By stimulating this signal transduction, T cell immunity against cancer cells can be reconstructed or enhanced.

[0241] Thus, in one embodiment, a method for stimulating an immune response in a subject comprises administering to the subject a bispecific anti-tumor antagonist described herein in combination with another immune checkpoint modulator as described above, thereby stimulating an immune response in the subject, such as inhibiting tumor growth or stimulating an antiviral response. In particular, the bispecific anti-tumor antagonist can be administered as a single antagonist or as a multispecific antagonist with binding specificity for multiple products.

[0242] In some embodiments, the bispecific anti-tumor antagonists of the present application can be combined with the following substances to stimulate an immune response: (i) an IgSF family protein that inhibits T cell activation, an antagonist of the B7 family or the TNF family, or a cytokine antagonist that inhibits T cell activation (e.g., IL-6, IL-10, TGF-β, VEGF or other immunosuppressive cytokines) and / or (ii) an agonist of a stimulatory receptor of the IgSF family, B7 family or TNF family that stimulates T cell activation for stimulating an immune response or an agonist of a cytokine. In some other embodiments, a combination of a bispecific anti-tumor antagonist and an anti-CTLA-4 antibody or CTLA-4 antagonist is administered to a subject. Exemplary anti-CTLA-4 antibodies used according to the present application include ipilimumab, trevilizumab, and tremelimumab.

[0243] In some embodiments, bispecific antagonists targeting different checkpoint regulator antagonists can be administered to subjects with cancers that exhibit high expression of immune checkpoint regulators. For example, in one embodiment, subjects with cancers that exhibit high expression of PVR (CD155) and / or adhesion protein-2 (CD112) and / or low expression of PD-L1 can be selected for monotherapy using a separate anti-TIGIT or anti-LAG-3 antibody or fragment thereof, or combination therapy in combination with a PD-1 antagonist or other immune checkpoint regulator antagonist. The bispecific antagonists of the present application can be co-administered with any additional agent, such as an antibody, antagonist, or drug, in an amount effective to stimulate the subject's immune response and / or apoptosis to further enhance, stimulate, or upregulate the subject's immune response and / or apoptosis.

[0244] In some embodiments, the bispecific anti-tumor antagonist is administered after treatment with a different anti-tumor antagonist. For example, in some embodiments, the bispecific anti-tumor antagonist of the present application may be administered only after treatment with a monospecific anti-tumor antagonist has failed, the treatment response is incomplete, or the tumor has recurred or recurred (e.g., "PD-1 failure"). In some embodiments, cancers that exhibit such failures can be screened for expression of PVR and / or adhesion protein-2, and only those with high levels of expression are treated with the bispecific anti-tumor antagonist of the present application.

[0245] In certain embodiments, the anti-tumor antagonist includes a dominant negative protein domain of an immune checkpoint regulator. In some specific embodiments, the dominant negative protein includes an extracellular domain derived from a group consisting of members selected from the following: PD-L1, PD-L2, PD-1, B7-1, B7-2, B7H3, CTLA-4, LAG-3, TIM-3, TIGIT, BTLA, VISTA, CD70, and combinations thereof. In certain specific embodiments, these extracellular domains are fused to the immunoglobulin constant region or Fc receptor in the antibodies described herein. Such mutants can bind to endogenous receptors, thereby forming a complex with insufficient signal transduction. In certain embodiments, the extracellular domain is fused to a monomer in an immunoglobulin constant region or Fc fragment or an oligomeric protein complex.

[0246] In certain embodiments, the dominant negative PD-L1 antagonist comprises the extracellular domain of PD-L1, PD-L2, or PD-1. In another embodiment, a dominant negative PD-1 antagonist is used that has a mutation so that it is no longer able to bind to PD-L1. An exemplary dominant negative protein is AMP-224 (co-developed by Glaxo Smith Kline and Amplimmune), which is a recombinant fusion protein that comprises the extracellular domain of PD-L2 and the Fc region of human IgG.

[0247] Exemplary immune checkpoint regulator agonists include, but are not limited to, members of the tumor necrosis factor (TNF) receptor superfamily, such as CD27, CD40, OX40, GITR, and 4-1BB (CD137) and its ligands or members of the B7-CD28 superfamily, including CD28 and ICOS (CD278). Other checkpoint regulator agonists include CD2, CDS, ICAM-1, LFA-1 (CD11a / CD18), CD30, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3, CD83 ligands. Immune checkpoint agonists may include antibodies or soluble fusion protein agonists comprising one or more costimulatory domains. Agonist antibodies include, but are not limited to, anti-CD40 mAbs, such as CP-870,893, lucatumumab, and dacetuzumab. anti-CD137 mAbs, such as BMS-663513urelumab and PF-05082566; anti-OX40 monoclonal antibodies; anti-GITR mAbs, such as TRX518; anti-CD27 mAbs, such as CDX-1127; and anti-ICOS mAbs.

[0248] Exemplary GITR agonists include, for example, GITR fusion proteins and anti-GITR antibodies (eg, bivalent anti-GITR antibodies), such as U.S. Patent Nos. 6,111,090 and 8,586,023; European Patent No.: 090505B1, U.S. Patent No. PCT Publication Nos. WO 2010 / 003118 and 2011 / 090754. Anti-GITR antibodies are described in, for example, U.S. Patent Nos. 7,025,962, 7,618,632, 7,812,135, 8,388,967, and 8,591,886; European Patent Nos. 1947183B1 and 1866339; PCT Publication Nos. WO 2011 / 028683, WO 2013 / 039954, WO 2005 / 007190, WO 2007 / 133822, WO 2005 / 055808, WO 99 / 40196, WO 2001 / 03720, WO 99 / 20758, WO 2006 / 083289, WO 2005 / 115451, WO 2011 / 051726. An exemplary anti-GITR antibody is TRX518.

[0249] Another family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the TNF family of molecules that bind to cognate TNF receptor family members, including CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137 / 4-1BB, TRAIL / Apo2-L, TRAILR1 / DR4, TRAILR2 / DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR / Fnl4, TWEAK, BAFFR, EDAR XEDAR, TACI, APRIL, BCMA, LTβR, LIGHT, DcR3, HVEM, VEGI / TL1A, TRAMP / D R3, EDR, EDA1, XEDAR, EDA2, TNFR1, Lymphotoxin α / TNFγ, TNFR2, TNFα, LTβR, Lymphotoxin α1(32, FAS, FASL, RELT, DR6, TROY, NGFR (see, e.g., Tansey, M G et al. (2009) Drug Discovery Today, 14(23-24): 1082-1088).

[0250] Immune checkpoint agonists or co-stimulatory molecules include cell surface molecules other than antigen receptors or their ligands required for an effective immune response, including but not limited to MHC class I molecules, MHC class II molecules, TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signal transducing lymphocyte activation molecules (SLAM proteins), activating NK cell receptors, BTLA, Toll ligand receptors, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a / CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (C D278), GITR, BAFFR, LIGHT, HVEM(LIGHTR), KIRDS2, SLAMF7, NKp80(KLRF1), NKp44, NKp30, NKp46, CD19, CD4 , CD8α, CD8β, IL2Rβ, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD1 1d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB 7. NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), CEACAM 1. CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​LAT, GADS, SLP-76, PAG / Cbp, CD19a and ligands that specifically bind to CD83.

[0251] In one aspect, the anti-PD-1 or anti-PD-L1 of the present invention can be used to mAbs stimulate T cell responses in combination with one or more of the following: (i) antagonists of proteins that inhibit T cell activation (e.g., immune checkpoint inhibitors), such as CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, Galectin-9 CEACAM-1, BTLA, CD69, Galectin-1, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD-1H, LAIR1, TIM-1, CD96, and TIM-4, and (ii) agonists of proteins that stimulate T cell activation, such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, CD40, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3, and CD28H.

[0252] Exemplary agents that regulate one of the above proteins and can be combined with the anti-PD-1 antibody or anti-PD-L1 antibody of the present application to treat cancer include, for example, YERVOY TM / ipilimumab or tremelimumab (anti-CTLA-4), galiximab (anti-B7.1), OPDIVO TM / nivolumab / BMS-936558 (anti-PD-1), pidilizumab / CT-01111 (anti-PD-1), KEYTRUDA TM / pembrolizumab / MK-3475 (anti-PD-1), AMP224 (anti-B7-DC / PD-L2), BMS-936559 (anti-B7-H1), MPDL3280A (anti-B7-H1), MEDI-570 (anti-ICOS), AMG557 (anti-B7H2), MGA271 (anti-B7H3), IMP321 (anti-LAG-3), urelumab / BMS-6635l3 and PF-05082566 (anti-CD137 / 4-1BB), CDX-1127 (anti-CD27), MEDI-6383 and MEDI-6469 (anti-OX40), RG-7888 (anti-OX40L), Atacicept (anti-TACI), CP-870893 (anti-CD40), lucatumumab (anti-CD40), dacetuzumab (anti-CD40), and muromonab-CD3 (anti-CD3).

[0253] Other molecules that can be combined with the anti-tumor antagonists described herein for the treatment of cancer include antagonists of inhibitory receptors on NK cells or agonists of activating receptors on NK cells. For example, antagonist anti-PD-1 and / or anti-PD-L1 antibodies can be combined with KIR antagonists (e.g., lirilumab), CSF-1R antagonists, such as RG7155.

[0254] Tumors evade host immune surveillance through a variety of mechanisms. Many of these mechanisms can be overcome by inactivating tumor-expressed immunosuppressive proteins. These include TGF-β, IL-10, and Fas ligand. Antibodies against each of these entities can be used in combination with the anti-tumor antagonists described herein to counteract the effects of immunosuppressive agents and promote host immune responses to tumors.

[0255] Other antibodies that activate the host immune response can be used in combination with anti-tumor antagonists described herein. These include molecules that activate DC function and antigen presentation on the surface of dendritic cells. Anti-CD40 antibodies can effectively replace T cell helper activity and can be used in combination with anti-tumor antagonists described herein. Activation antibodies against T cell costimulatory molecules (such as OX-40, CD137 / 4-1BB and ICOS) can also increase T cell activation levels.

[0256] In certain embodiments, the anti-tumor antagonists described herein can be co-administered with one or more other therapeutic agents, such as anticancer agents, radiotoxic agents, or immunosuppressants. Such co-administration can address problems caused by the development of resistance to the drug, changes in the antigenicity of tumor cells (which will render them unreactive with the antibody), and toxicity (by administering lower doses of one or more agents).

[0257] The anti-tumor antagonists described herein can be linked to the agent (as an immune complex) or can be administered separately from the agent. In the latter case (separate administration), the antibody can be administered before, after, or simultaneously with the agent, or can be co-administered with other known therapies, such as anti-cancer therapies, such as radiation. The anti-tumor antagonists described herein can be co-administered with one or more anti-cancer agents to provide two anti-cancer agents that act synergistically via different mechanisms, thereby producing a cytotoxic effect in human cancer cells.

[0258] The anti-tumor antagonists described herein can be combined with anti-cancer agents, such as alkylating agents; anthracycline antibiotics; antimetabolites; detoxification agents; interferons; polyclonal or monoclonal antibodies; EGFR inhibitors; HER2 inhibitors; histone deacetylase inhibitors; hormones; mitotic inhibitors; phosphatidylinositol-3-kinase (PI3K) inhibitors; Akt inhibitors; mammalian target of rapamycin (mTOR) inhibitors; proteasome inhibitors; poly (ADP-ribose) polymerase (PARP) inhibitors; Ras / MAPK pathway inhibitors; centrosome declustering agents; multikinase inhibitors; serine / threonine kinase inhibitors; tyrosine kinase inhibitors; VEGF / VEGFR inhibitors; taxanes or taxane derivatives, aromatase inhibitors, anthracyclines, drugs targeting microtubules, topoisomerase poisoning drugs, inhibitors of molecular targets or enzymes (e.g., kinases or protein methyltransferases), cytidine analogs, or a combination thereof.

[0259] Exemplary alkylating agents include, but are not limited to, cyclophosphamide (Cytoxan; Neosar); chlorambucil (Leukeran); melphalan (Alkeran); carmustine (BiCNU); busulfan (Busulfex); lomustine (CeeNU); dacarbazine (DTIC-Dome); oxaplatin (Eloxatin); carmustine (Gliadel); ifosfamide (Ifex); methylvinylpyrrolidone (Mustargen); busulfan (Myleran); carboplatin (Paraplatin); cisplatin (CDDP; Platinol); temozolomide (Temozolomide); thiotepa (Thiotepa); bendamustine (Treanda); or streptozocin (Zanosar).

[0260] Exemplary anthracycline antibiotics include, but are not limited to, doxorubicin (Adriamycin); liposomal doxorubicin (Doxil); mitoxantrone (Novantrone); bleomycin (Blenoxane); daunorubicin (Cerubidine); liposomal daunorubicin (DaunoXome); actinomycin (Cosmegen); epirubicin (Ellence); idarubicin (Idamycin); puromycin (Thioflavin); mitomycin (Mutamycin); pentostatin (Nipent); or valrubicin (Valstar).

[0261] Exemplary antimetabolites include, but are not limited to, fluorouracil (Adrucil); capecitabine (Hydrea); hydroxyurea (Hydrea); mercaptopurine (Purinol); pemetrexed (Alimta); fludarabine (Fludara); nelarabine (Arranon); cladribine (Cladribine Novaplus; clofarabine (Clolar); cytarabine (Cytosar-U); decitabine (Dacogen); liposomal cytarabine (DepoCyt); hydroxyurea (Droxia); pralatrexate (Folotyn); floxuridine (FUDR); gemcitabine (Gemzar); cladribine (Leustatin); fludarabine (Oforta); methotrexate (MTX; Rheumatrex); methotrexate (Trexall); thioguanine (Tabloid); TS-1 or cytarabine (Tarabine PFS).

[0262] Exemplary antidotes include, but are not limited to, amifostine (Ethyol) or mesna (Mesnex).

[0263] Exemplary interferons include, but are not limited to, interferon alpha-2b (Intron A) or interferon alpha-2a (Roferon-A).

[0264] Exemplary polyclonal or monoclonal antibodies include, but are not limited to, trastuzumab (Herceptin); ofatumumab (Arzerra); bevacizumab (Avastin); rituximab (Rituxan); cetuximab (Erbitux); panitumumab (Vectibix); tositumomab / iodine-131 tositumomab (Bexxar); alemtuzumab (Campath); ibritumomab (Zevalin; In-111; Y-90Zevalin); gemtuzumab tuzumab (Mylotarg); eculizumab (Soliris) ordenosumab.

[0265] Exemplary EGFR inhibitors include, but are not limited to, gefitinib (Iressa); lapatinib (Tykerb); cetuximab (Erbitux); erlotinib (Tarceva); panitumumab (Vectibix); PKI-166; canitinib (0-1033); matuzumab (Emd7200), or EKB-569.

[0266] Exemplary HER2 inhibitors include, but are not limited to, trastuzumab (Herceptin); lapatinib (Tykerb); or AC-480.

[0267] Exemplary histone deacetylase inhibitors include, but are not limited to, vorinostat (Zolinza), valproic acid, romidepsin, entinostat, abexinostat, gilvestrastat, and mocetinostat.

[0268] Exemplary hormones include, but are not limited to, tamoxifen (Soltamox; Nolvadex); raloxifene (Evista); progesterone (Megace); leuprorelin (Lupron; Lupron Depot; Eligard; Viadur); fulvestrant (Faslodex); letrozole (Femara); triptorelin (Trelstar LA; Trelstar Depot); exemestane (Aromasin); goserelin (Zoladex); bicalutamide (Casodex); anastrozole (Arimidex); fluoxymesterone (Androxy; Halotestin); medroxyprogesterone (Provera; Depo-Provera); estramustine (Emcyt); flutamide (Olesin); toremifene (Fareston); degarelix (Firmagon); nilutamide (Nilandron); abarelix (Plenaxis); or testolactone (Teslac).

[0269] Exemplary mitotic inhibitors include, but are not limited to, paclitaxel (Taxol; Onxol; Abraxane); docetaxel (Taxol); vincristine (Oncovin; Vincasar PFS); vinblastine (Velban); etoposide (Toposar; Etopophos; VePesid); teniposide (Vumon); ixabepilone (Ixempra); nocodazole; epothilone; vinorelbine (Navelbine); camptothecin (CPT); irinotecan (Camptosar); topotecan (Hycamtin); amcloline or lamellarin D (LAM-D).

[0270] Exemplary phosphatidylinositol 3-kinase (PI3K) inhibitors include wortmannin (an irreversible inhibitor of PI3K), demethoxyviridin (a derivative of wortmannin), LY294002 (a reversible inhibitor of PI3K); BKM120 (Buparlisib); Idelalisib (PI3K Delta inhibitor); duvelisib (IPI-145, a PI3Kδ and γ inhibitor); alpelisib (BYL719) (an α-specific PI3K inhibitor); TGR 1202 (formerly known as RP5264, an oral PI3Kδ inhibitor); and copanlisib (BAY 80-6946, a primary inhibitor of PI3Kα,δ isoforms).

[0271] Exemplary Akt inhibitors include, but are not limited to, Miltefosine, AZD5363, GDC-0068, MK2206, Perifosine, RX-0201, PBI-05204, GSK2141795, and SR13668.

[0272] Exemplary MTOR inhibitors include, but are not limited to, everolimus (Afinitor) or temsirolimus (Torisel); rapamune, ridaforolimus; deforolimus (AP23573), AZD8055 (AstraZeneca), OSI-027 (OSI), INK-128, BEZ235, PI-103, Torinl, PP242, PP30, Ku-0063794, WAY-600, WYE-687, WYE-354, and CC-223.

[0273] Exemplary proteasome inhibitors include, but are not limited to, bortezomib (PS-341), izumab (MLN2238), MLN 9708, dilanzomib (CEP-18770), carfilzomib (PR-171), YU101, opozomib (ONX-0912), marizomib (NPI-0052), and disufiram.

[0274] Exemplary PARP inhibitors include, but are not limited to, olaparib, iniparib, velaparib, BMN-673, BSI-201, AG014699, ABT-888, GPI21016, MK4827, INO-1001, CEP-9722, PJ-34, Tiq-A, Phen, PF-01367338, and combinations thereof.

[0275] Exemplary Ras / MAPK pathway inhibitors include, but are not limited to, trametinib, selumetinib, cobimetinib, O-1040, PD0325901, AS703026, R04987655, R05068760, AZD6244, GSK1120212, TAK-733, U0126, MEK162, and GDC-0973.

[0276] Exemplary centrosome declustering agents include, but are not limited to, griseofulvin; Noscapine, Noscapine derivatives, such as brominated Noscapine (e.g., 9-bromonascapine), reduced bromonascapine (RBN), N-(3-bromobenzyl) Noscapine, amino Noscapine and its water-soluble derivatives; CW069; phenanthracene-derived poly (ADP-ribose) polymerase inhibitor PJ-34; N2-(3-pyridylmethyl)-5-nitro-2-furanamide, N2-(2-thienylmethyl)-5-nitro-2-furanamide and N2-benzyl-5-nitro-2-furanamide.

[0277] Exemplary multi-kinase inhibitors include, but are not limited to, regorafenib; sorafenib (Nexavar); sunitinib (Sutent); BIBW 2992; E7080; Zd6474; PKC-412; motesanib; or AP24534.

[0278] Exemplary serine / threonine kinase inhibitors include, but are not limited to, ruboxistaurin; eril / escutel hydrochloride; flavopiridol; sebcicbb (CYC202; Roscovitrine); SNS-032 (BMS-387032); Pkc4l2; bromostatin; KAI-9803; SF1126; VX-680; Azdl 152; Arry-142886 (AZD-6244); SCIO-469; GW681323; CC-401; CEP-1347 or PD 332991.

[0279] Exemplary tyrosine kinase inhibitors include, but are not limited to, erlotinib (Tarceva); gefitinib (Iressa); imatinib (Gleevec); sorafenib (Nexavar); sunitinib (Sutent); trastuzumab (Herceptin); bevacizumab (Avastin); rituximab (Rituxan); lapatinib (Tykerb); cetuximab (Erbitux); panitumumab (Vectibix); everobmus (Afmitor); alemtuzumab (Campath); gemtuzumab (Mylotarg); temsirobmus (Torisel); pazopanib (Votrient); dasatinib (Spryvac cel); nilotinib (Tasigna); vatalanib (Ptk787; ZK222584); CEP-701; SU5614; MLN518; XL999; VX-322; Azd0530; BMS-354825; SKI-606CP-690; AG-490; WHI-P154; WHI-P131; AC-220; or AMG888.

[0280] Exemplary VEGF / VEGFR inhibitors include, but are not limited to, bevacizumab (Avastin); sorafenib (Nexavar); sunitinib (Sutent); ranibizumab pegaptirib or vandetinib.

[0281] Exemplary microtubule-targeting drugs include, but are not limited to, paclitaxel, docetaxel, vincristine, vinblastine, nocodazole, epothilone, and navirbine.

[0282] Exemplary topoisomerase-toxic drugs include, but are not limited to, teniposide, etoposide, doxorubicin, camptothecin, daunorubicin, dactinomycin, mitoxantrone, aminophylline, epirubicin, and idarubicin.

[0283] Exemplary taxanes or taxane derivatives include, but are not limited to, paclitaxel and docetaxel.

[0284] Exemplary general chemotherapeutic agents, anti-tumor agents, and anti-proliferative agents include, but are not limited to, octreotamine (Hexalen); isotretinoin (Accutane; Amnesteem; Claravis; Sotret); tretinoin (Vesanoid); azacitidine (Vidaza); bortezomib (Velcade); asparaginase (Elspar); levamisole (Ergamisol); mitotane (Lysodren); promazine (Matulane); pegaspargase (Oncaspar); denileukin (Denileukin); diftitox (Ontak); porfimer (Photofrin); aldesleukin (Proleukin); lenalidomide (Revlimid); bexarotene (Targretin); thalidomide (Thalomid); temsirolimus (Torisel); arsenic trioxide (Trisenox); verteporfin (Visudyne); mometasone (Leucenol); (1M tegafur-0.4M 5-chloro-2,4-dihydroxypyrimidine-1M potassium taurate) or lovastatin.

[0285] In certain embodiments, an anti-tumor antagonist described herein is administered at a subtherapeutic dose, another anti-immune checkpoint regulator antibody or antagonist is administered at a subtherapeutic dose, an angiogenesis antagonist is administered at a subtherapeutic dose, or a combination of any antagonists each administered at a subtherapeutic dose.

[0286] In certain embodiments, inhibition of TGFβ / TGFβRII, checkpoint regulators and / or angiogenic pathways can be combined with standard cancer treatments (e.g., surgery, radiation, and chemotherapy) according to conventional chemotherapy regimens. In these cases, it is possible to reduce the dose of the chemotherapeutic agent used. An example of such a combination is the use of a checkpoint regulator antagonist of the present application in combination with decarbazine for the treatment of melanoma. Another example of such a combination is the use of a checkpoint regulator antagonist of the present application in combination with interleukin 2 (IL-2) for the treatment of melanoma. It is believed that the combination of checkpoint regulator inhibition and chemotherapy can enhance apoptosis and increase tumor antigen presentation to cytotoxic immunity. Other synergistic combination therapies include checkpoint regulator inhibition through cell death when used in combination with radiation, surgery, or hormone deprivation. Each of these regimens produces a source of tumor antigens in the host.

[0287] In certain embodiments, the checkpoint regulator antagonists described herein can be used in multispecific antagonists or in combination with bispecific antibodies targeting tumor cells that express effector cells of Fcα or Fcγ receptors (see, for example, U.S. Patent Nos. 5,922,845 and 5,837,243). Bispecific antibodies can be used to target two separate antigens. For example, anti-Fc receptor / anti-tumor antigen (e.g., Her-2 / neu) bispecific antibodies have been used to target macrophages to cancer cells or tumors. This targeting can more effectively activate tumor-specific responses. The T cell arm of these reactions will be enhanced by the inhibitory effects of checkpoint regulators. Alternatively, antigens can be delivered directly to DCs using bispecific antibodies that bind to tumor antigens and dendritic cell-specific cell surface markers.

[0288] III. Nucleic Acids and Host Cells for Expression of Anti-tumor Antagonists

[0289] In another aspect, the present application provides nucleic acids encoding the anti-tumor antagonists (including heavy and light chains) of the present application, and expression vectors comprising such nucleic acids. In particular, the nucleic acids encode one or more HCDRs, LCDRs, HCVRs and / or LCVRs corresponding to any of the antibodies, antagonists or fragments described herein.

[0290] Thus, in one aspect, the present application provides one or more nucleic acids encoding any of the anti-tumor antagonists, antibodies, or antigen-binding portions thereof described herein.

[0291] In another aspect, the present application provides one or more expression vectors comprising one or more nucleic acids encoding any of the anti-tumor antagonists, antibodies, or antigen-binding portions thereof as described herein.

[0292] In another aspect, the present application provides a host cell transformed with one or more expression vectors comprising one or more nucleic acids encoding any of the anti-tumor antagonists, antibodies, or antigen-binding portions thereof described herein.

[0293] Conventional methods can be used (e.g., by using oligonucleotide probes that can specifically bind to the genes encoding the heavy and light chains of the monoclonal antibodies) to separate DNA encoding the antigen binding site from the monoclonal antibodies produced by hybridoma cells and sequence them. Alternatively, the amino acid sequence of the immunoglobulin of interest can be determined by direct protein sequencing, and a suitable encoding nucleotide sequence can be designed based on a universal codon table. In other cases, the nucleotide and amino acid sequences of the antigen binding site or other immunoglobulin sequences, including constant regions, hinge regions, etc., can be obtained from publicly available sources known in the art.

[0294] In one aspect, any binding antagonist fragment of the present application may comprise a synthetic DNA fragment using codon optimization corresponding to, for example, an antibody variable region domain. For example, a cDNA sequence encoding an immunoglobulin VH, VL, HC, LC, CH1, CH2, CH3 and / or framework region may be codon optimized for expression in various human, primate or mammalian cells, such as HEK or CHO cells. The present invention also describes a nucleic acid molecule comprising one or two nucleotide sequences encoding heavy and light chain variable regions, CDRs, hypervariable loops, and framework regions of an anti-PD-L1 antibody molecule, as described herein.

[0295] Expression vectors encoding specific bispecific anti-tumor antagonists can be used to synthesize the anti-tumor antagonists of the present disclosure in vitro in cultured cells, or they can be directly administered to patients to express the anti-tumor antagonists in vivo or ex vivo. As used herein, "expression vector" refers to a viral or non-viral vector that contains a polynucleotide encoding one or more polypeptide chains corresponding to the bispecific anti-tumor antagonists of the present disclosure in a form suitable for expression from the polynucleotide in a host cell for antibody preparation or direct administration as a therapeutic agent.

[0296] A nucleic acid sequence is "operably linked" to another nucleic acid sequence when the former has a functional relationship with the latter. For example, if the DNA for a sequence or signal peptide is expressed as a preprotein that participates in the secretion of a polypeptide, the DNA for the sequence or signal peptide may be operably linked to the DNA for the polypeptide. A promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are continuous, and in the case of a signal peptide, continuous and in reading phase. However, enhancers do not have to be continuous. Connection is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adapters or linkers may be used according to conventional practice.

[0297] Nucleic acid sequences used to express anti-tumor antagonists typically include an amino-terminal signal peptide sequence, which is removed from the mature protein. Because the signal peptide sequence can affect expression levels, the polynucleotide can encode any of a variety of different N-terminal signal peptide sequences. Those skilled in the art will appreciate that the design of the expression vector can depend on factors such as the choice of host cell to be transformed and the desired protein expression level.

[0298] The above-mentioned "regulatory sequence" refers to a DNA sequence necessary for expressing an operably linked coding sequence in one or more host organisms. The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cells or regulatory sequences that direct expression of a nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). Expression vectors typically contain sequences for transcription termination and may additionally contain one or more elements that actively influence mRNA stability.

[0299] Expression vectors contain one or more transcriptional regulatory elements, including promoters and / or enhancers, that direct the expression of anti-tumor antagonists. Promoters comprise DNA sequences that initiate transcription from a relatively fixed position relative to the transcription start site. Promoters contain the core elements required for the basic interaction between RNA polymerase and transcription factors and can be used in conjunction with other upstream elements and response elements.

[0300] As used herein, the term "promoter" should be used in its broadest context and includes transcriptional regulatory elements (TREs) from genomic genes or chimeric TREs derived therefrom, including TATA boxes or promoter elements for precise transcription initiation, with or without additional TREs (i.e., upstream activating sequences, transcription factor binding sites, enhancers, and silencers) that regulate the activation or repression of genes to which they are operably linked in response to developmental and / or external stimuli, as well as transactivating regulatory proteins or nucleic acids. A promoter may comprise a genomic fragment, or may comprise a chimera of one or more TREs bound together.

[0301] Preferred promoters are those that can guide high-level expression in target cells. Promoters can include constitutive promoters (e.g., HCMV, SV40, elongation factor-1α (EF-1α)) or those promoters that show preferential expression in specific cell types of interest. An enhancer generally refers to a DNA sequence that functions outside the transcription start site and can be located at the 5' or 3' end of the transcription unit. In addition, enhancers can be within introns and within coding sequences. Their length is generally between 10 and 300 bp and acts in cis. Enhancers play a role in increasing and / or regulating transcription from nearby promoters. Preferred enhancers are enhancers that guide high-level expression in antibody-producing cells. Cell or tissue-specific transcriptional regulatory elements (TREs) can be introduced into expression vectors to limit expression to the desired cell types. PolIII promoters (H1 or U6) are particularly suitable for expressing shRNA from which siRNA is expressed. Expression vectors can be designed to promote expression of anti-tumor antagonists in one or more cell types.

[0302] In certain embodiments, one or more expression vectors can be engineered to express an anti-tumor antagonist and one or more siRNAs targeting the Tie2 pathway, the VEGF pathway, or an immune checkpoint regulator.

[0303] siRNA is a double-stranded RNA that can be engineered to induce sequence-specific post-transcriptional gene silencing of mRNA. Synthetically produced siRNAs structurally mimic the type of siRNAs that are typically processed in cells by the Dicer enzyme. When expressed from an expression vector, the expression vector is engineered to transcribe short, double-stranded hairpin-like RNA (shRNA), which is then processed into a targeted siRNA within the cell. Synthetic siRNAs and shRNAs can be designed using well-known algorithms and synthesized using conventional DNA / RNA synthesizers.

[0304] In order to co-express the various chains of the anti-tumor antagonist, appropriate splice donor and splice acceptor sequences can be introduced to express two products. Alternatively, an internal ribosome binding sequence (IRES) or a 2A peptide sequence can be used to express multiple products from a single promoter. IRES provides a structure to which ribosomes can bind, which does not need to be at the 5' end of the mRNA. Therefore, it can guide the ribosome to initiate translation at the second start codon within the mRNA, thereby allowing more than one polypeptide to be produced from a single mRNA. The 2A peptide contains a short sequence that mediates co-translational self-cleavage of the peptides upstream and downstream of the 2A site, thereby allowing equimolar amounts of two different proteins to be produced from a single transcript. CHYSEL is a non-limiting example of a 2A peptide that causes the translating eukaryotic ribosome to release the growing polypeptide chain being synthesized without separating from the mRNA. The ribosome continues to translate, thereby producing a second polypeptide.

[0305] The expression vector may comprise a viral vector or a non-viral vector. Viral vectors may be derived from adeno-associated virus (AAV), adenovirus, herpes virus, vaccinia virus, poliovirus, poxvirus, retrovirus (including lentiviruses such as HIV-1 and HIV-2), Sindbis virus and other RNA viruses, alphavirus, astrovirus, coronavirus, orthomyxovirus, papillomavirus, paramyxovirus, parvovirus, mesothelioma virus, togavirus, etc. Non-viral vectors are simply "naked" expression vectors that are not packaged with virus-derived components (such as capsid and / or envelope).

[0306] In some cases, these vectors can be engineered to target certain diseases or cell populations by exploiting the inherent targeting properties of the viral vectors or by engineering these vectors into viral vectors. Specific cells can be "targeted" for both delivery of polynucleotides and expression. Thus, in this context, the term "targeting" can be based on the use of capsids, envelope proteins, endogenous or heterologous binding agents in the form of antibodies for delivery to specific cells, the use of tissue-specific regulatory elements to restrict expression to specific cell subsets, or both.

[0307] In some embodiments, expression of the antibody chain is under the control of a regulatory element, such as a tissue-specific or ubiquitous promoter. In some embodiments, a ubiquitous promoter, such as the CMV promoter, the CMV-chicken β-actin hybrid (CAG) promoter, a tissue-specific or tumor-specific promoter controls the expression of a particular antibody heavy or light chain, or a single-chain derivative thereof.

[0308] Non-viral expression vectors can be used for non-viral gene transfer, either by direct injection of naked DNA or by encapsulating polynucleotides encoding anti-tumor antagonists in liposomes, microparticles, microcapsules, virus-like particles, or red blood cells. Such compositions can be further linked to targeting domains by chemical coupling to facilitate targeted delivery of nucleic acids and / or entry into desired target cells. In addition, plasmid vectors can be incubated with synthetic gene transfer molecules, such as polymeric DNA-binding cations such as polylysine, protamine, and albumin, and linked to cell-targeting ligands, such as asialoorosomucoids, insulin, galactose, lactose, or transferrin.

[0309] Alternatively, naked DNA can be used. The uptake efficiency of naked DNA can be improved by compacting or using biodegradable latex beads. This delivery can be further improved by treating the beads to increase their hydrophobicity and thereby promote the disruption of endosomes and the release of DNA into the cytoplasm.

[0310] IV. Methods for Producing Bispecific Antibodies

[0311] In another aspect, the present application provides a host cell transformed with a nucleic acid or expression vector encoding the bispecific anti-tumor antagonist of the present application. The host cell can be any eukaryotic or prokaryotic cell capable of expressing the bispecific anti-tumor antagonist of the present application (including its immunoglobulin heavy and light chains).

[0312] In another aspect, a method for producing an anti-tumor antagonist comprises culturing a host cell transformed with one or more nucleic acids or expression vectors encoding the bispecific anti-tumor antagonist of the present invention under conditions that allow for the production and purification of the antagonist, antibody, or fragment thereof expressed in a suitable cell.

[0313] In yet another aspect, the present application provides a method for producing an antibody, comprising culturing cells to transiently or stably express one or more constructs encoding one or more polypeptide chains in an antibody; and purifying the antibody from the cultured cells. Any cell capable of producing a functional antibody can be used. In some preferred embodiments, the cells expressing the antibody are cells of eukaryotic or mammalian origin, preferably human cells. Cells from various tissue cell types can be used to express the antibody. In some other embodiments, the cells are yeast cells, insect cells, or bacterial cells. Preferably, the antibody-producing cells are stably transformed with a vector expressing the antibody.

[0314] One or more expression vectors encoding the heavy or light chains of the antibody can be introduced into the cells by any conventional method, such as naked DNA technology, cationic lipid-mediated transfection, polymer-mediated transfection, peptide-mediated transfection, viral-mediated infection, physical or chemical reagents or treatments, electroporation, etc. In addition, cells can be transfected with one or more expression vectors to express the antibody together with a selectable marker that promotes secretion of the antibody-expressing stable transformed clone. The antibodies produced by such cells can be collected and / or purified according to techniques known in the art, such as by centrifugation, chromatography, etc.

[0315] Examples of suitable selectable markers for mammalian cells include dihydrofolate reductase (DHFR), thymidine kinase, neomycin, the neomycin analog G418, hydromycin and puromycin. When such a selectable marker is successfully transferred into a mammalian host cell, the transformed mammalian host cell can survive if placed under selective pressure. There are two different classes of selection schemes that are widely used. The first class is based on the metabolism of the cell and the use of mutant cell lines that lack the ability to grow independently of a supplemented medium. Two examples are CHO DHFR cells and mouse LTK - Cells. These cells lack the ability to grow without supplemented nutrients such as thymidine or hypoxanthine. Because these cells lack certain genes necessary for the complete nucleotide synthesis pathway, they will not survive unless the missing nucleotides are provided in a supplemented medium. Another method of supplementing the medium is to introduce the complete DHFR or TK gene into cells lacking the corresponding gene, thereby changing their growth requirements. Individual cells that have not been transformed with the DHFR or TK gene will not survive in non-supplemented medium.

[0316] The second category is dominant selection, which refers to the selection scheme used in any cell type and does not require the use of mutant cell lines. These schemes usually use drugs to prevent the growth of host cells. Those cells with new genes will express proteins that transmit drug resistance and survive the selection. Examples of such dominant selection use drugs neomycin, mycophenolic acid or hygromycin. These three examples use bacterial genes under the control of eukaryotes to transmit resistance to appropriate drugs G418 or neomycin (geneticin), xgpt (mycophenolic acid) or hygromycin, respectively. Others include neomycin analogs G418 and puromycin.

[0317] Exemplary antibody-expressing cells include human Jurkat, human embryonic kidney (HEK) 293, Chinese hamster ovary (CHO) cells, mouse WEHI fibrosarcoma cells, and single-cell protozoan species, such as Leishmania tarentolae. Additionally, primary cells immortalized by c-myc or other immortalizing agents can be used to generate stably transformed antibody-producing cell lines.

[0318] In one embodiment, the cell line comprises a stably transformed Leishmania cell line, such as Leishmania tarentolae. Leishmania is known to provide a robust, fast-growing, single-cell host for high-level expression of eukaryotic proteins that display mammalian-type glycosylation patterns. A Leishmania eukaryotic expression kit is commercially available (Jena Bioscience GmbH, Jena, Germany).

[0319] In some embodiments, the cell line expresses at least 1 mg, at least 2 mg, at least 5 mg, at least 10 mg, at least 20 mg, at least 50 mg, at least 100 mg, at least 200 mg, at least 300 mg, at least 400 mg, or at least 500 mg of antibody per liter of culture.

[0320] In any suitable culture medium (e.g., RPMI, DMEM, and AIM ) After culturing and maintaining in the medium, the antibodies of the present application can be isolated from the cells expressing the antibodies. Conventional protein purification methods (e.g., affinity purification, chromatography, etc.) can be used to purify antibodies, including purification using Protein-A or Protein-G immunoaffinity purification. In some embodiments, the antibodies are engineered to be secreted into the culture supernatant for isolation therefrom.

[0321] V. Pharmaceutical Compositions and Methods of Treatment

[0322] Another aspect of the present application relates to pharmaceutical compositions and methods for treating cell proliferative diseases such as cancer, chronic infection, or immunologically impaired disease states. In one embodiment, the pharmaceutical composition comprises one or more anti-tumor antagonists of the present application. In some embodiments, the anti-tumor antagonists include: a combination of one or more TGF-β1 inhibitors or TGF-β1 RII inhibitors with the following substances: (1) PD-1 inhibitors or PD-L1 inhibitors; (2) or one or more angiogenesis inhibitors, such as VEGF inhibitors, VEGFR2 inhibitors, angiopoietin-1 / 2 inhibitors and Tie2R inhibitors. The domain antagonist is formulated with a pharmaceutically acceptable carrier. The pharmaceutical composition of the present application may comprise one or more different antibodies, one or more multispecific antibodies, one or more immunoconjugates, or a combination thereof, as described herein.

[0323] As described above, the methods of using the pharmaceutical compositions described herein comprise administering to a subject in need thereof an effective amount of a pharmaceutical composition according to the present invention.

[0324] Any suitable route or mode of administration can be used to provide a therapeutically or prophylactically effective dose of an antibody or antagonist to a patient. Exemplary routes or modes of administration include parenteral (e.g., intravenous, intraarterial, intramuscular, subcutaneous, intratumoral), oral, topical (nasal, transdermal, intradermal or intraocular), mucosal (e.g., nasal, sublingual, buccal, rectal, vaginal), inhalation, intralymphatic, intraspinal, intracranial, intraperitoneal, intratracheal, intravesical, intrathecal, intestinal, intrapulmonary, intralymphatic, intracavitary, intraorbital, intracapsular and intraurethral, ​​as well as local delivery via a catheter or stent.

[0325] The pharmaceutical composition comprising an antibody or antagonist according to the present disclosure can be formulated in any pharmaceutically acceptable carrier or excipient. As used herein, the term "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents and absorption delaying agents that are physiologically compatible. The pharmaceutical composition may include a suitable solid phase or gel phase carrier or excipient. Exemplary carriers or excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin and polymers (e.g., polyethylene glycol). Exemplary pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, etc. and combinations thereof. In many cases, it is preferred to include an isotonic agent, such as a sugar, a polyol such as mannitol, sorbitol or sodium chloride in the composition. The pharmaceutically acceptable carrier may further include a small amount of auxiliary substances, such as a wetting agent or emulsifier, a preservative or a buffer, which can extend the shelf life or effectiveness of the therapeutic agent.

[0326] Anti-tumor antagonists can be incorporated into pharmaceutical compositions suitable for parenteral administration. Suitable buffers include, but are not limited to, sodium succinate, sodium citrate, sodium phosphate, or potassium phosphate. Sodium chloride can be used at a concentration of 0-300 mM (optimally 150 mM for liquid dosage forms) to modify the toxicity of the solution. For lyophilized dosage forms, cryoprotectants can be included, primarily 0-10% sucrose (optimally 0.5-1.0%). Other suitable cryoprotectants include trehalose and lactose. For lyophilized dosage forms, bulking agents can be included, primarily 1-10% mannitol (optimally 2-4%). ​​Stabilizers can be used in both liquid and lyophilized dosage forms, primarily 1-50 mM (optimally 5-10 mM) L-methionine. Other suitable bulking agents include glycine, arginine, and polysorbate 80, which can be included as 0-0.05% (optimally 0.005-0.01%). Additional surfactants include, but are not limited to, polysorbate 20 and BRIJ surfactant.

[0327] The therapeutic anti-tumor antagonist formulation can be lyophilized and stored as a sterile powder, preferably under vacuum, and then reconstituted in bacteriostatic water (e.g., containing benzyl alcohol as a preservative) or in sterile water prior to injection. The pharmaceutical composition can be formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion.

[0328] The therapeutic agent in the pharmaceutical composition can be formulated in a "therapeutically effective amount" or a "prophylactically effective amount." A "therapeutically effective amount" refers to an amount effective at the dosage and time period necessary to achieve the desired therapeutic result. The therapeutically effective amount of the recombinant vector can vary depending on factors such as the disease to be treated, the severity and course of the disease, the route of administration, whether the antibody or drug is being administered for prophylactic or therapeutic purposes, the bioavailability of the particular drug, the ability of the anti-tumor antagonist to elicit the desired response in the individual, previous treatments, the patient's age, weight, and sex, the patient's clinical history and response to the antibody, the type of anti-tumor antagonist used, the discretion of the attending physician, etc. A therapeutically effective amount is also an amount in which any toxic or deleterious effects of the recombinant vector are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective at the dosage and time period necessary to achieve the desired prophylactic result.

[0329] Preferably, the polypeptide domains in the anti-tumor antagonists are derived from the same host to which they are to be administered, in order to reduce the inflammatory response to the administered therapeutic agent.

[0330] The anti-tumor antagonist is suitably administered to the patient at one time or over a series of treatments and may be administered to the patient at any time from diagnosis.The anti-tumor antagonist may be administered as sole therapy or in combination with other drugs or therapies useful in treating the condition.

[0331] As a general suggestion, a therapeutically effective or prophylactically effective amount of an anti-tumor antagonist is administered in an amount of about 1 ng / kg body weight / day to about 100 mg / kg body weight / day, whether administered in a single dose or multiple doses.In a specific embodiment, each anti-tumor antagonist is administered in a dose range of about 1 ng / kg body weight / day to about 10 mg / kg body weight / day, about 1 ng / kg body weight / day to about 1 mg / kg body weight / day, about 1 ng / kg body weight / day to about 100 μg / kg body weight / day, about 1 ng / kg body weight / day to about 10 μg / kg body weight / day, about 1 ng / kg body weight / day to about 1 μg / kg body weight / day, about 1 ng / kg body weight / day to about 100 ng / kg body weight / day, about 1 ng / kg body weight / day to about 10 ng / kg body weight / day, about 10 ng / kg body weight / day to about 100 mg / kg body weight / day, about 10 ng / kg body weight / day to about 10 mg / kg body weight / day, about 10 ng / kg body weight / day to about 1 mg / kg body weight / day, about 10 ng / kg body weight / day to about 100 μg / kg body weight / day, about 10 ng / kg body weight / day to about 10 μg / kg body weight / day, about 10 ng / kg body weight / day to about 1 μg / kg body weight / day, 10 ng / kg body weight / day to about 100 ng / kg body weight / day, about 100 ng / kg body weight / day to about 100 mg / kg body weight / day, about 100 ng / kg body weight / day to about 10 mg / kg body weight / day, about 100 n g / kg body weight / day to about 100 μg / kg body weight / day, about 100 ng / kg body weight / day to about 10 μg / kg body weight / day, about 100 ng / kg body weight / day to about 1 μg / kg body weight / day, about 1 μg / kg body weight / day to about 100 mg / kg body weight / day, about 1 μg / kg body weight / day to about 10 mg / kg body weight / day, about 1 μg / kg body weight / day to about 1 mg / kg body weight / day, about 1 μg / kg body weight / day to about 100 μg / kg body weight / day, about 1 μg / kg body weight / day to about 10 μg / kg body weight / day, about 10 μg / kg body weight / day to about 100 mg / kg body weight / day, about 10 μg / kg body weight / day g body weight / day to about 10 mg / kg body weight / day, about 10 μg / kg body weight / day to about 1 mg / kg body weight / day, about 10 μg / kg body weight / day to about 100 μg / kg body weight / day, about 100 μg / kg body weight / day to about 100 mg / kg body weight / day, about 100 μg / kg body weight / day to about 10 mg / kg body weight / day, about 100 μg / kg body weight / day to about 10 mg / kg body weight / day, about 100 μg / kg body weight / day to about 1 mg / kg body weight / day, about 1 mg / kg body weight / day to about 100 mg / kg body weight / day, about 1 mg / kg body weight / day to about 100 mg / kg body weight / day.

[0332] In other embodiments, the anti-tumor antagonist is administered at a dose of 500 μg to 20 g every three days, or at a dose of 25 mg / kg body weight every three days.

[0333] In other embodiments, each anti-tumor antagonist is administered in a range of about 10 ng to about 100 ng per single administration, about 10 ng to about 1 μg per single administration, about 10 ng to about 10 μg per single administration, about 10 ng to about 100 μg per single administration, about 10 ng to about 1 mg per single administration, about 10 ng to about 10 mg per single administration, about 10 ng to about 100 mg per single administration, about 10 ng to about 1000 mg per injection, about 10 ng to about 10,000 mg per single administration, about 100 ng to about 1 μg per single administration, about 100 n per single administration. g to about 10 μg, about 100 ng to about 100 μg per single dose, about 100 ng to about 1 mg per single dose, about 100 ng to about 10 mg per single dose, about 100 ng to about 100 mg per single dose, about 100 ng to about 1000 mg per single dose, about 100 ng to about 10,000 mg per injection, about 1 μg to about 10 μg per single dose, about 1 μg to about 100 μg per single dose, about 1 μg to about 1 mg per single dose, about 1 μg to about 10 mg per single dose, about 1 μg to about 100 mg per single dose, about 1 μg per injection About 1000 mg, about 1 μg to about 10,000 mg per single dose, about 10 μg to about 100 μg per single dose, about 10 μg to about 1 mg per single dose, about 10 μg to about 10 mg per single dose, about 10 μg to about 100 mg per single dose, about 10 μg to about 1000 mg per injection, about 10 μg to about 10,000 mg per single dose, about 100 μg to about 1 mg per single dose, about 100 μg to about 10 mg per single dose, about 100 μg to about 100 mg per single dose, about 100 μg to about 1000 mg per injection, About 100 μg to about 10,000 mg per single dose, about 1 mg to about 10 mg per single dose, about 1 mg to about 100 mg per single dose, about 1 mg to about 1000 mg per injection, about 1 mg to about 10,000 mg per single dose, about 10 mg to about 100 mg per single dose, about 10 mg to about 1000 mg per injection, about 10 mg to about 10,000 mg per single dose, about 100 mg to about 10,000 mg per injection, about 100 mg to about 10,000 mg per single dose, about 1000 mg to about 10,000 mg per single dose. The anti-tumor antagonist can be administered daily, every 2, 3, 4, 5, 6 or 7 days, or every 1, 2, 3 or 4 weeks.

[0334] In other specific embodiments, the amount of the anti-tumor antagonist can be administered at a dose of about 0.0006 mg / day, 0.001 mg / day, 0.003 mg / day, 0.006 mg / day, 0.01 mg / day, 0.03 mg / day, 0.06 mg / day, 0.1 mg / day, 0.3 mg / day, 0.6 mg / day, 1 mg / day, 3 mg / day, 6 mg / day, 10 mg / day, 30 mg / day, 60 mg / day, 100 mg / day, 300 mg / day, 600 mg / day, 1000 mg / day, 2000 mg / day, 5000 mg / day or 10,000 mg / day. As expected, the dosage will depend on the disease, size, age and condition of the patient.

[0335] In certain embodiments, the coding sequence of the anti-tumor antagonist is introduced into a suitable expression vector (e.g., a viral or non-viral vector) to express an effective amount of the anti-tumor antagonist in a patient suffering from a cell proliferative disease. In certain embodiments comprising administering, for example, one or more recombinant AAV (rAAV) viruses, the pharmaceutical composition may comprise rAAV in an amount of at least 10 10 , at least 10 11 , at least 10 12 , at least 10 13 or at least 10 14 Genome copies (GC) or recombinant virus particles / kg, or any range thereof. In certain embodiments, the pharmaceutical composition comprises an effective amount of a recombinant virus, such as rAAV, comprising at least 10 10 , at least 10 11 , at least 10 12 , at least 10 13 , at least 10 14 , at least 10 15 genome copies or recombinant viral particle genome copies, or any range thereof.

[0336] Doses can be tested in several art-recognized animal models applicable to any particular cell proliferative disorder.

[0337] Delivery methods may also include the use of polycation-conjugated DNA with or without viral ligands, ligand-linked DNA, liposomes, eukaryotic cell delivery vectors, deposition of photopolymerizable hydrogel materials, use of handheld gene transfer particle guns, ionizing radiation, nucleic acid neutralization or fusion with cell membranes, particle-mediated gene transfer, and the like.

[0338] The present invention is further illustrated by the following examples, which should not be construed as limiting.The contents of all references, patents and published patent applications cited throughout this application, as well as the figures and tables, are incorporated herein by reference.

[0339] example

[0340] Example 1: Production of monoclonal antibodies

[0341] Monoclonal antibodies (mAbs) of the present invention are generated and screened using techniques well known in the art, see, for example, Harlow and Lane (1988). Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York. Antigen-specific hybridoma mAbs are cloned, sequenced, and engineered using techniques well known in the art, see, for example, Lo. BKC Methods in Molecular Biology. TM .Volume 248 2004.Antibody Engineering.

[0342] Example 2: Design of bispecific anti-tumor antagonists

[0343] Figure 5A and 5B Two bispecific anti-tumor antagonists, Bi-PB-1 (or Bi-PLB-1) and Bi-PB-1 (or Bi-PLB-2), are shown. These antagonists contain a checkpoint regulating antibody backbone (anti-PD-1 or anti-PD-L1) and a TGF-β1 RII extracellular domain (TGF-β-RII ECD): (i) fused to the carboxyl terminus of the CH3 region of each of the two heavy chains ( Figure 5A ) or (ii) inserted into the CH3 region of the Fc loop 5B).

[0344] exist Figure 5A and 5B In the embodiment shown in , the bispecific antibody can have an IgG1 or IgG4 backbone. In addition, any one or more antibody specificities can be replaced by any other checkpoint regulator antagonist specificity and / or any tumor targeting antibody specificity, such as CD20, EGFR, etc.

[0345] Figure 6 Shows the corresponding Figure 5A and 5B Exemplary functional domain sequences of bispecific antibodies in .

[0346] Figure 7 A to Figure 7 B shows the corresponding Figure 5A and 5B Exemplary heavy chain (HC) and light chain (LC) sequences of bispecific antibodies are shown in .

[0347] Example 3: Design of other bispecific antagonists

[0348] Figures 8A-8C Designs of three different bispecific antagonists, Bi-AB-1, Bi-AlB-1, and Bi-ZB-1, are shown, each containing a carboxy-terminal TGF-β1 RII extracellular domain (ECD) in a mutant IgG1 (K447A) scaffold. Both Bi-AB-1 and Bi-AlB-1 contain amino-terminal anti-VEGF variable regions (VH1, VL1) from Avastin / bevacizumab; Bi-AlB-1 contains two amino acid substitutions (E6Q, LIV) in the VH region. Bi-ZB-1 contains an amino-terminal aflibercept domain upstream of the IgG1 Fc (K447A) region. In other embodiments, as an alternative to the mutant IgG1 (K447A) scaffold, the bispecific antagonist comprises a wild-type IgG1 scaffold, a different mutant IgG1 scaffold, an IgG2 scaffold, a mutant IgG2 scaffold, an IgG4 scaffold, or a mutant IgG4 scaffold.

[0349] Figure 9A and 9B Shows the corresponding Figures 8A-8C The various functional domain sequences of the bispecific antagonists are shown in .

[0350] Figure 10 Shows the corresponding Figures 8A-8C The heavy chain (HC) and light chain (LC) amino acid sequences of the bispecific antagonist are shown in .

[0351] Figure 11 Summary Figures 8A-8C The arrangement of functional domains in the bispecific antagonist is shown in FIG.

[0352] Example 4: Figure 10-11 Expression and purification of antagonists

[0353] Figure 12 Figure 2 is a Coomassie blue-stained polyacrylamide gel showing increased expression levels of antagonists containing wt VEGF-A or mutants E6Q and L11V mutations (i.e., Bi-AB-1, Bi-AlB-1, respectively) when transiently transfected into HEK293 cells as determined by non-reducing polyacrylamide gel electrophoresis (PAGE). Figure 12 The titers shown in were determined by quantifying cell supernatants using a POROS A column (Applied Biosystems). The results of this analysis showed that the expression level of Bi-AlB-1 was increased by 167% relative to Bi-AB-1.

[0354] Figure 13AShown are size exclusion chromatography (SEC) curves showing the relative levels of high molecular weight (HMW) species, low molecular weight (LMW) species, and dimers produced by Protein A purified Bi-AB-1 and Bi-AlB-1. Figure 13B The percentage of dimer (98.6% for Bi-AB-1 and 98.7% for Bi-AlB-1) greatly exceeded the amount of HMW (1%) and LMW (0.4%) species as determined by SE-UPLC using a Tosoh TSKgelUP-G3000SWXL column. These results indicate that fusion of the TGF-β1 RII extracellular domain (ECD) to Bi-AB-1 and Bi-AlB-1 did not result in significant levels of high molecular weight (HMW) or low molecular weight (LMW) species.

[0355] Figures 14A-14B Coomassie blue-stained PAGE analysis of supernatants obtained after transient transfection of Bi-ZB-1 under non-reducing and reducing conditions is shown. The results of this analysis confirmed that Bi-ZB-1 had good transient expression levels (220 μg / ml) after 8 days of cell growth in vitro.

[0356] Figure 15 Size exclusion chromatography (SEC) curves are shown, showing that Protein A purified Bi-ZB-1 has low levels of high molecular weight (HMW, 3.4%) and low molecular weight (LMW, 0.5%) species compared to the dimer (96.1%).

[0357] Example 5: Figures 8A-8C Functional characterization of antitumor antagonists in

[0358] To evaluate the ability of the anti-VEGF antagonist Bi-AlB-1 to antagonize VEGF-mediated activation of VEGFR2 (i.e., the cognate receptor), a cell-based luciferase assay was performed. In this experiment, a recombinant HEK-293 cell line expressing human VEGFR2 and firefly luciferase constructs under the control of a NFAT response element was stimulated with huVEGF165 in the presence of serial dilutions of the anti-VEGF antagonist (Bi-AlB-1). The results of this assay are shown in Figure 16 As expected, increasing levels of anti-VEGF antagonists gradually neutralized the ability of VEGF165 to activate VEGFR2 and induce NFAT-mediated luciferase activity.

[0359] To evaluate the ability of the bispecific antagonist Bi-AlB-1 to bind simultaneously to TGF-β1 and VEGF165, a sandwich ELISA assay was performed. In this experiment, huTGF-β1 was coated on a 96-well plate and blocked with 5% BSA. Serial dilutions of Bi-AlB-1 were then added and incubated, followed by the addition of biotinylated huVEGF165. Bound molecules were detected by streptavidin-HRP using TMB substrate. The results of this assay are shown in Figure 17 In this study, we showed that the bispecific antagonist Bi-AlB-1 can simultaneously bind to both TGF-β1 and VEGF165.

[0360] To assess the ability of TGF-β1 RII ECD to antagonize TGF-β1-mediated activation of human TGF-β1RII (i.e., the cognate receptor), a cell-based luciferase assay was performed. In this experiment, recombinant HEK-293 cells expressing the human TGF-β1 RII receptor and firefly luciferase construct under the control of a SMAD response element were stimulated with huTGF-β1 in the presence of serial dilutions of antibodies fused to the TGF-β1 RII ECD (Bi-AlB-1, Bi-ZB-1). The results of this analysis are presented in Figure 18 As expected, increasing levels of antibodies containing the TGF-β1RII ECD gradually neutralized the ability of TGF-β1 to activate human TGF-β1 RII and induce NFAT-mediated luciferase activity. In this case, Bi-AlB-1 and Bi-ZB-1 exhibited similar antagonistic potency, as reflected by an IC50 of 0.32 nM for Bi-AlB-1 and an IC50 of 0.31 for Bi-ZB-1. These IC50s are comparable to those of the control TGFBR2 fusion product (IC50 = 0.20 nM).

[0361] In order to evaluate the in vivo pharmacokinetic properties of Bi-AlB-1, a pharmacokinetic curve was generated. In short, 10 mg / kg of each antagonist was injected intravenously into the tail vein of 6-10 week old female CD1 mice (n=2 mice per molecule). Serum was harvested 3 minutes, 3 hours, 1 day, 3 days, 7 days and 10 days after injection. In order to detect antibodies in serum, 96-well ELISA plates were coated with 5 μg / ml goat anti-human IgG F (ab') 2 fragments and then blocked with 5% milk in PBS. Mouse serum serially diluted in 5% milk and purified protein molecules serially diluted as standard were added to the plate. After incubation with peroxidase-coupled mouse anti-human IgG and further washing, the bispecific antagonist Bi-AlB-1 ( Figure 19) antibody. The results showed that the half-life (T 1 / 2 ) is 7.4-16 days.

[0362] Example 6: Design of a bispecific PD-1 / PD-L1 antagonist with TGF-β1 ECD

[0363] Figures 20A-20B Two bispecific anti-tumor antagonists Bi-PB-1.2 ( Figure 20A ) and Bi-PLB-1.2( Figure 20B ), each comprising an antibody framework (IgG4K447A or IgG1 K447A) with variable region domains from anti-PD-1 and anti-PD-L1, respectively, and additionally including the TGF-β-RII ECD fused to the carboxyl terminus of each heavy chain CH3 region.

[0364] Figure 19 Shown in Figure 20A and 20B Figure 24 shows the functional domain sequences present in the bispecific antibody. Figure 20A and 20B The heavy chain (HC) and light chain (LC) amino acid sequences of the bispecific antagonist are shown in . Figure 23 The arrangement of the functional domains in the bispecific antagonists shown in 20A and 20B is summarized.

[0365] Example 7: Figures 20A-20B Expression and purification of bispecific antagonists in

[0366] Figure 24A Shown are native polyacrylamide gel (PAGE) analyses demonstrating increased expression of Bi-PB-1.2 and Bi-PLB-1.2 in transient expression systems following protein A affinity purification compared to the parental control antibody (2P17). Figure 24B Size exclusion chromatography (SEC) curves are shown, indicating that protein A-purified Bi-PB-1.2, Bi-PLB-1.2 and 2P17 (Benchmark) from transiently transfected HEK293 cells have low levels of high molecular weight (HMW) and low molecular weight (LMW) species compared to the dimerized molecules (dimers), as shown in Figure 24. Figures 25A-25B It was shown that the dimer, HMW and LMW forms of Bi-PB-1.2 and Bi-PLB-1.2 showed good stability at 4 °C for a period of at least 4 weeks.

[0367] Example 8: Figures 20A-20B Functional characterization of Bi-PB-1.2 and Bi-PLB-1.2 antagonists

[0368] 1. Binding of Bi-PB-1.2 to PD-1 and TGF-β1 by biolayer interferometry

[0369] Biointerferometry was performed using the Octet RED96 system (ForteBio Octet RED96 system) to characterize the binding kinetics of antibodies against His-tagged human PD-1 protein or His-tagged TGF-β1. 20 nM antibody was loaded onto the anti-human IgG capture biosensor. Binding of the analyte (HIs-tagged human PD-1 or TGF-β1 protein) was observed by placing the biosensor in a well containing a 2- or 3-fold serial dilution of the analyte (the highest concentration was 72 nM) for 5 minutes. Dissociation was measured after the biosensor was transferred to the kinetic buffer alone and the interferometer signal was monitored for 10 minutes. The observed on and off rates (Ka and Kd) were fitted using a 1:1 binding global fit model containing at least 5 test concentrations, and the equilibrium binding constant Kd was calculated.

[0370] Figures 26A-26E Results are shown for PD-1 and TGF-β1 bound to Bi-PB-1.2 ( Figure 26A , 26B) and the corresponding anti-PD-1 antibody and benchmark (M7824 from Merck KGA) (respectively Figure 26C , 26D) and their resulting binding affinity constants ( Figure 26E The results showed that Bi-PB-1.2 had better binding affinity to PD-1 and TGF-β1 than both the anti-PD-1 benchmark and the M7824 benchmark.

[0371] 2. Binding of Bi-PLB-1.2 to PD-L1 and TGF-β1 by bio-layer interferometry

[0372] Binding of Bi-PLB-1.2 to PD-L1 and TGF-β1 was determined by biolayer interferometry as described above for Bi-PB-1.2. Figures 27A-27E showed that PD-1 and TGF-β1 bind to Bi-PB-1.2 (respectively Figure 27A , 27B) and the corresponding anti-PD-1 and anti-TGF-β1 benchmark antibodies (respectively Figure 27C , 27D) and the resulting binding affinity constant ( Figure 27E The results showed that the binding affinity of Bi-PLB-1.2 to TGF-β1 was higher than that of the TGF-β1 ECD benchmark, and the binding affinity of Bi-PLB-1.2 to PD-L1 was comparable to that of the anti-PD-L1 benchmark.

[0373] 3. Bi-PB-1.2 and Bi-PLB-1.2 bind to PD-1 / PD-L1 simultaneously

[0374] Figure 28A An ELISA assay demonstrating simultaneous binding of TGF-β1 and PD-1 by Bi-PLB-1.2 is shown, in which 96-well plates coated with huTGF-β1 were incubated with serially diluted samples of Bi-PB-1.2 and then with His-tagged huPD-1, and the bound molecules were detected by anti-His tag-HRP using TMB substrate. Figure 28B An ELISA assay demonstrating simultaneous binding of TGF-β1 and PD-L1 by Bi-PLB-1.2 is shown. A 96-well plate coated with hu TGF-β1 was incubated with serially diluted samples of Bi-PLB-1.2 and then with His-tagged huPD-L1, with bound molecules detected by anti-His-tagged HRP using TMB substrate. The EC50 value reflects the half-maximal effective concentration that produces half the response between baseline and maximum response for binding to human PD-1 or PD-L1.

[0375] 4. Bi-PB-1.2 effectively blocked the binding of PD-L1 and TGF-β1 to their receptors

[0376] Blocking assays were performed to calculate the IC50 values ​​corresponding to the binding between Bi-PB-1.2 and PD-L1 compared to an anti-PD-1 benchmark antibody. Briefly, two-fold serial dilutions of Bi-PB-1.2 or benchmark antibodies were prepared (highest antibody concentration: 128 nM; three replicates for each mAb). Human PD-1-transfected CHO-K1 cells were washed with FACS buffer (0.5% BSA, 2 mM EDTA in PBS) and incubated at 10 °C for 24 h. 6 Resuspended at a concentration of 100 μg / ml. FITC-labeled human PD-L1-Fc protein was added to human PD-1 transfected CHO-K1 cells at a final concentration of 7 μg / ml and mixed thoroughly. Without incubation, 2,000 CHO-K1 cells (containing PD-L1 protein) in 20 μl FACS buffer were immediately added to a 96-well round-bottom plate, and 20 μl or 2-fold serial dilutions of antibody were immediately added to the cells and incubated at 4°C for 30 minutes. The cells were then washed and resuspended in 30 μl 7AAD solution. 35 μl of 10% neutral formalin buffer solution was then added and incubated for 15 minutes, and then analyzed using the iQue intelligent system. The results of this analysis are shown in Figure 2. Figure 29AAs expected, increasing levels of Bi-PB-1.2 gradually blocked the ability of PD-L1 to bind to its receptor. Furthermore, the calculated IC50 value of Bi-PB-1.2 for PD-L1 was found to be comparable to the IC50 of the anti-PD-1 benchmark for PD-L1.

[0377] To evaluate the ability of TGF-β1 RII ECD to antagonize TGF-β1-mediated activation of human TGF-β1RII (i.e., the cognate receptor), a cell-based luciferase assay was performed. In this experiment, a construct expressing human TGF-β1 RII receptor and firefly luciferase under the control of a SMAD response element was stimulated with hu TGF-β1 in the presence of a serial dilution of Bi-PB-1.2 containing the TGF-β1 RII ECD. Biological activity was determined by a decrease in luciferase-mediated luminescence.

[0378] The results of this assay are shown in Figure 29B As expected, increasing levels of antibodies containing the TGF-β1RII ECD gradually neutralized the ability of TGF-β1 to activate human TGF-β1 RII and induce NFAT-mediated luciferase activity. Furthermore, the calculated IC50 value of Bi-PB-1.2 for TGF-β1 was found to be comparable to the IC50 of the anti-PD-1 benchmark for TGF-β1.

[0379] 5. Bi-PB-1.2 binds to human and macaque PD-1 with similar activity

[0380] To evaluate the ability of Bi-PB-1.2 to bind to human and macaque PD-1, serial dilutions of Bi-PB-1.2 were added to CHO-K1 cells (20,000 cells / well) overexpressing human or macaque PD-1. The mixture was incubated at 4°C for 20 minutes, washed three times, and stained with a secondary antibody, PE-labeled F(ab')2-goat anti-human IgG Fc (Thermo H10104), for 20 minutes at 4°C. The cells were washed, resuspended in 7AAD solution, and fixed in 10% neutral buffered formalin for 15 minutes before analysis using the iQue Intelligent System. Figures 30A-30B showed that Bi-PB-1.2 interacts with human PD-1 ( Figure 30A ) and macaque PD-1( Figure 30B As expected, the anti-human PD-1 benchmark antibody was similarly found to bind to human PD-1 ( Figure 30A ) and macaque PD-1( Figure 30B). The corresponding EC50 values ​​reflecting the half-maximal effective concentration (EC50) that produces half the baseline and maximum response for binding to human PD-1 and macaque PD-1, respectively, were also determined. In this case, the EC50 values ​​show that Bi-PB-1.2 has similar binding properties to the benchmark antibody.

[0381] 6. Bi-PLB-1.2 effectively blocks the binding of PD-1 and TGF-β1 to their receptors

[0382] Blocking assays were performed to calculate IC50 values ​​for binding of Bi-PLB-1.2 to PD-L1 compared to an anti-PD-L1 benchmark antibody, essentially as described in Example 8, Section 4, supra. Figure 31A Increasing concentrations of Bi-PLB-1.2 or an anti-PD-L1 benchmark antibody progressively blocked PD-1 binding to PD-L1-TGFBR2. As reflected by the obtained IC50 values, the bispecific antibody was comparable to the anti-PD-L1 benchmark.

[0383] To calculate IC50 values ​​corresponding to the binding of Bi-PLB-1.2 to TGF-β1 compared to an anti-TGF-β1 benchmark antibody, a cell-based assay as described in Example 8, Section 4 was performed. Figure 31B Serial dilutions of Bi-PLB-1.2 and an anti-PDL1-TGFBR2 benchmark antibody are shown to block the activation of luciferase expression by TGF-β1 under the control of a SMAD response element. As reflected by the IC50 values ​​obtained, the bispecific antibody exhibited similar binding properties to the anti-TGF-β1 benchmark.

[0384] 7. Bi-PLB-1.2 binds to human and macaque PD-1 with similar activity

[0385] To assess the ability of Bi-PLB-1.2 to bind to human and cynomolgus PD-L1, serial dilutions of Bi-PLB-1.2 were added to CHO-K1 cells (20,000 cells / well) overexpressing human or cynomolgus PD-L1 essentially as described in Example 9, Section 5. Figures 32A-32B Bi-PLB-1.2 was shown to bind to human PD-L1 ( Figure 32A ) and macaque PD-L1( Figure 32B The obtained EC50 values ​​reflect the half-maximal effective concentration (EC50), which is determined to produce a response halfway between the baseline and maximum response relative to binding to human PD-1 and macaque PD-1, respectively.

[0386] 8. Bi-PB-1.2 enhances T cell activation

[0387] Human T cell assays were performed to demonstrate the functionality of the Bi-PB-1.2 antibody. Briefly, normal healthy human PBMCs collected from donors 1 and 2 were activated with SEB (Toxin Technology, Cat. No. BT202). To determine IFN-γ production, 100,000 cells were stimulated with 0.5 μg / ml SEB in a 96-well plate. 25,000 tumor suppressor SHP77 cells were added to provide an inhibitory signal. 66 nM Bi-PB-1.2 mAb or isotype control antibody was added. After 5 days, IFN-γ and IL-2 in the supernatant were examined by ELISA. Figures 33A-33B The results show that Bi-PB-1.2 treatment resulted in IFN-γ (donor 1, 40A; donor 2, Figure 33B ) and IL-2 (donor 1, 40C; donor 2, Figure 33D ) increase.

[0388] 9. Bi-PLB-1.2 enhances T cell activation and overcomes the inhibitory effect of tumor cells on T cells better than the parental anti-PD-L1 antibody

[0389] Figures 34A-34D The effects of Bi-PLB-1.2 on human PBMC (donor 8, Figure 34A ; Donor 9, Figure 34B ) caused by increased IFN-γ secretion. Figures 34C-34D Bi-PLB-1.2 showed the effects of Bi-PLB-1.2 on human PBMC (Donor 8, Figure 34C ; Donor 9, Figure 34D These results are consistent with the idea that Bi-PLB-1.2 is better than the parental anti-PD-L1 antibody at overcoming the inhibitory effects of tumor cells on T cells.

[0390] 11. Bi-PB-1.2 and Bi-PLB-1.2 have improved pharmacokinetics in mice compared to benchmark antibodies

[0391] To evaluate the in vivo pharmacokinetic properties of Bi-PB-1.2, Bi-PLB-1.2 and benchmark antibodies, pharmacokinetic curves were generated. Briefly, 10 mg / kg of each antagonist was injected intravenously into the tail vein of 6-10 week old female CD1 mice (n = 2 mice per molecule). Serum was harvested 3 minutes, 3 hours, 1 day, 3 days, 7 days and 10 days after injection. To detect antibodies in serum, 96-well ELISA plates were coated with 5 μg / ml goat anti-human IgG F(ab')2 fragments and then blocked with 5% milk in PBS. Mouse serum serially diluted in 5% milk and serially diluted purified protein molecules as standards were added to the plates.

[0392] After incubation with peroxidase-conjugated mouse anti-human IgG and further washing, Bi-PB-1.2 ( Figure 35A ), Bi-PLB-1.2( Figure 35C ) and benchmark ( Figure 35E ) antibody (PDL1-TGFBR2, M8724). The injected antibody Bi-PB-1.2 ( Figure 35B ), Bi-PLB-1.2( Figure 35D ) and benchmark ( Figure 35F The results of this analysis showed that Bi-PB-1.2 and Bi-PLB-1.2 had improved pharmacokinetic properties in mice compared to the benchmark antibody.

[0393] The above description is intended to teach one of ordinary skill in the art how to practice the present invention, and is not intended to detail all modifications and variations that would become apparent to one of ordinary skill in the art upon reading this description. However, all such obvious modifications and variations are intended to be included within the scope of the present invention, which is defined by the appended claims. Unless the context clearly indicates otherwise, the claims are intended to cover the claimed components and steps in any order that effectively achieves the desired purpose. Sequence Listing <110> Jingshang Biopharmaceutical Company <120> Antitumor antagonists <130> 2022-003 PCT2 (130779) <150> US 62 / 691,658 <151> 2018-06-29 <150> US 62 / 823,989 <151> 2019-03-26 <160> 228 <170> PatentIn version 3.5 <210> 1 <211> 5 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 1 Asn Phe Leu Met Ser 1 5 <210> 2 <211> 17 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 2 Thr Ile Ser Gly Gly Gly Arg Asp Thr Tyr Tyr Val Asp Ser Val Lys 1 5 10 15 Gly <210> 3 <211> 8 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 3 Arg Thr Thr Tyr Ser Met Asp Tyr 1 5 <210> 4 <211> 5 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 4 Asn Ser Tyr Leu Tyr 1 5 <210> 5 <211> 17 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 5 Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe Lys 1 5 10 15 Thr <210> 6 <211> 11 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 6 Arg Asp Tyr Asn Tyr Asp Gly Gly Phe Asp Ser 1 5 10 <210> 7 <211> 5 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 7 Asn Ser Tyr Ile Tyr 1 5 <210> 8 <211> 12 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 8 Arg Arg Asp Tyr Arg Tyr Asp Gly Gly Phe Asp Ser 1 5 10 <210> 9 <211> 5 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 9 Thr Tyr Tyr Ile Tyr 1 5 <210> 10 <211> 17 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 10 Gly Ile Asn Pro Gly Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe Lys 1 5 10 15 Ile <210> 11 <211> 11 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 11 Arg Tyr His Gly Tyr Asp Gly Gly Leu Asp Tyr 1 5 10 <210> 12 <211> 5 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 12 Ser Tyr Tyr Ile His 1 5 <210> 13 <211> 17 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 13 Trp Ile Phe Pro Gly Ser Gly Asn Ser Lys Tyr Asn Glu Asn Phe Lys 1 5 10 15 Gly <210> 14 <211> 9 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 14 Ser Glu Thr Tyr Asp Tyr Gly Asp Tyr 1 5 <210> 15 <211> 11 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 15 Leu Ala Ser Gln Thr Ile Gly Thr Trp Leu Ala 1 5 10 <210> 16 <211> 7 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 16 Ala Ala Thr Ser Leu Ala Asp 1 5 <210> 17 <211> 9 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 17 Gln Gln Phe Tyr Ser Ile Pro Trp Thr 1 5 <210> 18 <211> 12 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 18 Arg Ala Ser Ser Thr Leu Tyr Ser Asn Tyr Leu His 1 5 10 <210> 19 <211> 7 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 19 Arg Ala Ser Phe Leu Ala Ser 1 5 <210> 20 <211> 9 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 20 Gln Gln Gly Ser Ser Ile Pro Leu Thr 1 5 <210> twenty one <211> 12 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> twenty one Ser Ala Ser Ser Ser Leu Tyr Ser Ser Tyr Leu His 1 5 10 <210> twenty two <211> 12 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> twenty two Arg Ala Ser Ser Ser Leu Tyr Ser Asn Tyr Leu His 1 5 10 <210> twenty three <211> 15 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> twenty three Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Phe Ser Tyr Ile His 1 5 10 15 <210> twenty four <211> 7 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> twenty four Leu Ala Ser Asn Leu Glu Ser 1 5 <210> 25 <211> 9 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 25 Gln His Thr Trp Glu Leu Pro Asn Thr 1 5 <210> 26 <211> 11 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 26 Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala 1 5 10 <210> 27 <211> 7 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 27 Ser Ala Ser Tyr Arg Tyr Ser 1 5 <210> 28 <211> 9 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 28 Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr 1 5 <210> 29 <211> 117 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 29 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe 20 25 30 Leu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Thr Ile Ser Gly Gly Gly Arg Asp Thr Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Arg Thr Thr Tyr Ser Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 30 <211> 107 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 30 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Thr Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Thr Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Tyr Ser Ile Pro Trp [[ID=*44]]85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 31 <21**1> 120 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 31 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Asp Tyr Thr Phe Thr Asn Ser 20 25 30 Tyr Leu Tyr Trp Leu Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Thr Arg Thr Thr Ser Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Val Val Tyr Tyr Cys 85 90 95 Thr Arg Arg Asp Tyr Asn Tyr Asp Gly Gly Phe Asp Ser Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 32 <211> 108 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 32 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Phe Thr Cys Arg Ala Ser Ser Thr Leu Tyr Ser Asn 20 25 30 Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Ala Ser Phe Leu Ala Ser Gly Val Pro Ser Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln 65 70 75 80 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ser Ile Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 33 <211> 120 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 33 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Asp Tyr Thr Phe Thr Asn Ser 20 25 30 Tyr Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Thr Arg Val Thr Ser Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Val Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Asp Tyr Arg Tyr Asp Gly Gly Phe Asp Ser Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 34 <211> 108 <212> PRT <213> Artificial Sequence <220> <22^3> Synthetic <400> 34 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Leu Tyr Ser Ser 20 25 30 Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Note: There might be a small error in your original text where you have <22^3> which is likely a typo. I translated it as <22^3> as-is, but it should probably be something like <223>. Adjust it according to your needs.35 40 45 Ile Tyr Arg Ala Ser Phe Leu Ala Ser Gly Val Pro Ser Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln 65 70 75 80 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ser Ile Pro 85 90 95 Leu Thr Phe Gly Ala Gly Thr Lys Leu Asp Leu Lys 100 105 <210> 35 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 35 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Asp Tyr Thr Phe Thr Asn Ser 20 25 30 Tyr Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Thr Arg Val Thr Ser Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Val Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Asp Tyr Asn Tyr Asp Gly Gly Phe Asp Ser Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 36 <211> 108 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 36 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Phe Thr Cys Arg Ala Ser Ser Ser Leu Tyr Ser Asn 20 25 30 Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Ala Ser Phe Leu Ala Ser Gly Val Pro Ser Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln 65 70 75 80 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ser Ile Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 37 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 37 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Tyr Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Asn Pro Gly Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Ile Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Tyr His Gly Tyr Asp Gly Gly Leu Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 38 <211> 111 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 38 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly 1 5 10 15 Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 20 25 30 Gly Phe Ser Tyr Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn 65 70 75 80 Pro Val Glu Ala Asn Asp Thr Ala Asn Tyr Tyr Cys Gln His Thr Trp 85 90 95 Glu Leu Pro Asn Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 39 <211> 117 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 39 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Phe Pro Gly Ser Gly Asn Ser Lys Tyr Asn Glu Asn Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Glu Thr Tyr Asp Tyr Gly Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 40 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 40 Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Ala Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 41 <211> 5 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 41 Asn Tyr Trp Met His 1 5 <210> 42 <211> 17 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 42 Met Ile His Pro Asn Thr Asn Asn Tyr Asn Tyr Asn Glu Lys Phe Lys 1 5 10 15 Ser <210> 43 <211> 12 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 43 Ser Asp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr 1 5 10 <210> 44 <211> 5 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 44 Ser Tyr Trp Met His 1 5 <210> 45 <211> 17 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 45 Met Ile His Pro Asn Val Gly Ser Thr Asn Tyr Asn Glu Lys Phe Lys 1 5 10 15 Ser <210> 46 <211> 12 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 46 Ser Arg Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr 1 5 10 <210> 47 <211> 17 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 47 Met Ile His Pro Asn Ser Gly Gly Asn Asn Tyr Asn Glu Lys Phe Lys 1 5 10 15 Ser <210> 48 <211> 12 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 48 Ser Trp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr 1 5 10 <210> 49 <211> 17 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 49 Met Ile His Pro Thr Gly Val Ser Thr Asp Tyr Asn Glu Lys Phe Lys 1 5 10 15 Ser <210> 50 <211> 6 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 50 Ser Asp Tyr Ala Trp Asn 1 5 <210> 51 <211> 16 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 51 Tyr Ile Ser Asp Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 52 <211> 11 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 52 Ser Phe Leu Arg Leu Arg Ser Tyr Phe Asp His 1 5 10 <210> 53 <211> 5 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 53 Ser Tyr Gly Ile Asn 1 5 <210> 54 <211> 17 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 54 Cys Ile Tyr Ile Gly Asn Asp Tyr Thr Asn Tyr Asn Glu Lys Phe Lys 1 5 10 15 Gly <210> 55 <211> 9 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 55 Ala Tyr Tyr Gly Ser Arg Val Asp Tyr 1 5 <210> 56 <211> 11 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 56 Arg Ala Ser Gln Asp Ile Asp Asn Tyr Leu Asn 1 5 10 <210> 57 <211> 7 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 57 Tyr Thr Ser Arg Leu His Ser 1 5 <210> 58 <211> 9 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 58 Gln Gln Gly Tyr Thr Leu Pro Trp Thr 1 5 <210> 59 <211> 11 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 59 Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 60 <211> 7 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 60 Tyr Thr Ser Arg Leu Gln Ser 1 5 <210> 61 <211> 9 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 61 Gln Gln Gly Asn Thr Leu Pro Trp Thr 1 5 <210> 62 <211> 9 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 62 Gln Gln Gly Asp Thr Leu Pro Trp Thr 1 5 <210> 63 <211> 11 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 63 Lys Ala Ser Gln Asp Val Asn Val Ala Val Ala 1 5 10 <210> 64 <211> 7 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 64 Trp Ala Ser Thr Arg His Ile 1 5 <210> 65 <211> 9 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 65 Gln Gln His Tyr Ser Thr Pro Tyr Thr 1 5 <210> 66 <211> 11 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 66 Lys Ala Ser Gln Asp Ile Asn Lys Tyr Ile Ala 1 5 10 <210> 67 <211> 7 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 67 Tyr Thr Ser Thr Leu Gln Pro 1 5 <210> 68 <211> 8 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 68 Leu Gln Tyr Asp Asn Leu Tyr Thr 1 5 <210> 69 <211> 8 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 69 Gln Ser Ile Ser Asp Tyr Leu His 1 5 <210> 70 <211> 8 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 70 Cys Ala Ser Gln Ser Ile Ser Gly 1 5 <210> 71 <211> 9 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 71 Gln Asn Gly His Ser Phe Pro Tyr Thr 1 5 <210> 72 <211> 121 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 72 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Trp Met His Trp Met Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Met Ile His Pro Asn Thr Asn Asn Tyr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Arg Val Thr Ser Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Val Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Asp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 73 <211> 107 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 73 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Asp Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Lys Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Tyr Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 74 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 74 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45<00​​​​​​​​​​​​​​​ Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 75 <211> 107 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 75 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 76 <211> 121 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 76 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Met Ile His Pro Asn Ser Gly Gly Asn Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Trp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 77 <211> 107 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 77 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 78 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 78 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Met Ile His Pro Thr Gly Val Ser Thr Asp Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Asp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 79 <211> 107 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 79 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Lys Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Asp Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 80 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 80 Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp 20 25 30 Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 35 40 45 Met Gly Tyr Ile Ser Asp Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu 50 55 60 Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 65 70 75 80 Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Asn Ser Phe Leu Arg Leu Arg Ser Tyr Phe Asp His Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 81 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 81 Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Asn Val Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35 40 45 Phe Trp Ala Ser Thr Arg His Ile Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala 65 70 75 80 Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 82 <211> 119 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 82 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 35 40 45 Gly Trp Cys Ile Tyr Ile Gly Asn Asp Tyr Thr Asn Tyr Asn Glu Lys 50 55 60 Phe Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala 65 70 75 80 Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Ala Tyr Tyr Gly Ser Arg Val Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <210> 83 <211> 106 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 83 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Phe Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Lys Tyr 20 25 30 Ile Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 His Tyr Thr Ser Thr Leu Gln Pro Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Arg Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Tyr Thr 85 90 95 Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 84 <211> 119 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 84 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 35 40 45 Gly Trp Cys Ile Tyr Ile Gly Asn Asp Tyr Thr Asn Tyr Asn Glu Lys 50 55 60 Phe Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala 65 70 75 80 Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Ala Tyr Tyr Gly Ser Arg Val Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <210> 85 <211> 104 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 85 Glu Ile Val Leu Thr Gln Ser Pro Val Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Gln Ser Ile Ser Asp Tyr Leu His Trp 20 25 30 Tyr Leu Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Lys Cys Ala 35 40 45 Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser 50 55 60 Gly Ser Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe 65 70 75 80 Ala Val Tyr Tyr Cys Gln Asn Gly His Ser Phe Pro Tyr Thr Phe Gly 85 90 95 Gly Gly Thr Lys Val Glu Ile Lys 100 <210> 86 <211> 121 <212> PRT <213> Synthetic Sequence <220> <223> Synthetic <400> 86 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala [[ID=,40]]1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Met Ile His Pro Asn Ser Gly Gly Asn Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Trp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 87 <211> 107 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 87 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Asp Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Lys Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Tyr Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 88 <211> 205 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 88 Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu 1 5 10 15 Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val 20 25 30 Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 35 40 45 Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe 50 55 60 Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu 65 70 75 80 Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 85 90 95 Gln Thr Asn Thr Ile Ile Asp Val Val Leu Ser Pro Ser His Gly Ile 100 105 110 Glu Leu Ser Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr 115 120 125 Glu Leu Asn Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys 130 135 140 His Gln His Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gln Ser Gly 145 150 155 160 Ser Glu Met Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly Val Thr 165 170 175 Arg Ser Asp Gln Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met I80 185 190 Thr Lys Lys Asn Ser Thr Phe Val Arg Val His Glu Lys 195 200 205 <210> 89 <211> 136 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 89 Ile Pro Pro His Val Gln Lys Ser Val Asn Asn Asp Met Ile Val Thr 1 5 10 15 Asp Asn Asn Gly Ala Val Lys Phe Pro Gln Leu Cys Lys Phe Cys Asp 20 25 30 Val Arg Phe Ser Thr Cys Asp Asn Gln Lys Ser Cys Met Ser Asn Cys 35 40 45 Ser Ile Thr Ser Ile Cys Glu Lys Pro Gln Glu Val Cys Val Ala Val 50 55 60 Trp Arg Lys Asn Asp Glu Asn Ile Thr Leu Glu Thr Val Cys His Asp 65 70 75 80 Pro Lys Leu Pro Tyr His Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro 85 90 95 Lys Cys Ile Met Lys Glu Lys Lys Lys Pro Gly Glu Thr Phe Phe Met 100 105 110 Cys Ser Cys Ser Ser Asp Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu 115 120 125 Glu Tyr Asn Thr Ser Asn Pro Asp 130 135 <210> 90 <211> 123 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 90 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 91 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 91 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile 35 40 45 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 92 <211> 595 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 92 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Phe Pro Gly Ser Gly Asn Ser Lys Tyr Asn Glu Asn Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Glu Thr Tyr Asp Tyr Gly Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Gly Gly Gly Gly 435 440 445 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ile Pro Pro His Val 450 455 460 Gln Lys Ser Val Asn Asn Asp Met Ile Val Thr Asp Asn Asn Gly Ala 465 470 475 480 Val Lys Phe Pro Gln Leu Cys Lys Phe Cys Asp Val Arg Phe Ser Thr 485 490 495 Cys Asp Asn Gln Lys Ser Cys Met Ser Asn Cys Ser Ile Thr Ser Ile 500 505 510 Cys Glu Lys Pro Gln Glu Val Cys Val Ala Val Trp Arg Lys Asn Asp 515 520 525 Glu Asn Ile Thr Leu Glu Thr Val Cys His Asp Pro Lys Leu Pro Tyr 530 535 540 His Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro Lys Cys Ile Met Lys 545 550 555 560 Glu Lys Lys Lys Pro Gly Glu Thr Phe Phe Met Cys Ser Cys Ser Ser 565 570 575 Asp Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu Glu Tyr Asn Thr Ser 580 585 590 Asn Pro Asp 595 <210> 93 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 93 Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Ala Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 94 <211> 602 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 94 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Met Ile His Pro Asn Ser Gly Gly Asn Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Trp Tyr Gly Ser Ser Pro Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445 Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 450 455 460 Gly Ser Ile Pro Pro His Val Gln Lys Ser Val Asn Asn Asp Met Ile 465 470 475 480 Val Thr Asp Asn Asn Gly Ala Val Lys Phe Pro Gln Leu Cys Lys Phe 485 490 495 Cys Asp Val Arg Phe Ser Thr Cys Asp Asn Gln Lys Ser Cys Met Ser 500 505 510 Asn Cys Ser Ile Thr Ser Ile Cys Glu Lys Pro Gln Glu Val Cys Val 515 520 525 Ala Val Trp Arg Lys Asn Asp Glu Asn Ile Thr Leu Glu Thr Val Cys 530 535 540 His Asp Pro Lys Leu Pro Tyr His Asp Phe Ile Leu Glu Asp Ala Ala 545 550 555 560 Ser Pro Lys Cys Ile Met Lys Glu Lys Lys Lys Pro Gly Glu Thr Phe 565 570 575 Phe Met Cys Ser Cys Ser Ser Asp Glu Cys Asn Asp Asn Ile Ile Phe 580 585 590 Ser Glu Glu Tyr Asn Thr Ser Asn Pro Asp 595 600 <210> 95 <211> 214 <212> PRT <213> Synthetic Sequence <220> <223> synthetic <400> 95 Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Ala Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 96 <211> 123 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 96 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 97 <211> 330 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 97 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 225 230 235 240 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330 <210> 98 <211> 330 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 98 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 225 230 235 240 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Ala 325 330 <The 210th position> 99 <The 211th position> 227 <The 212th position> PRT <The 213th position> Artificial sequence <The 220th position> <The 223rd position> Synthetic <400> 99 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Ala 225 [[ID=?]]<210> 100 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 100 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 It should be noted that the "?" in the translation of is due to the unclear "210" in the original text. If this is a specific code or has a known meaning, it needs to be adjusted according to the actual situation. Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 <210> 101 <211> 21 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 101 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly Ser Gly 20 <210> 102 <211> 610 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 102 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 450 455 460 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ile Pro Pro His Val Gln 465 470 475 480 Lys Ser Val Asn Asn Asp Met Ile Val Thr Asp Asn Asn Gly Ala Val 485 490 495 Lys Phe Pro Gln Leu Cys Lys Phe Cys Asp Val Arg Phe Ser Thr Cys 500 505 510 Asp Asn Gln Lys Ser Cys Met Ser Asn Cys Ser Ile Thr Ser Ile Cys 515 520 525 Glu Lys Pro Gln Glu Val Cys Val Ala Val Trp Arg Lys Asn Asp Glu 530 535 540 Asn Ile Thr Leu Glu Thr Val Cys His Asp Pro Lys Leu Pro Tyr His 545 550 555 560 Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro Lys Cys Ile Met Lys Glu 565 570 575 Lys Lys Lys Pro Gly Glu Thr Phe Phe Met Cys Ser Cys Ser Ser Asp 580 585 590 Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu Glu Tyr Asn Thr Ser Asn 595 600 605 Pro Asp 610 <210> 103 <211> 214 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 103 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1, 5, 10, 15 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 20, 25, 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile 35 40 45 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 104 <211> 610 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 104 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys<​​​​​​Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 450 455 460 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ile Pro Pro His Val Gln 465 470 475 480 Lys Ser Val Asn Asn Asp Met Ile Val Thr Asp Asn Asn Gly Ala Val 485 490 495 Lys Phe Pro Gln Leu Cys Lys Phe Cys Asp Val Arg Phe Ser Thr Cys 500 505 510 Asp Asn Gln Lys Ser Cys Met Ser Asn Cys Ser Ile Thr Ser Ile Cys 515 520 525 Glu Lys Pro Gln Glu Val Cys Val Ala Val Trp Arg Lys Asn Asp Glu 530 535 540 Asn Ile Thr Leu Glu Thr Val Cys His Asp Pro Lys Leu Pro Tyr His 545 550 555 560 Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro Lys Cys Ile Met Lys Glu 565 570 575 Lys Lys Lys Pro Gly Glu Thr Phe Phe Met Cys Ser Cys Ser Ser Asp 580 585 590 Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu Glu Tyr Asn Thr Ser Asn 595 600 605 Pro Asp 610 <210> 105 <211> 589 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 105 Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu 1 5 10 15 Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val 20 25 30 Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 35 40 45 Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe 50 55 60 Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu 65 70 75 80 Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 85 90 95 Gln Thr Asn Thr Ile Ile Asp Val Val Leu Ser Pro Ser His Gly Ile 100 105 110 Glu Leu Ser Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr 115 120 125 Glu Leu Asn Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys 130 135 140 His Gln His Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gln Ser Gly 145 150 155 160 Ser Glu Met Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly Val Thr 165 170 175 Arg Ser Asp Gln Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met 180 185 190 Thr Lys Lys Asn Ser Thr Phe Val Arg Val His Glu Lys Asp Lys Thr 195 200 205 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 210 215 220 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 225 230 235 240 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 245 250 255 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 260 265 270 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 275 280 285 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 290 295 300 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 305 310 315 320 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 325 330 335 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 340 345 350 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 355 360 365 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 370 375 380 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 385 390 395 400 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 405 410 415 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Ala 420 425 430 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 435 440 445 Gly Gly Gly Ser Gly Ile Pro Pro His Val Gln Lys Ser Val Asn Asn 450 455 460 Asp Met Ile Val Thr Asp Asn Asn Gly Ala Val Lys Phe Pro Gln Leu 465 470 475 480 Cys Lys Phe Cys Asp Val Arg Phe Ser Thr Cys Asp Asn Gln Lys Ser 485 490 495 Cys Met Ser Asn Cys Ser Ile Thr Ser Ile Cys Glu Lys Pro Gln Glu 500 505 510 Val Cys Val Ala Val Trp Arg Lys Asn Asp Glu Asn Ile Thr Leu Glu 515 520 525 Thr Val Cys His Asp Pro Lys Leu Pro Tyr His Asp Phe Ile Leu Glu 530 535 540 Asp Ala Ala Ser Pro Lys Cys Ile Met Lys Glu Lys Lys Lys Pro Gly 545 550 555 560 Glu Thr Phe Phe Met Cys Ser Cys Ser Ser Asp Glu Cys Asn Asp Asn 565 570 575 Ile Ile Phe Ser Glu Glu Tyr Asn Thr Ser Asn Pro Asp 580 585 <210> 106 <211> 480 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 106 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe[[ID=三十年]] 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys<asc="3022">85 90 95 Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly​​​Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 450 455 460 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ile Pro Pro His Val Gln 465 470 475 480 <210> 107 <211> 481 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 107 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 450 455 460 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ile Pro Pro His Val Gln 465 470 475 480 Lys <210> 108 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 108 Asp Asn Asn Gly Ala Val Lys Phe Pro Gln Leu Cys Lys Phe Cys Asp 1 5 10 15 Val Arg Phe Ser Thr Cys Asp Asn Gln Lys Ser Cys Met Ser Asn Cys 20 25 30 Ser Ile Thr Ser Ile Cys Glu Lys Pro Gln Glu Val Cys Val Ala Val 35 40 45 Trp Arg Lys Asn Asp Glu Asn Ile Thr Leu Glu Thr Val Cys His Asp 50 55 60 Pro Lys Leu Pro Tyr His Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro 65 70 75 80 Lys Cys Ile Met Lys Glu Lys Lys Lys Pro Gly Glu Thr Phe Phe Met 85 90 95 Cys Ser Cys Ser Ser Asp Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu 100 105 110 Glu Tyr Asn Thr Ser Asn Pro Asp 115 120 <210> 109 <211> 130 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 109 Lys Ser Val Asn Asn Asp Met Ile Val Thr Asp Asn Asn Gly Ala Val 1 5 10 15 Lys Phe Pro Gln Leu Cys Lys Phe Cys Asp Val Arg Phe Ser Thr Cys 20 25 30 Asp Asn Gln Lys Ser Cys Met Ser Asn Cys Ser Ile Thr Ser Ile Cys 35 40 45 Glu Lys Pro Gln Glu Val Cys Val Ala Val Trp Arg Lys Asn Asp Glu 50 55 60 Asn Ile Thr Leu Glu Thr Val Cys His Asp Pro Lys Leu Pro Tyr His 65 70 75 80 Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro Lys Cys Ile Met Lys Glu 85 90 95 Lys Lys Lys Pro Gly Glu Thr Phe Phe Met Cys Ser Cys Ser Ser Asp 100 105 110 Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu Glu Tyr Asn Thr Ser Asn 115 120 125 Pro Asp 130 <210> 110 <211> 465 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <222> (1)..(1) <223> pyro <400> 110 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Phe Pro Gly Ser Gly Asn Ser Lys Tyr Asn Glu Asn Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Glu Thr Tyr Asp Tyr Gly Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Ala Gly Gly Gly Gly ... 435 440 445 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ile Pro Pro His Val 450 455 460 Gln 465 <210> 111 <211> 466 <212> PRT <213> Artificial Sequence <220> <"223"> Synthetic <220> <221> misc_feature <222> (1)..(1) <223> pyro <400> 111 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Phe Pro Gly Ser Gly Asn Ser Lys Tyr Asn Glu Asn Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Glu Thr Tyr Asp Tyr Gly Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro<000331​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 450 455 460 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ile Pro Pro His Val Gln 465 470 475 480 Lys Ser Val Asn Asn Asp Met Ile Val Thr Asp Asn Asn Gly Ala Val 485 490 495 Lys Phe Pro Gln Leu Cys Lys Phe Cys Asp Val Arg Phe Ser Thr Cys 500 505 510 Asp Asn Gln Lys Ser Cys Met Ser Asn Cys Ser Ile Thr Ser Ile Cys 515 520 525 Glu Lys Pro Gln Glu Val Cys Val Ala Val Trp Arg Lys Asn Asp Glu 530 535 540 Asn Ile Thr Leu Glu Thr Val Cys His Asp Pro Lys Leu Pro Tyr His 545 550 555 560 Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro Lys Cys Ile Met Lys Glu 565 570 575 Lys Lys Lys Pro Gly Glu Thr Phe Phe Met Cys Ser Cys Ser Ser Asp 580 585 590 Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu Glu Tyr Asn Thr Ser Asn 595 600 605 Pro Asp 610 <210> 113 <211> 595 <212> PRT <213> Artificial Sequence<00,03418><220> <223> Synthetic <400> 113 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Phe Pro Gly Ser Gly Asn Ser Lys Tyr Asn Glu Asn Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Glu Thr Tyr Asp Tyr Gly Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Ala Gly Gly Gly Gly 435 440 445 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ile Pro Pro His Val 450 455 460 Gln Lys Ser Val Asn Asn Asp Met Ile Val Thr Asp Asn Asn Gly Ala 465 470 475 480 Val Lys Phe Pro Gln Leu Cys Lys Phe Cys Asp Val Arg Phe Ser Thr 485 490 495 Cys Asp Asn Gln Lys Ser Cys Met Ser Asn Cys Ser Ile Thr Ser Ile 500 505 510 Cys Glu Lys Pro Gln Glu Val Cys Val Ala Val Trp Arg Lys Asn Asp 515 520 525 Glu Asn Ile Thr Leu Glu Thr Val Cys His Asp Pro Lys Leu Pro Tyr 530 535 540 His Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro Lys Cys Ile Met Lys 545 550 555 560 Glu Lys Lys Lys Pro Gly Glu Thr Phe Phe Met Cys Ser Cys Ser Ser 565 570 575 Asp Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu Glu Tyr Asn Thr Ser 580 585 590 Asn Pro Asp 595 <210> 114 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 114 Ser Val Asn Asn Asp Met Ile Val Thr Asp Asn Asn Gly Ala Val Lys 1 5 10 15 Phe Pro Gln Leu Cys Lys Phe Cys Asp Val Arg Phe Ser Thr Cys Asp 20 25 30 Asn Gln Lys Ser Cys Met Ser Asn Cys Ser Ile Thr Ser Ile Cys Glu 35 40 45 Lys Pro Gln Glu Val Cys Val Ala Val Trp Arg Lys Asn Asp Glu Asn 50 55 60 Ile Thr Leu Glu Thr Val Cys His Asp Pro Lys Leu Pro Tyr His Asp 65 70 75 80 Phe Ile Leu Glu Asp Ala Ala Ser Pro Lys Cys Ile Met Lys Glu Lys 85 90 95 Lys Lys Pro Gly Glu Thr Phe Phe Met Cys Ser Cys Ser Ser Asp Glu 100 105 110 Cys Asn Asp Asn Ile Ile Phe Ser Glu Glu Tyr Asn Thr Ser Asn Pro 115 120 125 Asp <210> 115 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 115 Ser Val Asn Asn Asp Met Ile Val Thr Asn Asn Asn Gly Ala Val Lys 1 5 10 15 Phe Pro Gln Leu Cys Lys Phe Cys Asp Val Arg Phe Ser Thr Cys Asp 20 25 30 Asn Gln Lys Ser Cys Met Ser Asn Cys Ser Ile Thr Ser Ile Cys Glu 35 40 45 Lys Pro Gln Glu Val Cys Val Ala Val Trp Arg Lys Asn Asp Glu Asn 50 55 60 Ile Thr Leu Glu Thr Val Cys His Asp Pro Lys Leu Pro Tyr His Asp 65 70 75 80 Phe Ile Leu Glu Asp Ala Ala Ser Pro Lys Cys Ile Met Lys Glu Lys 85 90 95 Lys Lys Pro Gly Glu Thr Phe Phe Met Cys Ser Cys Ser Ser Asp Glu 100 105 110 Cys Asn Asp Asn Ile Ile Phe Ser Glu Glu Tyr Asn Thr Ser Asn Pro 115 120 125 Asp <210> 116 <211> 129 )<212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 116 Ser Val Asn Asn Asp Met Ile Val Ser Asn Asn Asn Gly Ala Val Lys 1 5 10 15 Phe Pro Gln Leu Cys Lys Phe Cys Asp Val Arg Phe Ser Thr Cys Asp 20 25 30 Asn Gln Lys Ser Cys Met Ser Asn Cys Ser Ile Thr Ser Ile Cys Glu 35 40 45 Lys Pro Gln Glu Val Cys Val Ala Val Trp Arg Lys Asn Asp Glu Asn 50 55 60 Ile Thr Leu Glu Thr Val Cys His Asp Pro Lys Leu Pro Tyr His Asp 65 70 75 80 Phe Ile Leu Glu Asp Ala Ala Ser Pro Lys Cys Ile Met Lys Glu Lys 85 90 95 Lys Lys Pro Gly Glu Thr Phe Phe Met Cys Ser Cys Ser Ser Asp Glu 100 105 110 Cys Asn Asp Asn Ile Ile Phe Ser Glu Glu Tyr Asn Thr Ser Asn Pro 115 120 125 Asp <210> 117 <211> 136 <212> PRT​​​​​​​​​​​​​​​​​Val Arg Phe Ser Thr Cys Asp Asn Gln Lys Ser Cys Met Ser Asn Cys 35 40 45 Ser Ile Thr Ser Ile Cys Glu Lys Pro Gln Glu Val Cys Val Ala Val 50 55 60 Trp Arg Lys Asn Asp Glu Asn Ile Thr Leu Glu Thr Val Cys His Asp 65 70 75 80 Pro Lys Leu Pro Tyr His Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro 85 90 95 Lys Cys Ile Met Lys Glu Lys Lys Lys Pro Gly Glu Thr Phe Phe Met 100 105 110 Cys Ser Cys Ser Ser Asp Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu 115 120 125 Glu Tyr Asn Thr Ser Asn Pro Asp 130 135 <210> 118 <211> 136 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 118 Ile Pro Pro His Val Gln Asn Ser Val Asn Asn Asp Met Ile Val Thr 1 5 10 15 Asn Asn Asn Gly Ala Val Lys Phe Pro Gln Leu Cys Lys Phe Cys Asp 20 25 30 Val Arg Phe Ser Thr Cys Asp Asn Gln Lys Ser Cys Met Ser Asn Cys 35 40 45 Ser Ile Thr Ser Ile Cys Glu Lys Pro Gln Glu Val Cys Val Ala Val 50 55 60 Trp Arg Lys Asn Asp Glu Asn Ile Thr Leu Glu Thr Val Cys His Asp 65 70 75 80 Pro Lys Leu Pro Tyr His Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro 85 90 95 Lys Cys Ile Met Lys Glu Lys Lys Lys Pro Gly Glu Thr Phe Phe Met 100 105 110 Cys Ser Cys Ser Ser Asp Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu 115 120 125 Glu Tyr Asn Thr Ser Asn Pro Asp 130 135 <210> 119 <211> 136 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 119 Ile Pro Pro His Val Gln Gln Ser Val Asn Asn Asp Met Ile Val Ser 1 5 10 15 Asn Asn Asn Gly Ala Val Lys Phe Pro Gln Leu Cys Lys Phe Cys Asp 20 25 30 Val Arg Phe Ser Thr Cys Asp Asn Gln Lys Ser Cys Met Ser Asn Cys 35 40 45 Ser Ile Thr Ser Ile Cys Glu Lys Pro Gln Glu Val Cys Val Ala Val 50 55 60 Trp Arg Lys Asn Asp Glu Asn Ile Thr Leu Glu Thr Val Cys His Asp 65 70 75 80 Pro Lys Leu Pro Tyr His Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro 85 90 95 Lys Cys Ile Met Lys Glu Lys Lys Lys Pro Gly Glu Thr Phe Phe Met 100 105 110 Cys Ser Cys Ser Ser Asp Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu 115 120 125 Glu Tyr Asn Thr Ser Asn Pro Asp 130 135 <210> 120 <211> 136 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 120 Ile Pro Pro His Val Gln Asn Ser Val Asn Asn Asp Met Ile Val Ser 1 5 10 15 Asn Asn Asn Gly Ala Val Lys Phe Pro Gln Leu Cys Lys Phe Cys Asp 20 25 30 Val Arg Phe Ser Thr Cys Asp Asn Gln Lys Ser Cys Met Ser Asn Cys 35 40 45 Ser Ile Thr Ser Ile Cys Glu Lys Pro Gln Glu Val Cys Val Ala Val 50 55 60 Trp Arg Lys Asn Asp Glu Asn Ile Thr Leu Glu Thr Val Cys His Asp 65 70 75 80 Pro Lys Leu Pro Tyr His Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro 85 90 95 Lys Cys Ile Met Lys Glu Lys Lys Lys Pro Gly Glu Thr Phe Phe Met 100 105 110 ​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Val Arg Phe Ser Thr Cys Asp Asn Gln Lys Ser Cys Met Ser Asn Cys 35 40 45 Ser Ile Thr Ser Ile Cys Glu Lys Pro Gln Glu Val Cys Val Ala Val 50 55 60 Trp Arg Lys Asn Asp Glu Asn Ile Thr Leu Glu Thr Val Cys His Asp 65 70 75 80 Pro Lys Leu Pro Tyr His Asp Phe Ile Leu Glu Asp Ala Ala Ser Pro 85 90 95 Lys Cys Ile Met Lys Glu Lys Lys Lys Pro Gly Glu Thr Phe Phe Met 100 105 110 Cys Ser Cys Ser Ser Asp Glu Cys Asn Asp Asn Ile Ile Phe Ser Glu 115 120 125 Glu Tyr Asn Thr Ser Asn Pro Asp 130 135 <210> 122 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 122 Thr Asp Asn Asn Gly Ala Val Lys Phe Pro Gln Leu Cys Lys Phe Cys 1 5 10 15 Asp Val Arg Phe Ser Thr Cys Asp Asn Gln Lys Ser Cys Met Ser Asn 20 25 30 It should be noted that there seems to be a small error in the tag "0003686" in the original text. It is likely a double-typed "0". I have translated it as "0003686" as accurately as possible while maintaining the integrity of the original content. If this is a specific format requirement, it may need to be adjusted according to the actual situation.Cys Ser Ile Thr Ser Ile Cys Glu Lys Pro Gln Glu Val Cys Val Ala 35 40 45 Val Trp Arg Lys Asn Asp Glu Asn Ile Thr Leu Glu Thr Val Cys His 50 55 60 Asp Pro Lys Leu Pro Tyr His Asp Phe Ile Le...

Claims

1. An anti-tumor antagonist, which consists of two heavy chains and two light chains. Each heavy chain comprises a VH domain, a CH1 domain, a CH2 domain, a CH3 domain, a connecting peptide and a TGF-β1RII extracellular domain (ECD) from the N-terminus to the C-terminus. Each light chain consists of a VL domain and a CL domain from N-terminus to C-terminus. wherein the VH domain comprises the amino acid sequence shown in SEQ ID NO: 96; and wherein the VL domain comprises the amino acid sequence shown in SEQ ID NO: 91, The TGF-β1RIIECD comprises the amino acid sequence shown in SEQ ID NO: 89; The anti-tumor antagonist specifically binds to human VEGF-A through the VH and VL domains, and specifically binds to human TGF-β1 through the TGF-β1RIIECD.

2. The anti-tumor antagonist according to claim 1, wherein Each heavy chain comprises a sequence selected from the group consisting of SEQ ID NOs: 97, 98, 115-122, and 127-129.

3. The anti-tumor antagonist according to claim 2, wherein Each heavy chain comprises the sequence shown in SEQ ID NO:

98.

4. The anti-tumor antagonist according to claim 1, wherein Each heavy chain comprises the sequence shown in SEQ ID NO:

101.

5. Use of the anti-tumor antagonist according to any one of claims 1 to 4 for preparing a medicament for treating non-small cell lung cancer.

Citation Information

Patent Citations

  • Human antithrombin III, DNA sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin III, and pharmaceutical compositions comprising it

    EP0090505B1

  • Mammalian cell surface antigens; related reagents

    EP1947183B1

  • Anti-VEGF antibodies

    US20030190317A1

  • Antibodies to vascular endothelial cell growth factor

    US20030203409A1

  • Vascular endothelial cell growth factor antagonists

    US20030206899A1